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Abstract
Glucuronides are a class of phase II metabolites that are significant in the 
detoxification of xenobiotics and endogenous compounds. Synthetic samples of 
glucuronides are important, and can be used as analytical standards, as well as in 
stability studies in elucidating structure activity relationships with respect to toxicity. 
The FDA states that if a metabolite is excreted in >10 % of the initial dose, it must be 
investigated in relation to any adverse drug reactions. Recently we have looked at O- 
acyl (AGs) and A/-glucuronides.
l-p-O-acyl glucuronides (AGs) have long been known to be reactive metabolites which 
can covalently modify body proteins. The consequences are still unclear and it is not 
certain that AGs are directly toxic. An update on the latest methods of synthesis of 
AGs will be given, together with insight into the stability of AGs, and their interactions 
with proteins. The current high concern in the pharmaceutical industry over all 
reactive metabolites and the occurrence of AGs as major metabolites of common 
drugs such as Ibuprofen and Diclofenac emphasise the significance of this work.
/V-Glucuronides have been relatively little studied, but they are important for a 
number of amine-containing drugs. They are unique human metabolites and are 
therefore not detected in pre-clinical toxicology. We have lately developed synthetic 
methods for this class, especially quaternary ammonium glucuronides of aliphatic 
tertiary amines whose synthesis was previously unsatisfactory.
i
Valuable information on the acid and base stability of /V-glucuronides, together with 
the underlying chemistry of anomeric quaternary ammonium glucosides, has been 
gathered as a result. Typical examples are the A/+-glucuronides of Amitriptyline and 
Imipramine, commonly-used tricyclic antidepressants, whose syntheses will be given 
to illustrate our methodology.
Amitriptyline W'-Glucuronide Imipramine AT-Glucuronide
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Chapter One: Introduction
1.1 Drug Metabolism
Metabolism of drugs and other xenobiotics is an important process in all mammals; it 
is the body's way of eliminating unwanted, often biologically active foreign substances. 
All food and drugs taken orally and absorbed through the intestinal tract are passed via 
the portal vein directly to the liver, where the hepatocytes of the liver produce 
metabolising enzymes that form Phase I and II metabolites1,2. There are other sites for 
the metabolism of xenobiotics including the lungs, kidneys, gut and skin, but the liver is 
generally considered to be the most important
Phase I Metabolism
Phase I metabolism, generally oxidations, reductions and hydrolytic reactions, involves 
functional group changes in which small polar groups are added to make the molecule 
more hydrophilic; or a methyl group removed in order to expose a more polar group, 
eg -OH, -NH, COOH (figure 1.1.1). The majority of the Phase I oxidative metabolism is 
mediated by cytochrome P450 enzymes3.
2
Chapter One: Introduction
Figure 1.1.1: Some examples of Phase I metabolism3
The availability of cytochrome P450 enzymes is controlled by genetics, endogenous 
hosts and environmental factors4. There are some drugs which can inhibit production 
of metabolites of other drugs via interactions with other CYP enzymes. For example, 
Cimetidine (1.1) was shown to affect drug metabolism in both humans and animal 
species5 (figure 1.1.2). Grapefruit juice is known to inhibit intestinal cytochrome P450 
enzyme CYP 3A4, which increases the bioavailability of drugs metabolised by this 
enzyme, leading to overdose effects6. This was discovered in 1989, and has been 
shown to cause deaths due to drug overdose. He et al.7 extracted bergamottin (1.2) 
from grapefruit juice and found that this inhibited CYP 3A4 (figure 1.1.2).
3
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Cimetidine (1.1) Bergamottin (1.2)
Figure 1.1.2: Compounds found to inhibit Cytochrome P450 enzymes
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Phase II Metabolism
During Phase II metabolism a polar group is added, catalysed by transferase enzymes. 
The addition of polar groups increases the molecule's water solubility and therefore 
aids excretion. Many metabolites formed during phase I are then able to undergo 
conjugation during phase II metabolism. The reaction that occurs in Phase II is 
normally conjugation with; glucuronic acid, sulfates, glutathione or amino acids (figure 
1.1.3)8.
UDP glucuronosyltransferase
ROH
Glucuronic acid conjugation 
HO
UDP
UDP glycosyltransferase
ROH
Glucose conjugation
3'-Phosphoadenosine-5'-phosphosulphate
Ar— OH ----------------------------------------------------------------------- *■ A r— O — S — OH
II
O
Sulfation
Figure 1.1.3: Most common forms of phase II metabolism
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1.2 Glucuronidation
Glucuronidation is the most common type of phase II metabolism for both xenobiotics, 
(drugs, carcinogens and other environmental pollutants), and of endogenous 
compounds such as bilirubin and steroids9. Glucuronides are formed in the body as a 
means of reducing biological activity and for the elimination of xenobiotics and 
endogenous compounds, via the urine, and bile (and hence the faeces). Conjugation 
with glucuronic acid is via a reactive functional group within the drug molecule. More 
common reactive functional groups known to undergo glucuronidation are; carboxylic 
acids, phenols, alkyl alcohols, amines, and thiols.
Glucuronidation in the body occurs via UDP-Glucuronic acid (1.3), this is an SN2 
reaction catalysed by UDP-Glucuronosyltransferase enzymes10 which are found in 
many major organs, but predominantely in the liver (scheme 1.2.1). The SN2 nature of 
the reaction gives rise to 3-configured glucuronides. Once the nucleophilic group has 
reacted with UDP-Glucuronic acid (1.3) to form the glucuronide, UDP is generated, 
which is then reformed to UDP-GA. The structure of UDP-Glucuronic acid was 
elucidated by Storey and Dutton in 195511.
6
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Scheme 1.2.1: The reaction scheme for the formation of an O-glucuronide, and how
UDP is reformed to UDP-GA
The bond that is formed between the drug and glucuronic acid is known as the 
glycosidic bond. There are also enzymes that can hydrolyse the glycosidic bond, and 
these are called glucuronidases.
As part of drug design and development, it is important to understand drug 
metabolism1 so that in the future predictive tools may be used. Such predictive tools 
would then hopefully lead to more informed drug design that will eliminate potential 
toxic metabolites at an early stage.
7
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1-fL-O-Aryl Glucuronides and O-Alkyl Glucuronides
O-aryl or alkyl glucuronides are formed from a reactive phenol or alcohol group 
present in the drug molecule. These classes have been known for many years and 
have been well documented in the literature as metabolites of many drugs9. It is 
believed that generally this class of glucuronide is formed in order to detoxify and 
deactivate the drug molecule and predominantly has no toxicological implications.
An example of a drug which forms O-glucuronides is morphine. There are two sites 
where glucuronidation occurs; the alkyl alcohol which gives morphine-6-glucuronide 
(M6G (1.4)), and the phenolic alcohol which forms morphine-3-glucuronide (M3G 
(1.5)) (figure 1.2.2). The M6G metabolite is thought to have a higher potency as an 
analgesic than morphine12'13'15, whereas M3G is thought to be purely detoxifying. The 
M6G metabolite is the minor formed, giving a ratio of 1:4 of M6G to M3G.
Figure 1.2.2: Morphine-6-O-Glucuronide and Morphine-3-O-Glucuronide
A typical method used to synthesise O-glucuronides is the Koenigs-Knorr reaction. The 
aglycone is coupled to the sugar activated by anomeric bromine (1.6), which is 
promoted by Ag(l) salts (scheme 1.2.3)16. A disadvantage to this method is the 
formation of the orthoester (1.7) and the undesired a-product (1.8) (scheme 1.2.3). A 
method developed which eliminates the orthoester by-product is the use of anomeric 
esters, activated by Lewis acids such as SnCl417.
8
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Scheme 1.2.3: Koenigs-Knorr reaction, products and by-products
A method typically used for phenols, is the formation of the potassium, sodium or 
lithium phenolate, which is then reacted with the anomeric bromine (1.6)18. Ando et 
al. formed the potassium phenolate of mycophenolic acid and used this in their 
Koenigs-Knorr coupling reaction (scheme 1.2.4)19.
Ag2C 0 3
RO-K+
Quinoline
AcO
Scheme 1.2.4: Reaction carried out by Ando et al. using the potassium phenolate of
mycophenolic acid
9
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l-$-0-Acyl Glucuronides
1-P-O-acyl glucuronides originate from a drug containing a carboxylic acid group and 
form an ester bond with glucuronic acid at the anomeric position. It is believed that 
acyl glucuronides (AGs) are in some cases reactive metabolites which can lead to 
adverse drug reactions, thought to be due to their interactions with proteins20. An 
example of an acyl glucuronide suspected to form covalent adducts with proteins is 
zomepirac AG21 (1.9) (figure 1.2.5).
Recently it has been reported22 that pharmaceutical companies are becoming more 
wary of potential drug discovery targets which possess a carboxylic acid functional 
group due to potential AG formation. There are drugs known to form AGs that are 
relatively safe, such as Ibuprofen (1.10) (figure 1.2.6), which indicates more research is 
required in this field to fully understand why some carboxylic acid containing drugs are 
'safe' and some extremely toxic.
Site of glucuronidation
Figurel.2.6: Ibuprofen (1.10) which is dosed as a racemate 
See chapter two for more details on AGs.
10
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N-Glucuronides and fit-Glucuronides
W-glucuronidation has only been discovered relatively recently (~1970s) and is being 
detected much more frequently for a wide range of drugs23. /V-glucuronidation is 
common for drugs such as tricyclic antidepressants, antipsychotics and antihistamines 
which contain a tertiary amine group. Upon glucuronidation these drugs form a 
zwitterionic species. There are many examples of drugs which have been isolated as 
their A/+-glucuronide such as Amitriptyline /V/+-glucuronide (1.11) (figure 1.2.7) which 
has been isolated in about 12 % of the initial administered dose24.
Figure 1.2.7: Amitriptyline A/+-Glucuronide
It is known that secondary and primary amines form glucuronides to give the 
respective neutral species. The /V-glucuronide of Norgallopamil (1.12) and 
Norverapamil (1.13) (scheme 1.2.8) have been isolated as biliary metabolites from rats 
dosed with the corresponding tertiary amines, Gallopamil and Verapamil25. This 
suggests demethylation during phase I metabolism, followed by A/-glucuronidation 
during phase II metabolism.
11
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OMe
R: OMe; Norgallopamil N-Glucuronide (1.12) 
H; Norverapamil /V-Glucuronide (1.13)
Figure 1.2.8
See Chapter three for more details on JV-glucuronides
12
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l-^-S-Glucuronides
S-Glucuronides are not as common as other types of glucuronides. A recent example of 
an S-glucuronide is HMR109826 (1.14), a novel KATp-blocking agent (figure 1.2.9). 
Tanaproget-S-glucuronide (1.15) has been synthesised and characterised by NMR by 
Keating et al.27 (figure 1.2.9). There have been limited studies of S-glucuronides, they 
are thought to be similar to O-glucuronides with respect to toxicity and hydrolysis.
CN
HMR1098-S-glucuronide (1.14)
Figure 1.2.9
Dutton et al.28 used in their investigation biosynthetic samples of o-aminothiophenol, 
p-nitrothiophenol, diethyldithiocarbamic acid and thiolphenol glucuronides, they 
concluded that hydrolytically, thiol glucuronides are similar to O-glucuronides.
13
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Glycosylation
Conjugation of xenobiotics and endogenous compounds with glucuronic acid is by far 
the most prevalent type of sugar conjugation, but other sugars are known to undergo 
conjugation, which include glucose, xylose and ribose29.
Fevery et a!.30 demonstrated that although UDPGA is the primary UDP-sugar co­
substrate used for the bilirubin esterification in mammals, two other UDP-sugars; UDP- 
glucose (UDPG) (1.16), and UDP-xylose (1.17), are also potential co-substrates (figure 
1.3.1).
H
Figure 1.3.1
14
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l-$-0-Acyl Glucosides
The glycosylation process is found frequently in insects and plants31, but to a lesser 
extent in mammals. Walse et a!.32 found that the Caribbean fruit fly releases 
glycoconjugated pheromones named Suspensoside A (1.18) and B (1.19) (figure 1.3.2).
(6R)-Suspensoside B (1.19) (6S)-Suspensoside A (1.18)
Figure 1.3.2: The two diastereoisomeric pheromones produced by the Caribbean fruit
fly
They synthesised both isomers using the bromosugar (1.20) as the glycosyl donor, in 
the presence of Hg (II) (scheme 1.3.3). They then deprotected the acetate groups 
using sodium methoxide in methanol to give an overall yield of ~35 % (scheme 1.3.3).
Scheme 1.3.3: Conditions used by Walse et al. to form the glycosylpheromones,
Suspensoside A and B.
15
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A selective and potent endothelin ETA receptor antagonist underwent significant acyl 
glucuronidation and acyl glucosidation in human liver microsomes33 to give (1.21) 
(figure 1.3.4).
Figure 1.3.4: Example of an acyl glucoside of a selective endothelin ETA receptor
antagonist
16
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O-Aryl/Alkyl Glucosides
Kamimura et al.34 found that a phase I metabolite of Indeloxazine (1.22) formed by rats 
is excreted as its a-glucoside (1.23) (scheme 1.3.5). This is rare, and most glucoside 
metabolites are found with the 3 configuration due to the Sn2 reaction with UDP- 
Glucose.
PhasePhase
22) 2324
Scheme 1.3.5: Proposed a-O-glucoside of an Indeloxazine phase I metabolite
The diol (1.24) formed during phase I metabolism may have a part to play in the 
formation of the a-glucoside (scheme 1.3.6). Due to the anomeric effect, it would be 
expected that the a-glucoside would be more thermodynamically stable than the 3- 
glucoside.
Scheme 1.3.6: Possible mechanism for the formation of the a-glucoside
17
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Cervenkova et al.35 carried out investigations to probe the potential of Olomoucine 
(1.25) type derivatives such as Bohemine (1.26) (figure 1.3.7) towards glycosylation. 
They did in vitro examinations on mouse, rat, and monkey as well as human liver and 
kidney microsomes. They found the mouse liver and kidney microsomes contained 
high levels of bohemine-l-O-3-glucoside, but very little was detected in rat, monkey 
and human microsomes.
HN' Ph
Olomoucine (1.25)
Figure 1.3.7: Bohemine and Olomoucine; two potential candidates for O-Glucoside
formation
An important point made is that they cannot be certain that conjugation is occurring 
on the hydroxyl group, there is also potential for /V-glucosidation to occur.
18
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N-Giucosides
Although rare /V-glycosylation is known; it is thought to be a detoxification mechanism 
for xenobiotics. Duggan et at.36 found that a xanthine oxidase inhibitor, forms an N- 
glucoside (1.27) via the 1,2,4-triazole ring (figure 1.3.8).
Figure 1.3.8: 3-(4-Pyrimidinyl)-5-(4-pyridyl)-l,2,4-triazole /V-glucoside
Phénobarbital was found by Tang et al.37 to form an /V-glucoside (1.28) in vivo. Two 
male volunteers were given Phénobarbital. Both metabolised Phénobarbital as an N- 
glucoside (1.28) (figure 1.3.9) with the metabolite being isolated from urine in 24 and 
30 % of the administered dose.
Tang et al. made a synthetic sample to compare to the in vivo sample isolated. The 
acetylated compound was isolated from the reaction of N-(2,3,4,6-tetraacetyl-l-3-D- 
glucopyranosyl)urea (1.29) with 2-ethyl-2-phenylmalonyl chloride (1.30) to give the
19
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product (1.31) in 34 % yield (scheme 1.3.10). The product was not deprotected 
through to the final compound; the reason is not stated but perhaps due to the 
instability of the compound during deprotection.
Scheme 1.3.10: Reaction conditions to form the acetylated phénobarbital W-Glucoside
1.4 Introduction to Glucose
D-Glucose is a naturally occurring sugar and is the most abundant of its type. It plays a 
vital role in biochemical transformations such as cellular respiration (Krebs cycle). L- 
Glucose is not a naturally occurring sugar and cannot be used in biochemical pathways 
like D-Glucose.
Structure:
Glucose is known to be most stable as the six membered pyranose, with the ring in the 
chair conformation. This conformation is favoured in both the solid state and in 
solution. When glucose is dissolved in D20, with immediate measurement by NMR, the 
spectra shows mainly the a-D-glucose (1.32)38. On standing in solution the amount of 
3-D-Glucose (1.33) increases until there is approximately a 50:50 mixture of the a and 
3-anomers which occurs via mutarotation (scheme 1.4.1).
20
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OH
H<fta H9.o H<fta OH
HO
1-a-D-Glucose (1.32) 1-P-D-Glucose (1.33)
Scheme 1.4.1
The furanose ring ((1.34) and (1.35)) is much less favourable compared to the 
pyranose ring, and by NMR spectroscopy the furanose is not detected. The acyclic 
form can be represented by the Fischer projection (1.36) (scheme 1.4.2); this 
schematic shows the open chain aldehyde, but this is unfavoured compared to the six 
membered hemiacetal. Although the open chain aldehyde is unfavoured it plays a vital 
role in many reactions.
21
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Fischer projection of D-Glucose 
(1.36)
a-furan form of D-glucose 
(1.35)
P-D-Glucose in the 4C 1 
conformation 
(1.33)
l-D-Glucose in the 1C4 
conformation
a-L-Glucose in the a-L-Glucose in the
4C, conformation 1C4 conformation
OH
fS-L-Glucose in the p-L-Glucose in the
4C, conformation 1C4 conformation
Scheme 1.4.2
22
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1.5 Introduction to Glucuronic Acid
D-Glucuronic acid (1.37) (figure 1.5.1) is a naturally occurring uronic acid, mainly 
utilised in metabolism of xenobiotics and bilirubin. In the body the reactive species is 
UDP Glucuronic acid (1.3); this is synthesised from UDP Glucose by UDP-glucose 6- 
dehydrogenase (scheme 1.2.1).
Glucuronic acid (1.37) 
Figure 1.5.1
Importantly, Glucuronic acid is found copolymerised in a 1:1 ratio with substituted 2- 
amino-2-deoxy-D-glucose in heparin, chondroitin 4- and 6-sulfates and hyaluronic 
acid39.
Heparin's main purpose is thought to be defensive at the site of tissue injury to 
prevent invasion of bacteria and other foreign materials40 In medicine it is used as an 
anticoagulant to prevent deep vein thrombosis (DVT). Heparin is heavily sulfated, and 
contains repeating units (figure 1.5.2). Another sugar found in heparin is L-iduronic 
acid, which is the C5 epimer of glucuronic acid.
o
II
Figure 1.5.2: One of the repeating units found in Heparin sulphate
23
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Hyaluronic acid is found in connective, epithelial and neural tissues. It is a polymer of 
the disaccharide of D-glucuronic acid and D-N-acetylglucosamine, linked together via 
alternating P-1,4 and P-1,3 glycosidic bonds (figure 1.5.3).
OH
Figure 1.5.3: The P-1,4 repeating unit found in hyaluronic acid
When isolated from aqueous solution, D-glucuronic acid crystallises as monoclinic 
plates in the glucurono-3,6-lactone form (1.38)39. The glucuronolactone is hydrolysed 
readily at high pH to the glucuronate (the sodium or potassium salt) (scheme 1.5.4).
K
Scheme 1.5.4: Hydrolysis of glucurono-3,6-lactone (1.38) to give potassium
glucuronate.
24
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Structural studies of glucuronic acid have shown that the potassium salt exhibits the 
pyranose conformation in which all the hydroxyl groups and the carboxylate ion are in 
the lower energy equatorial position41.
1.6 The Anomeric Effect
It is known that cyclohexane rings prefer to have substituents in the equatorial 
position, with this being the more favoured lower energy orientation of the 
cyclohexane ring. When it comes to a pyranose ring system, any electronegative 
substituent at the C l position prefers to be axial even though sterically this is 
unfavourable. This was first discovered by Edwards and Lemieux and is now called the 
Edward Lemieux effect or the anomeric effect42,43. There are two main reasons for this 
phenomenon; the dipole-dipole interaction between the ring oxygen and the 
electronegative substituent, and the stereoelectronic effect.
The endocyclic sp3 hybridised oxygen lone pairs form a dipole which points in the 
exocyclic direction42. The dipole-dipole interaction between the endocyclic oxygen 
and the C l heteroatom substituent in P-D-Glucose (1.33) is unfavourable as they are 
almost parallel and point in the same direction (figure 1.6.1). The opposite is true for 
a-D-Glucose (1.32) were the dipoles are almost in opposite directions (figure 1.6.1)
Figure 1.6.1: Direction of the dipoles in both a and 3-glucose
The stereoelectronic effects are due to the lone pairs of the endocyclic oxygen. The 
axial orientation of the p-orbital that the lone pair occupies is synperiplanar to the 
antibonding orbital of the anomeric substituent of the a-isomer. It is therefore
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possible for the lone pair of the endocyclic oxygen to donate electron density into the 
o* orbital, thus stabilising the o* orbital (figure 1.6.2). This interaction results in a 
shortening of the O (endocyclic)-Cl bond and a lengthening of the C l-0  (exocyclic) 
bond.
Figure 1.6.2: The o* orbital is stabilised in the a-conformation
These stabilising effects apply to the 4Ci a-anomer and the *C4 P-anomer i.e where the 
substituent is axial (figure 1.6.3) with the 4Ci conformation being the most stable.
HO
4C, a-D-Glucose 1C 4 P-D-Glucose
Figure 1.6.3: The two conformations stabilised by the anomeric effect
1.7 The Reverse Anomeric effect (RAE)
The Reverse Anomeric effect describes the tendency for a positively charged, 
electronegative anomeric substituent to prefer the equatorial position. Whether the 
Reverse Anomeric effect exists has been debated, and it has been suggested that it is 
purely for steric reasons that such substituents prefer the equatorial position44.
It would be expected that a positively charged substituent would have an enhanced 
anomeric effect rather than a RAE in terms of the molecular orbital interpretation. A
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cationic substituent lowers the a*, which would lead to a stronger interaction between 
the oxygen lone pair HOMO and the o* orbital of the C-X+ bond.
The first example where a RAE was postulated was the /V-(a-glycosyl)-pyridinium ion 
(1.39)45'46'47. These results have been questioned as to whether the effect is due 
simply to steric repulsions of the axial pyridinium ion (scheme 1.7.1).
Scheme 1.7.1: Pyridinium species thought to exhibit the RAE
Another example which is thought to exhibit the RAE is N-(tri-0-acetyl-a-D- 
xylopyranosyl)imidazole, where there is a shift from the axial 4Ci conformer (1.40) to 
the equatorial XC4 conformer (1.41) (> 95 %) upon protonation with trifluoroacetic 
acid47 (scheme 1.7.2). The ratios before protonation of the two conformers 4Ci :1C4 are 
65:35, and it is thought that protonation does not affect steric bulk. It has been said 
that the shift in equilibrium is due to possible solvation effects, which effectively 
increase the substituent size44.
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Perrin et a!.48 have shown in NMR titration studies using d-trifluoroacetic acid that the 
the equilibrium is actually shifted towards the a-anomer, showing a normal anomeric 
effect.
Jones and Kirby et al.49 came to the conclusion that such an effect does not exist 
during their studies. They used 1,3-dioxane as a substitute for the pyranose ring 
system, and a azaadamante substituent (figure 1.7.3). They believe that the two 
conformers are almost sterically neutral with a slight preference for (1.43) over (1.42) 
due to the shorter bond length of N+-CH3 compared to C-CH3 ( (1.43) is favoured by 
RAE). They actually found that a conformer close to (1.42) was preferred in solution.
Figure 1.7.3: The two possible conformers, with (1.42) being preferred in solution
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2.1 Introduction to lß-O-Acyl Glucuronides
l-ß-0-Acyl glucuronides are phase II metabolites formed from a drug molecule 
possessing a reactive carboxylic acid moiety. There have been many carboxylic acid 
containing drugs isolated as their acyl glucuronide, such as (Sj-ibuprofen (1.10)1, (S)- 
naproxen (2.1), and mycophenolic acid (2.2)2 (figure 2.1.1).
Ibuprofen (1.10) Naproxen (2.1) Mycophenolic Acid (2.2)
Figure 2.1.1: Carboxylic acid containing drugs.
In some cases the acyl glucuronide can be active itself against the receptor or enzyme 
target; these are called active metabolites. Acyl glucuronides are also known as 
reactive metabolites due to their ability to covalently bind to proteins; these modified 
proteins can lead to Adverse Drug Reactions (ADRs). Many drugs removed from 
market due to toxicity have been carboxylic acids, known to form acyl glucuronides3. 
Benoxaprofen (2.3), Alcofenac (2.4), Ibufenac (2.5) and Tienilic acid (2.6) (figure 2.1.2) 
all form acyl glucuronides, and all have been removed from the market due to 
toxicological implications. There is no evidence that implicates solely the acyl 
glucuronide of each drug being the reason for such adverse drug reactions, and more 
investigations are required.
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Figure 2.1.2
Acyl glucuronides of endogenous substances are known such as bilirubin diglucuronide 
(2.7) (figure 2.1.3). Bilirubin originates from the breakdown of heme in red blood cells; 
without removal a build up can lead to jaundice. The conjugation of two glucuronic 
acid molecules to bilirubin increases its aqueous solubility and hence aids excretion via 
the faeces.
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2.2 The Reactivity of 1-fi-O-Acyl Glucuronides
The electrophile nature of the acyl glucuronide leads to substitution reactions with 
nucleophilic molecules in proteins such as -NH2, -SH and -OH groups. The protein may 
become directly acylated (2.8) and is therefore modified by the drug molecule4 
(scheme 2.2.1).
Acyl glucuronides can also migrate between adjacent hydroxyl groups resulting in 2-0- 
(2.9), 3-O-(2.10) and 4-0-(2.11) isomers which are not readily hydrolysed by 0- 
glucuronidase. Once migration has occurred only the 1-a-acyl glucuronide can be 
formed on the ester group returning to the anomeric position5. The 2-0-, 3-0- and 4- 
O- isomers can undergo mutarotation via the aldehyde form of the sugar resulting in a 
and 3 isomers of each migratory product (scheme 2.2.1). The migration is pH 
dependent occurring at neutral to slightly alkaline environments2. Once migration has 
occurred, the acyl group in the 2-, 3-, and 4-position is less reactive towards 
nucleophilic attack by proteins. The open chain aldehyde form of the sugar is able to 
react with nucleophilic groups within proteins, which again leads to a modified protein 
(2.12); this process is called glycation (Scheme 2.2.1).
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Scheme 2.2.1: Pathways which can occur in the body once the acyl glucuronide is
formed
Quantitative structure-activity relationships (QSAR's) have been studied by 
Vanderhoeven et al.6 to establish if there is relationship between the structure of the 
acyl glucuronide and its ability to migrate or hydrolyse. The degradation rate (kd) is a 
combination of the hydrolysis and migration; in general acyl migration is dominant in 
vitro. The reaction rate is followed by 1H NMR, looking at the disappearance of the 
anomeric proton of the ip-0-acyl isomer as the reaction progresses in the NMR tube 
under physiological conditions.
They studied various AGs of para-substituted benzoic acids. They found a good 
correlation between the Hammett constant (op) and degradation rate ((log)kd) which
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indicates the nucleophilic nature of the reaction. They found that p = + 1.63 indicating 
the build up of negative charge during the reaction.
There have been reported differences in acyl migration rates between diasteriomeric 
AGs, such as the AGs of (R)- and (S)- Ibuprofen (1.10)7. It has been shown that both 
isomers hydrolyse at the same rate; therefore the difference in kd must be due to 
migration. The ^-isom er (kd 0.387 h 1) migrates at a faster rate than the ^-isom er (kd 
0.188 h"1). There have been several postulated reasons for this, one being steric 
effects. It has been suggested that the distance between the aglycone at C l and the 
attacking 2-alkoxide nucleophile is greater for the (Sj-isomer and therefore leads to 
slower migration8.
A study carried out by Hasegawa9 on the AGs of (R) and (S>2-phenyl propionoic acid, 
found that the free energy of activation AG for the transacylation of the ^-iso m er 
was smaller than that for the fS^-isomer, therefore the ^-isom er would be more 
reactive.
Molecular modelling calculations carried out by Berry et al.10 on (/?y^-2-phenyl 
propionoic acid derived AGs showed that the difference in rates of migration can be 
explained by the transition states of the ortho ester. From calculations it is believed 
that in the lower energy transition state (2.13) (scheme 2.2.2) if R3 is methyl [(S)- 
isomer) then the interaction between the axial anomeric hydrogen and the methyl 
group are significant enough to force the fSj-isomer into the higher energy transition 
state (2.14).
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CO ,
-O
Y
h 0
Ph
Higher energy transition state (2.14)
R2
Lower energy transition state (2.13)
Scheme 2.2.2: The orthoester transition states for the migration of the acyl group
A difference in isomer reactivity has also been observed in protein binding studies. 
Bischer et al.11 found that ^-naproxen AG had a stronger affinity for protein binding 
compared to (Sj-naproxen AG (fSj-Naproxen (2.1)).
It has in general been found that the more substituted the a-carbon, the slower the 
rate of migration. NMR studies carried out by Johnson10 showed that increasing a- 
methyl substitution of phenyl acetic acid AGs slowed down migration and hydrolysis. 
Phenylacetic acid AG (2.15) had the fastest kd of 2.353 h'1, méthylation at the a-carbon 
slowed the degradation to 0.903 h"1 and 0.405 h"1 for the (R)- (2.16) and (S)- (2.17) 
mono-a-methyl phenylacetic acid AGs respectively and 0.029 h'1 for the di-a-methyl 
phenylacetic acid AG (2.18) (figure 2.2.3).
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(2 .1 7 ) (2 .1 8 )
Figure 2.2.3: Increased a-substituted phenyl acetic acid AGs, from left to right
migration slows down.
2.3 Stability of 1-^-O-Acyl Glucuronides in Physiological media
The stability of acyl glucuronides in physiological media has been studied; an example 
of which is Zomepirac12 (2.19) (figure 2.3.1). Zomepirac is an anti-inflammatory drug 
which was removed from the market due to ADR's. The Zomepirac AG is readily 
cleaved by 3-glucuronidase to give back the parent compound. At pH 7.4, 37°C in an 
aqueous system, the half life of Zomepirac AG was found to be 27 mins. At 
physiological pH four other fractions have been isolated other than the Zomepirac AG. 
Hasegawa et a!.13 postulated that the four other isolated compounds were due to acyl 
migration, as the migratory products are not cleaved by 3-glucuronidase.
Telmisartan (2.20) (figure 2.3.1) is an angiotensin II receptor antagonist. Telmisartan- 
acyl glucuronide has been found to be one of the most stable AGs, having a half life of 
26h at pH 7.4. This was confirmed by Ebner et a!.12 during in vitro experiments that 
indicated very low covalent binding of Telmisartan-acyl glucuronide to human serum 
albumin (HSA).
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Cl
Figure 2.3.1: Zomepirac (2.19) and Telmisartan (2.20)
There is a general trend between the half life of an AG and its reactivity (Table 2.3.2). 
For drugs such as Tolmetin (2.21) and Zomepirac (2.19) which have been removed 
from the market due to ADRs they clearly have shorter half lives compared to 
Ibuprofen (1.10), which is classed as a relatively safe drug. There are of course other 
mechanisms which take part in drug toxicity; a measure of AG half life does not give its 
toxicological profile. Benoxaprofen (2.3) has a half life of 2 h, but was withdrawn from 
the market due to reports of fatal cholestatic jaundice. ^-Naproxen (2.1), which has a 
half life of 1.8 h is still a drug marketed today and has in the UK become available over 
the counter as a treatment for primary dysmenorrhoea.
Half life (t* (h))
Tolmetin (2.21) 0.26
Zomepirac (2.19) 0.45
Diclofenac (2.22) 0.5
(7?J-Fenoprofen (2.23) 0.98
Indomethacin (2.24) 1.4
(7?J-Car profen 1.76
fSJ-Fenoprofen 1.93
(S)-Carprofen (2.25) 3.09
(5^-lbuprofen (1.10) 3.3
Furosemide (2.26) 5.3
Valproic acid (2.27) 79
Table 2.3.2: First Order half lifes of 1-O-AGs in aqueous buffer, pH 7.4, 37°C14
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Furosemide (2.26)
Figure 2.3.3: Compounds that form AGs in order from left to right of shortest half life
(see table 2.3.2).
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2.4 Previous Synthesis of 1-ß-O-Acyl Glucuronides
To synthesise O-acyl glucuronides in previous years required the use of 'fully' 
protected sugars15. The protecting groups generally used were acetate, benzyl, 
pivaloate, allyl and silyl. Removal of these groups can be achieved in various ways 
including hydrolysis, hydrogenation and Pd catalysed removal (table 2.4.1). Such 
removal of certain protecting groups can be incompatible with the O-acyl bond e.g. 
NaOH hydrolysis of the acetate groups can result in hydrolysis of the O-acyl bond.
Protecting Group Removal
Acetate 1M NaOH/KOH,
Pivaloate Or Aspergillus lipase16
Benzyl H2(g), Pd/C
Allyl -o o
Silyl HF in MeCN
Table 2.4.1: Conditions of removal of well used protecting groups
Bugianesi et at.17 synthesised Indomethacin-ip-O-acyl glucuronide (2.28) from 2,2,2- 
trichloroethoxycarbonyl (Troc) protected glucuronic acid (2.29). They used DCC in THF 
to couple Indomethacin in fairly good yields (50 %) (scheme 2.4.2). The synthesis to 
make the Troc protected sugar was lengthy (six steps) and originated from Tri-O- 
acetyl-l-bromo-a-D-glucopyranuronic methyl ester (1.6). They then removed the Troc 
protecting groups using Zn dust in acetic acid. This removed the protecting groups 
successfully but the Zn proved difficult to remove.
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Scheme 2.4.2: Conditions for the synthesis of Indomethacin AG (2.28)
Protecting groups are frequently utilised in sugar chemistry but it was found recently 
that when synthesising O-acyl glucuronides, selectivity can be obtained at the 
anomeric OH group to give just the mono-acylated compound. The carboxylic acid 
moiety of the starting glucuronic acid can be selectively protected which increases the 
solubility of the glucuronic acid in organic media, but masks the carboxylic acid group 
during the coupling step. The criteria for the protecting group should be; stability 
during the coupling step and, ease of removal without disrupting either the O-acyl 
bond or any functional groups within the aglycone.
Juteau et al.18 used allyl glucuronate (2.30) as the intermediate in synthesising the acyl 
glucuronide bond. They used the Mitsunobu method to couple the carboxylic acid to 
the anomeric position (scheme 2.4.3).
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Scheme 2.4.3: Mitsunobu reaction to make the protected O-acyl glucuronide
They found that aromatic carboxylic acids gave mixtures of a and 3 isomers (1:5) 
during the Mitsunobu coupling with modest yields of 20-40 %. Aliphatic carboxylic 
acids gave the lowest yields (~20 %) as a/3 mixtures.
The Mitsunobu method goes via an SN2 mechanism giving inversion at the anomeric 
centre. They were still able to isolate a higher percentage of the 3-anomer. This 
suggests that due to the anomeric effect, the a-phosphonium is the more stable 
intermediate (2.31) (figure 2.4.4). They also observed the formation of the lactone by­
product (2.32) (figure 2.4.4), which co-eluted with the a-product in a 1:1 ratio.
The last step in the sequence was removal of the allyl protecting group which was 
accomplished with Pd(0) and pyrrolidine in THF (scheme 2.4.5). Traces of Pd(0) were 
difficult to remove from the final product.
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(2.30) °
Scheme 2.4.5: Deprotection of allyl ester glucuronate
Pd<°> Pyrrolidine
THF
HO
O
O
Perrie et al.19 found that using HATU to form an activated ester (2.33) gave higher 
yields compared to the Mitsunobu method with >98% 3 selectivity. They tried HOBt in 
combination with DIC and found this to be an effective coupling reagent, but HATU 
gave higher yields. HATU is believed to be superior due to its hydrogen bonding 
abilities (figure 2.4.6) which renders the carbonyl more electrophilic20.
Figure 2.4.6: Hydrogen bonding which can occur with the activated ester of HATU.
Their studies showed that base strength was critical with N-methyl morpholine (NMM) 
and DABCO being the favoured bases. They found pyridine was not basic enough and 
the reaction was slow. Stronger unhindered bases such as 4-dimethylaminopyridine 
(DMAP) and triethylamine gave overreaction.
The method employed by Perrie et al. uses a selective acylation of the 1-O-alkoxide. It 
was found by Schmidt21'22,23 that the 3-alkoxide (2.34) is more nucleophilic than the a- 
alkoxide (2.35). This is suggested to be due to steric effects and the kinetic anomeric 
effect. The a-alkoxide can often be trapped at lower temperatures owing to its greater 
thermodynamic stability. An equilibrium between the a and 3-alkoxides via the open 
chain aldehyde (2.36) means that the more reactive 3-alkoxide reacts with the 
activated ester (2.33) leaving the a-alkoxide to continue to equilibrate (scheme 2.4.7).
\
N
R
(2.33)
45
Chapter Two: Acyl Glucuronides
(2.35)
Scheme 2.4.7: The P-alkoxide reacts with the activated ester while the a-alkoxide
equilibrates
Bowkett et al.24 focussed their work on the GA protecting group used during the 
coupling step. They utilised benzyl glucuronate (2.37) which is stable during the HATU 
coupling step, and easily removed by catalytic transfer hydrogenation (or conventional 
hydrogenation). They were able to remove the benzyl group during hydrogenolysis of 
mycophenolic AG (2.38) without disrupting the double bond present (scheme 2.4.8). 
Unfortunately, aryl halides were cleaved during the deprotection. They also found 
formation of isopropyl ester during the deprotection (~2 % by NMR) if the reaction was 
prolonged. Transesterification could be avoided by using conventional hydrogenation 
at room temperature.
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HATU, NMM 
Mycophenolic acid 
MeCN
Scheme 2.4.8: Reaction conditions used by Bowkett to remove the benzyl group
Retinoyl 3-glucuronide (2.39) was synthesised via the acid fluoride of retinoic acid 
(2.40) (figure 2.4.9) by Barua et al.25. They synthesised the acid fluoride from the 
carboxylic acid and DAST. They then reacted the acid fluoride with Glucurono-3,6- 
lactone which gave mainly the desired product. The coupled glucurono-3,6-lactone 
was then opened up to give the free acid using 0.1N KOH (scheme 2.4.9).
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This method works well for retinoic acid but most AGs cannot withstand the alkaline 
conditions used to open the glucurono-3,6-lactone during the final step.
Baba et al.26 reported the synthesis of AGs of diclofenac (2.22), mefenamic acid (2.41) 
(scheme 2.4.10) and (S)-naproxen (2.1) using enzymes to selectively remove the acetyl 
and methyl ester protecting groups. They form the glycosidic bond using an SN2 
reaction between the bromo sugar (1.6) and the cesium salt of the drug molecule to 
give yields of 46-79 %. They then screened various enzymes, but found that lipase AS 
Amano (LAS) selectively removed the acetyl groups and the methyl ester was removed 
using esterase from porcine liver (PLE) (scheme 2.4.10).
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Mefenamic Acid (2.41)
Scheme 2.4.10
2.5 Aims of the 1-^-0-Acyl Glucuronide project
Previous synthesis of acyl glucuronides has its disadvantages; we therefore believed 
that further optimisation was required, particularly the protecting group used to mask 
the glucuronic acid.
The allyl protecting group used by both Juteau and Perrie is removed by Pd (0), but 
both found Pd residues difficult to remove completely from the final product. It is 
crucial to remove any heavy metals such as palladium before carrying out in vivo and in 
vitro studies, as their presence may affect results. The benzyl glucuronate employed 
by Bowkett proved to be removed more cleanly than the allyl protecting group, but 
removal entailed hydrogenation and aromatic halides are not tolerated.
We have also looked at different coupling methods to form the acyl bond. The 
Mitsunobu method gives mixtures of anomers, low yields, and formation of the 
lactone by-product mentioned previously (figure 2.4.4). In comparison, using the 
HATU reagent employed by Perrie gives higher yields and 3-selectivity. The 
disadvantages of using HATU are; the cost of HATU (£40.70 per g), and the inability to 
perform larger scale reactions (maximum ~0.6 mmol scale).
We therefore aimed to find a protecting group where aryl halides would be tolerated 
during deprotection. We wanted a coupling method which would give higher yields,
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be more cost effective and capable of being carried out on larger scales whilst still 
giving ß-selectivity.
2.6 Results and Discussions of the Synthesis of 1^-0-Acyl Glucuronides
p-Nitrobenzyl Glucuronate
The carboxylic acid moiety of glucuronic acid is a reactive functional group so during 
the synthesis of acyl glucuronides it requires protecting with a suitable group. The 
protecting group initially examined was the p-nitrobenzyl group (PNB) (2.42). It was 
thought that the PNB group would be cleaved more readily by hydrogenation than the 
benzyl ester which is known as a protecting group24. The theory was that the nitro 
group would be reduced first to give p-aminobenzyl ester (2.43), which would readily 
cleave due to the electron donating amino group (scheme 2.6.1).
(2.42)
O
(2.43)
Scheme 2.6.1: Intermediates during the hydrogenation of p-nitrobenzyl ester
In the synthesis of the p-nitrobenzyl glucuronate (2.44) by alkylataion, 
tetraethylammonium hydroxide was used initially as the base (scheme 2.6.2). This 
reaction appeared to give many by-products which were difficult to separate from the 
p-nitrobenzyl glucuronate.
Scheme 2.6.2: Synthesis of the PNB glucuronate using tetraethylammonium hydroxide
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The product was finally synthesised by using a polymer bound fluoride as base19,24. It 
seems that the base strength is crucial for the success of the reaction, and that the 
fluoride anion is better than the hydroxyl anion. Another base used for the reaction 
was tetrabutylammonium fluoride (TBAF), but this appeared to generate a higher yield 
of glucurono-3,6-lactone. The glucurono-3,6-lactone (2.45) is readily formed under 
basic conditions, with the carbonyl carbon of the ester being attacked by the 3-OH 
(scheme 2.6.3).
0 ,N
(2-4* )  (2.45)
Scheme 2.6.3: Mechanism for the formation of glucurono-3,6-lactone under basic
conditions
Deprotection of the PNB group, which is the final step, proved more troublesome than 
anticipated. The optimisation was carried out on the p-chloro substituted benzoic AG 
(2.46). It was important to retain the chloride during deprotection (figure 2.6.4) to 
improve upon the benzyl glucuronate deprotection.
Figure 2.6.4: p-chloro substituted benzoic AG used in the optimisation of the
deprotection step
The reaction conditions tried are summarised in table 2.6.5. Rajagopal et at.27 used 
Palladium catalysed transfer hydrogenolysis with formate salts. Formate salts have 
hydrogen donating abilities when used in conjunction with Pd/C (10 mol %). We tried
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similar conditions to Rajagopal in the hydrogenation of the PNB group (entry 2, table 
2.6.5).
Reaction Reagents Solvent Temperature
Reaction
time
Yield
1
Catalytic
transfer
hydrogenation
Pd/C, 1,4- 
cyclohexadiene
iPrOH 60°C 3h N.P.I
2
Hydrogenation
using
Formates
Pd/C, Formic acid, 
triethylamine
iPrOH 60°C 4h N.P.I
3
Catalytic
hydrogenation
Pd/C (30 mol %),
H2(g)
iPrOH: 
THF (2:1)
RT 30mins
60%
+
Loss 
of Cl
4
Catalytic
hydrogenation
Pd/C (30 mol %), 
H2(g), H+ resin
iPrOH: 
THF (2:1)
RT 20mins 94%
Table 2.6.5: Reaction conditions tried to deprotect PNB glucuronate (2.47)
It was found that when using catalytic hydrogenation (entry 3 in table 2.6.5) aromatic 
chlorine was replaced by hydrogen. To overcome this problem H+ resin was added to 
the reaction mixture (entry 4 in table 2.6.5), which gave the desired product (2.47) in 
94 % yield. The H+ resin's role is not entirely clear; thoughts are that it speeds up the 
removal of the p-amino intermediate (2.48), with the reaction going to completion 
before cleavage of the aryl chloride (figure 2.6.6). The same reaction conditions were 
tried on the p-bromobenzoic AG, but cleavage of the more labile bromine ensued.
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Figure 2.6.6
2
Acetoxymethyl Protecting Group
It was thought that a protecting group which could be selectively cleaved using 
enzyme hydrolysis would be of great use. A 'collapsing' ester glucuronate (2.49) 
(scheme 2.6.7) was initially looked at and the hopes were that it would be easily 
removed by either enzyme or very mild chemical hydrolysis. Such groups are used in 
prodrugs, which are then metabolised in vivo to the active form of the drug.
HO
Scheme 2.6.7: Mechanism for the removal of the 'collapsing' ester group
To introduce this protecting group several methods were investigated. Unfortunately 
on analysis of the reaction it was observed that the major product was in fact the 
glucurono-3,6-lactone (2.45). This is formed readily due to the labile nature of the 
protecting group, which can also act as a leaving group (scheme 2.6.8).
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OH
OH
(2.45)
0 + 0A A
Scheme 2.6.8: Mechanism to form the glucurono-3,6-lactone from the 'collapsing'
ester
OH
p-Methoxybenzyl Glucuronate
Another protecting group that we looked at was p-methoxybenzyl (PMB). The same 
conditions used to synthesise the p-nitrobenzyl glucuronate (polymer bound fluoride) 
were used to synthesise p-methoxybenzyl glucuronate (2.50). Tetrabutylammonium 
fluoride (TBAF) (scheme 2.6.9) can be used as an alternative base for this reaction, as 
the formation of the glucuronolactone (2.45) is less favourable. This is probably due to 
the donating effect of the p-methoxy group.
Scheme 2.6.9: Reaction conditions when using TBAF as base
It was thought that the p-methoxybenzyl group would be easily removed by mild acid 
hydrolysis. Various conditions were tried: these are summarised in table 2.6.10. The 
conditions that gave optimal results were 10 % v/v solution of TFA (90 % aq) in DCM 
(O.lg/ml).
54
Chapter Two: Acyl Glucuronides
Reaction Reagents Solvent Temp
Reaction
time
Yield
1
Mild acid 
hydrolysis
Formic acid 
(XS)
Dioxane 60°C 5h
no
reaction
observed
2
Catalytic
transfer
hydrogenation
Pd/C(20mol%)
1,4-
cyclohexadiene
Dioxane 60°C 5h N.P.I
3
Mild acid 
hydrolysis
Amberlite H+ 
resin
Dioxane 60°C ~24h
no
reaction
observed
4
Mild acid 
hydrolysis
TFA (90 % aq) 
(10%v/v)
DCM
0°C to 
RT
2-5h 52-98%
Table 2.6.10: Summary of conditions used to remove the p-methoxybenzyl protecting
group
In retrospect it may have been the use of the polar solvent dioxane which may have 
inhibited the hydrolysis of the PMB group; it is potentially a good Lewis base.
It was also important to have water present during the deprotection to react with the 
cation generated (2.51) (scheme 2.6.11), without the presence of water no reaction 
was observed.
(2.51)
-H+
Scheme 2.6.11: Water as a cation scavenger in the PMB deprotection reaction
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The AGs formed using using this method of deprotection are summarised in figure
2 .6.12.
HO
HO
CO,H
HO
CO,H
HO
HO
HO
(2.55) (2.54)
Scheme 2.6.12: Acyl glucuronides synthesised by the PMB protected GA, via HATU
coupling (see next pg).
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Coupling Methods 
Peptide Coupling Reagents
The reagent we initially chose to use was HATU (2.56); we used the same conditions as 
Perrie et al.19 to exploit the effectiveness of our PMB Glucuronate (2.50) and PNB 
Glucuronate (2.44) in the reaction (scheme 2.6.13).
Activated ester
Scheme 2.6.13: Mechanism for the coupling step using HATU to activate the carboxylic
acid
The coupling method using HATU was carried out with various carboxylic acids 
comprising, primary, secondary, and substituted benzoic acids to give the protected 
AGs summarised in figure 2.6.14.
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R = PMB (2.61 ) 45 % R = PNB (2.59) 52 %
R = PMB (2.63) 45 %
R = PNB (2.58) 44 % 
R = PMB (2.62) 55 %
R = PNB (2.57) 32 % 
R = PMB (2.65) 44 %
R = PMB (2.64) 55 %
Figure 2.6.14: Products formed using the HATU method
We found that the PMB glucuronate (2.50) and PNB glucuronate (2.44) gave yields 
comparable to the benzyl (2.37) and allyl glucuronate (2.3) during the coupling 
reaction using HATU. We therefore moved on to look at other coupling methods as we 
had initially intended.
Other coupling reagents have been looked at: these included HOBt (2.66), and PFP 
(2.67) with either DIC (2.68) or DCC (2.69) (figure 2.6.15).
58
Chapter Two: Acyl Glucuronides
DCC (2.69) DIC (2.68) Pentafluorphenol (PFP) (2.67)
Figure 2.6.15: Coupling reagents
DIC (2.68) is thought to react with the carboxylic acid initially; this forms an O-acyl urea 
(2.70) (scheme 2.6.16) that undergoes reaction with HOBt (2.66). We found that HOBt 
with DIC was less effective than HATU (2.51), giving yields of 26 % with phenyl acetic 
acid (HATU gives 55 % with phenyl acetic acid). DIC used on its own can cause 
problems as once the O-acyl isourea is formed it can then react with itself to form an 
A/-acylurea (2.71) (scheme 2.6.15).
o
(2.70) Unreactive by-product (2.71)
Scheme 2.6.16: Formation of the unreactive N-acylurea from DCC or DIC type reagents
R2 —  N ~  — N — R3
Another reaction carried out was to use a combination of HOBt (2.66), DIC (2.68) and 
pentafluorophenol (PFP) (2.67). With the addition of the PFP, the final activated 
derivative is understood to be the PFP ester (2.72) (figure 2.6.17). This is a better 
activating group in comparison to HOBt (2.73) due to the electron withdrawing nature 
of the fluorines, which enhance the electrophilic nature of the carbonyl.
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F
O
F F
RA o F
F
(2.72) (2.73)
Figure 2.6.17: Activated ester of PFP (2.72) and HOBt (2.73)
This reaction gave a 26 % yield which was less efficient than the HATU method which 
gives 40-70 % yields. To study this further an experiment was performed with DIC 
(2.68) and PFP (2.67), i.e. removal of HOBt. There is literature evidence of successful 
peptide coupling reactions using PFP and DCC28. No product was isolated from this 
reaction suggesting that the previous result was from formation of the HOBt activated 
ester (2.73) (figure 2.6.17).
Mixed Anhydrides
Other ways of activating carboxylic acids include forming; mixed anhydride, acid 
chlorides and acid fluorides. Mixed anhydrides have been used successfully in peptide 
coupling chemistry29. We first looked at using di-tert-butyl dicarbonate (Boc anhydride 
[Boc20]) and phenyl acetic acid to form the required mixed anhydride. The phenyl 
acetic acid (2.74), Boc20 and NMM were reacted together initially for lh  before adding 
the PMB glucuronate (2.50) (scheme 2.6.18).
(2.74) o(2.64)
Scheme 2.6.18: Reaction conditions for the mixed anhydride method
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On analysis of this reaction it appeared that the major component of the reaction was 
the mixed anhydride (2.75), suggesting that the mixed anhydride was not reactive 
enough (figure 2.6.19). Only a 6 % yield of the desired P-product (2.64) was isolated, 
no a-anomer was isolated.
~1.5ppm
(2.75)
Figure 2.6.19: The mixed anhydride of phenyl acetic acid and the NMR chemical shifts
It was thought that the t-butyl group may be too sterically hindered reducing the 
reactivity. DABCO (pKa 8.8), which is a stronger base, was tried but this gave no 
product. The next reagent investigated to form the mixed anhydride was 
ethylchloroformate; this gave no reaction at all (scheme 2.6.20).
Y 'o
Pentafluorophenol diphenylphosphinate (FDDP) (2.76) mixed anhydrides30 were 
studied next. The intermediate FDDP (2.76) was synthesised from diphenylphosphinic 
chloride and pentafluorophenol (scheme 2.6.21).
Scheme 2.6.21: Reaction conditions for the synthesis of FDDP
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Once the FDDP (2.76) had been isolated it was reacted on with phenyl acetic acid for 
30mins before addition of the PMB glucuronate (2.50). By TLC there appeared to be 
some desired product, but many by-products. On purification of the reaction it was 
difficult to separate the desired product from by-products. The crude yield after 
purification was 44 % (with purity of ~60 %); it was decided that this route was not 
worth pursuing.
Acid Fluorides
Acid fluorides have been used in peptide coupling chemistry by Carpino et al31 when 
dealing with acid sensitive protected amino acids. They noted that acid fluorides have 
a greater stability compared to acid chlorides towards neutral oxygen nucleophiles 
such as water or methanol, but appear to have nearly equal reactivity toward anionic 
nucleophiles.
To synthesise the acid fluoride we used cyanuric fluoride and pyridine (scheme 2.6.22), 
similar to the method of Kokotos and Noula32. The reaction went in quantitative yield 
and was analysed by IR; the acid fluoride carbonyl stretch was measured at 1844.8 cm" 
1 compared to the carboxylic acid stretch which is 1709.6 cm 1.
Pyridine
DCM
(2.77)
Scheme 2.6.22: Reaction conditions for the formation of phenylacetyl fluoride
The acid fluoride (2.77) was added to the coupling reaction with PMB Glucuronate 
(2.50) as a solution in DCM (scheme 2.6.23). Several reactions were carried out under 
various conditions (table 2.6.24).
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O (277 )
Base
DCM/MeCN
(2.50)
(2.64)
Scheme 2.6.23: Coupling reaction of PMB Glucuronate and phenylacetyl fluoride
Base (eq) Solvent Reaction
Time
Reaction
Temp
Yield
1 NMM (2eq) MeCN/DCM 5h RT 31% and 
diacylated 
product
2 DABCO (2eq) MeCN/DCM 5h RT N.P.I
3 NMM (leq) MeCN/DCM 5h RT 27%
and
diacylated
product
4 Pyridine (leq) MeCN/DCM 5h RT diacylated 
product only
5 NMM(leq) MeCN/DCM 6.5h o o n 40%
6 NMM (leq) MeCN/DCM 6.5h -10°C 36%
Tab e 2.6.24: Reaction Conditions used with phenyl acetyl fluoride and PMB
glucuronate
We started with two equivalents of NMM, but found that there was over reaction 
giving diacylation. We then reduced the NMM to one equivalent and found that the 
diacylation was not reduced to any extent. Reducing the temperature from RT to 0°C 
increased the yield from 27 % to 40 % (Entries 3 & 5 in table 2.6.24), and reduced the 
diacylated product. Using DABCO as a base resulted in no desired product (Entry 2 in 
table 2.6.24). Pyridine gave only the diacylated product (Entry 4 in table 2.6.24). It is
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possible that the pyridinium salt is formed which results in a more reactive pyridinium 
species (2.78) (scheme 2.6.25).
Scheme 2.6.25: Formation of the more reactive pyridinium species
2.7 Conclusions and future work
Due to the synthesis of AGs we have been able to investigate SAR between increased 
a-substituted phenyl acetic acid and kd and have studied the differences in (R) and (S)- 
ibuprofen with respect to acyl migration. This has given more insight into the 
relationship between structure and kd. The pharmaceutical industry is becoming more 
concerned about toxic metabolites so it is important to investigate such relationships.
We have found the use of PMB glucuronate a good alternative to benzyl glucuronate 
when trying to synthesise AGs of carboxylic acids containing aromatic halogens. We 
also avoid the use of heavy metals during deprotection meaning the compounds made 
can be used in proteomic and in vivo studies.
The acyl fluoride chemistry requires further optimisation, but could be used as an 
alternative to HATU. Initially we set out to find a cheaper, higher yielding and scalable 
alternative. Although the yields have not superseded those of HATU, the reagents 
used to synthesise the acid fluoride are cheaper than HATU (cyanuric fluoride £8.50 
per g, HATU £40.70 per g). The reactions also appear to tolerate solvents other than 
acetonitrile; the HATU method does not tolerate other solvents. We were able to 
carry out the reaction on a 2 mmol scale, giving similar yields to the respective 0.6 
mmol reaction. This is not possible when using HATU; using greater than 0.6 mmol of 
glucuronate gives lower yields of product.
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3.1 Introduction to l-$-0-Acyl Glucosides
In mammals glucuronidation is known as the main metabolic pathway for 
xenobiotics and endogenous compounds. In plants, bacteria, insects and molluscs 
glycosylation has been well documented13 as a significant metabolic pathway.
Plants use glycosylation to detoxify xenobiotic and endogenous compounds such as 
2,4,5-trichlorophenol. The detoxification of compounds can be broken down into 
three stages. The first stage is transformation (phase I), followed by conjugation 
(phase II), and then internal compartmentalisation and storage (phase III), with 
storage sites being the vacuole or cell wall.4,5
More examples of glycosylation as a detoxification process and where it occurs have 
already been mentioned, and can be found in the general introduction.
3.2 Previous Synthesis of l-fi-O-Acyl Glucosides
Retinoic acids such as o//-trans-retinoic acid (ATRA), 13-c/s-retinoic acid (13-c/s-RA) 
(3.1) (scheme 3.2.1), and other retinoids are currently used for treatment of 
dermatological disorders and chemotherapeutic agents against various endothelial 
cancers, breast cancer, and endometrial cancer. These compounds are too toxic in 
higher mammals for the prevention of cancer, and many side effects have limited 
their use. Retinoid Acyl glucosides (3.2) have been synthesised in an attempt to 
form less toxic compounds for the treatment of cancer. Xiang et a!.6 took the 
bromo-sugar (1.20) and 13-c/s-RA (3.1) in the presence of KOH with DMAP as 
catalyst to give the product in 53 % yield (scheme 3.2.1). They then deprotected 
(3.3) using dibutyltin oxide as a catalyst in methanol to give the final product in 50 
% yield (scheme 3.2.1).
68
Chapter Three: Acyl Glucosides
There are examples of acyl glucoside conjugates of drugs such as Ibuprofen (1.10). 
Uhrig et at.7 hoped that by adding the glucose moiety, they would increase the 
bioavailabilty of ibuprofen. They used the trichloroacetimidate sugar (3.4) to form 
the conjugated intermediate, which gave them the desired product (3.5) in 67 % 
yield. Deprotection of the benzyl groups was carried out by hydrogenation giving a 
76 % yield of (3.6) (scheme 3.2.2). They found the product (3.6) to be very 
unstable, even when stored at -20°C.
Scheme 3.2.2
Wen et a!.8 synthesised three pentacyclic triterpene glycoconjugates to evaluate 
structure activity relationships for the inhibition of rabbit muscle glycogen 
phosphorylase a (GPa). They found that these compounds had reduced activity. To 
synthesise the conjugates they first formed the bromo sugar (1.20) and then
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coupled this to the triterpenes; oleanolic acid (3.7), ursolic acid (3.8) and corosolic 
acid (3.9), in the presence of potassium carbonate. The intermediates were then 
deprotected using NaOH in methanol and THF (scheme 3.2.3).
75-92 % Yield
(3.7) Oleanolic acid R1 = H, R2 = H, R3 = Me
(3.8) Ursolic acid R1 = H, R2 = Me, R3 = H
(3.9) Corosolic acid R1 = OH, R2 = Me, R3 = H
Scheme 3.2.3
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3.3 Results and Discussions of the Synthesis of l-$-0-Acyl Glucosides
Our aim in synthesising 1-3-O-acyl glucosides was to study acyl migration by NMR in 
the glucose series. We chose the phenyl acetic acid series, with increasing a-methyl 
substitution so that we could compare our results to the glucuronic acid series.
Synthesis
We decided to use 6-O-trityl glucose (3.10) as our glucose source; we knew that this 
was easily made, and is a stable intermediate. To form the glycosidic bond we used 
our selective acylation method, using HATU to form the activated ester, which gave 
us the intermediates in 49-55 % yield (scheme 3.3.1). At this stage the 
diastereoisomers of the mono-methyl derivatives (3.11) were separated by 
chromatography. The deprotection step was then carried out using TFA (aq) in 
DCM, and was complete within 30 minutes as determined by TLC (scheme 3.3.1). 
The products were purified by column chromatography, to give yields of 88-92 %.
OTr
HATU, NMM
(3.12), (3.11) or 
HO "OH (3.13), MeCN
(3.10)
(3.14) R = phenyl
(3.15) R = (RJ-a-methyl phenyl
(3.16) R = (SJ-a-methyl phenyl
(3.17) R = dimethyl phenyl
TFA (aq)
(3.12) R1 = R2 = H 
f/?)-(3.11)R1 = H, R2 = Me 
(S)-(3.11)R1 = Me, R2 = H
(3.13) R1 = R2 = Me
DCM,RT
(3.18) R = phenyl
(3.19) R = (R)-a-methyl phenyl
(3.20) R = (S)-a-methyl phenyl
(3.21) R = dimethyl phenyl
Scheme 3.3.1: Reaction conditions to form Acyl glucosides
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The compounds were then studied by NMR at Imperial College London by Caroline 
Johnson. Each compound was dissolved in a buffer solution of sodium phosphate 
(pH 7.4). The degradation rate (kd) was then measured by taking the integration of 
the l-|3-anomenc proton at the beginning of the reaction and at various time points. 
A plot of In (anomeric proton integral at timepoint/anomeric proton integral at t = 
0) vs timepoint gives kd (the slope of the graph). This gives the kd value for 
migration from the 1-3-position to the 2-position i.e. the initial migration (scheme 
2.2.1, pg. 36). Half life is calculated from kd using the equation: ti/2 = In2/kd
The half lives measured for the four acyl glucosides are shown in table 3.3.2, and 
those measured for the equivalent glucuronides are shown in table 3.3.3 for 
comparison.
Conjugated acid to 
glucose
kdfh1) ti/2(h)
phenylacetic acid (3.12)
1.419 0.49
/?-a-methyl phenylacetic 
acid (3.11)
0.782 0.89
S-a-methyl phenylacetic 
acid (3.11)
0.476 1.46
Di-a-methyl phenylacetic 
acid (3.13)
0.043 16
Table 3.3.2: Measurements taken for the glucose series kd (degradation rate)
72
Chapter Three: Acyl Glucosides
Conjugated acid to GA
kdfh1) ti/2 (h)
phenylacetic acid (3.12)
2.353 (0.628 LC­
MS)
0.29 (1.5 LC­
MS)
R-a-methyl phenylacetic 
acid (3.11)
0.903 0.78
S-a-methyl phenylacetic 
acid (3.11)
0.405 1.71
Di-a-methyl phenylacetic 
acid (3.13)
1
0.029 23.3
Table 3.3.3: Measurements taken for the GA series
Both series show the same trend; increasing a-substitution at the acyl group slows 
down the rate of migration (scheme 2.2.3 pg. 39). The results show that 
degradation and half life rates are faster for the S-a-methyl phenyl acetic acid (S- 
(3.11)) and the di-a-methyl phenyl acetic acid (3.13) glucosides compared to the GA 
series. The R-a-methyl phenyl acetic acid (R-(3.11)) and phenyl acetic acid (3.12) 
glucosides gave slower degradation and half life rates compared to the GA series. 
We still see the same general trend with respect to increased substitution and (R) 
and (S)-isomers. The phenyl acetic glucuronide derivative measurements are not 
certain due to solubility issues; LCMS rates have also been measured (table 3.3.3).
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4.1 Introduction to Neutral N-Glucuronides
/V-Glucuronides are formed with xenobiotics that contain amines, amides, 
hydroxylamines, carbamates, ureas, thioureas and sulphonamides.
/V-Glucuronidation of aryl and alkyl amines, amides, sulphonamides, and 
heterocyclic amines has been reported to occur in vitro and in vivo in many animal 
species and humans. These compounds upon glucuronidation afford a neutral N- 
glucuronide (figure 4.1.1).
Figure 4.1.1: Examples of /V-Glucuronides, (Sulphadimethoxine1, Benzidine2, 
Pimobendan3, Nirvanol4, -A/-Glucuronides)
The antiepileptic drug Retigabine5 has two sites where A/-Glucuronidation occurs; 
the primary aryl amine (4.5) and the secondary aryl amine (4.6) (figure 4.1.2). The 
major metabolite is that of the primary amino group; Hiller et a!.6 determined the 
levels of /V-Glucuronide in plasma of a male volunteer and found rapid and 
extensive /V-glucuronidation even 20 mins after dosing.
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Figure 4.1.2: Two metabolites of Retigabine formed in vivo
4.2 Introduction to Quaternary Ammonium N*-Glucuronides
Glucuronidation of either an aliphatic or aromatic tertiary amine group in a 
molecule results in a quaternary ammonium-linked glucuronide metabolite (N+- 
glucuronide).7 /V+-Glucuronidation is common for drugs such as antipsychotics 
(Loxapine (4.7)), Hi antihistamines (Azatidine (4.8)), tricyclic antidepressant drugs 
(Amitriptyline (4.9)) (Figure 4.2.1), and heterocyclic containing drugs such as 
Midazolam (4.10) (scheme 4.2.2).
Figure 4.2.1: Loxapine (5C), Azatidine (6C) and Amitriptyline (7C)
Midazolam first undergoes oxidation to l'-hydroxymidazolam (4.11), and then 
undergoes phase II metabolism to form the /\/+-glucuronide8 (4.12) (scheme 4.2.2). 
There has been speculation that the parent drug also undergoes direct N+- 
Glucuronidation8.
77
Chapter Four: yV-Glucuronides and N-Glucosides
Scheme 4.2.2: Metabolism of Midazolam
There is evidence that W+-Glucuronides are specific human metabolites9. It is 
believed that the species differences are due to the glucuronysltransferase enzymes 
responsible for /\/+-Glucuronidation.
A further example of a quaternary A/+-Glucuronide is Ketotifen-A/+-Glucuronide10. 
Ketotifen (4.13) is an antiallergic drug and used for the treatment of asthma and 
other allergic conditions (figure 4.2.3). The seven membered ring is non-planar and 
so gives rise to chirality. The enantiomers differ in pharmacological potency but the 
drug is administered as a racemic mixture. This drug is thought to be one that gives 
the highest concentrations of A/+-glucuronide excreted in human urine (24%) of the 
initial dose. Doxepin A/+-Glucuronide (Doxepin (4.14), figure 4.2.3) has also been 
found in high concentrations in human urine (23% of the dose).
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Doxepin (4.14)
Figure 4.2.3
Species specific glucuronidation is exhibited by Ketotifen (4.13)11. In rat hepatocyte 
cultures, ketotifen underwent the same /V-demethylation and A/-oxidation reactions 
as those observed in vivo. In human hepatocytes the major metabolites were those 
from ketoreduction and A/+-glucuronidation. Rabbit hepatocytes also produced the 
/V+-glucuronide of the parent drug. This suggests that rabbits might share the same 
metabolic pathway as humans.
A/+-glucuronides may not always be detected in the excretory media (urine, faeces, 
bile) as they can be hydrolysed back to the parent drug during excretion.
'I am of the opinion that the formation of /V-Glucuronides is much more 
widespread than we have hitherto realised. In fact, there are probably several
types of /V-Glucuronides formed in vivo which are quite unstable........ I agree it is
quite possible that the /V-Glucuronides of drugs are formed on an appreciable scale 
but are not readily detectable because of their instability'
Professor R. T. Williams12
Although /V-Glucuronidation is generally thought to be a detoxification process, 
there is evidence that quaternary ammonium compounds are associated with the 
release of histamine7. Breyer-Pfaff et a!.13 found that dosing of Amitriptyline-/V+-
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Glucuronide (1.11) to a human volunteer resulted in flushing and tachycardia, with 
the study being terminated due to these toxic side effects.
It was found by Calligaro et a/.14 that Olanzapine (4.15), which is an antipsychotic 
agent, forms both Phase I and Phase II metabolites. The Phase II metabolites are 
conjugates with glucuronic acid. There are two sites for A/-Glucuronidation, one 
being the nitrogen of the secondary amine (4.16) and the second through the 
tertiary amine of the piperazine ring (4.17) (Figure 4.2.4)
Olanzapine (4.15) 10-N-Glucuronide (4.16) 4'-N+-Glucuronide (4.17)
Figure 4.2.4: Olanzapine and the two /V-Glucuronides that have been isolated from
humans
Synthesis of Olanzapine A/+-Glucuronide (4.17) was carried out by Calligaro et a!.14 
When they followed the procedure of Luo et al.15, reacting the bromo-sugar (1.6) 
with the parent drug in a two phase system they were able to form the desired 
product (scheme 4.2.5) but in low yield, with a purity of 60 %. After hydrolysis of 
the protecting groups, they were able to isolate the product (4.17) but were unable 
to separate the impurities.
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ÛNI
R
(4.15)
1 )  Benzene 
NaHC 03(aq)
pH 8.4
2) HCI
-O  
HO 
(4.17)
Scheme 4.2.5: Reaction conditions used by Calligaro et al. in the synthesis of 
Olanzapine /V+-Glucuronide (4.17)
There have been many /V+-Glucuronide metabolites isolated from nicotine, one of 
which is (S)-(-)-cotinine-/\/+-Glucuronide (4.19) (figure 4.2.6) which forms the 
glycosidic bond via the pyridine ring nitrogen. Upadhyaya et a!.16 found that 
excreted nicotine-A/+-glucuronide (4.20) and (S)-(-)-cotinine-A/+-glucuronide (4.19) 
account for 3-5 % and 12-17 % respectively, of the initial dose of nicotine. Work by 
Caldwell et o/.17 confirmed that this was the major unidentified Phase II metabolite 
by synthesising (S)-(-J-cotinine A/+-glucuronide (4.19).
Figure 4.2.6: (S)-(-)-cotinine-/V+-Glucuronide (4.19) and nicotine-A/+-glucuronide
(4.20)
Nitrosamines, derived from nicotine, are known to be carcinogens found in tobacco 
products. Two that are believed to play a significant role in cancer induction in 
humans are 4-(methylnitrosamino)-l-(3-pyridyl)-l-butanone (NNK (4.21)) and N- 
nitrosonornicotine (NNN (4.22)) (figure 4.2.7). Upadhyaya eta/.16 synthesised NNK- 
/V+-Glucuronide and NNN-/V+-Glucuronide to try to determine whether these were 
significant metabolites isolated from human urine of patients using tobacco 
products. Later work by Wiener et a!.18 showed by HPLC analysis that NNAL-A/+- 
glucuronide (4.23) is a significant metabolite of nicotine.
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NNAL-AT-Glucuronide (4.23) 
Figure 4.2.7
4.3 The Reactivity and Stability of rf^-Glucuronides and rf^-Glucosides
During this section I will discuss the reactivity and stability of both /V-glucuronides 
and /V-glucosides. There are differences between the neutral species originating 
from primary and secondary amines, and the quaternary ammonium salts with 
respect to stability under acidic to basic conditions.
In general, the /V-glucuronides of primary and secondary amines are unstable in 
acidic media. In contrast /V+-glucuronides are relatively stable at neutral pH and 
hydrolyse in basic but not acidic media.7 This is due to there being no site for 
protonation on the /V+-Glucuronide. It was found by Hawes7 that Doxepin N+- 
glucuronide (4.24) (figure 4.3.1) was stable over the pH range of 1-10 for 3 months, 
whereas significant degradation occurred at pH 11 after 1 month. On the other 
hand Clozapine A/+-glucuronide (4.25) (figure 4.3.1), did not adhere to the general 
pattern of greater stability at acidic pH. Clozapine A/+-glucuronide (4.25) is fairly 
stable over the pH range of 4-11 however significant degradation occurred at pH 1, 
pH 2 and pH 3 after 3 weeks of storage, with half life times of 70, 51 and 86 days 
respectively.
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Figure 4.3.1
Takitani et al.19 synthesised various N-Glucuronides from D-glucuronic acid sodium 
salt and primary alkyl and aryl amines. They studied the dissociation of the amine 
and its relationship to pH and found that aniline A/-glucuronide (4.26) (scheme 
4.3.1) was more stable than butylamine /V-glucuronide (4.27) (scheme 4.3.1) over a 
range of pH (4.4-7.4). This is probably due to aniline being less basic than 
butylamine suggesting that the dissociation goes via protonation.
It is believed that the C-N bond of A/-Glucuronides and /V-Glucosides can undergo 
hydrolysis, mutarotation and Amadori rearrangement depending on the functional 
group attached to nitrogen and reaction conditions. Iminium ion (4.28) formation is 
a key step for all three processes. Once the iminium ion has formed there are 
several pathways that this intermediate can take (scheme 4.3.2).
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Scheme 4.3.2: Mutarotation, Hydrolysis and Amadori rearrangement of /V-Glucoside
Amadori Rearrangement
The Amadori rearrangement occurs slowly in the solid state at 25°C but rapidly in 
hot alchoholic solution (scheme 4.3.3), showing the requirement of a mild acid 
catalyst. Hodge et aI.20 carried out some studies on the stability of N- 
glycosylarylamines and the conditions in which they undergo the Amadori re­
arrangement. They found that rearrangement occurs not just with primary aryl 
amine A/-glycosides but also with glycosyl derivatives of piperidine, morpholine, 
diethanolamine and 3-phenylethylamine. The conditions under which the re­
arrangement occurs is usually heating in an alcohol, but in some cases it is 
necessary to add ethyl malonate to promote re-arrangement20.
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Scheme 4.3.3: The Amadori rearrangement catalysed by methanol
The Amadori rearrangement is known to occur in foods21. The initial reaction is the 
condensation between a reducing sugar and either a protein or amino acid. This 
reaction is termed the Maillard reaction and its products are precursors responsible 
for aromas and flavours in many foods. Once condensation has occurred the 
Amadori rearrangement can take place.
Proline is one of the most important amino acids in the study of food related 
Maillard reactions. Its products are responsible for the aromas in roasted foods. 
The Amadori product, /V-(l-Deoxy-3-D-fructopyranos-l-yl)-L-proline (4.29) (figure 
4.3.4) has been found in many food stuffs such as liquorice root, dried apricots, and
Figure 4.3.4: /V-(l-Deoxy-3-D-fructopyranos-l-yl)-L-proline
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There have been Amadori rearranged type products isolated from the ipecac 
root22,23. The drug Ipecac comes from the dried roots of either CephaeUs 
ipecacuanha A. Richard or Cephaelis acuminata Karsten belonging to the family 
Rubiaceae. It has been used since the beginning of the 17th century as an emetic 
and expectorant, and was further used to treat dysentery in the 18th century. The 
Ipecac root contains many alkaloids, the main alkaloid being Emetine. Related to 
emetine are cephaeline and neocephaeline which were all isolated as Amadori type 
species, 2'-N-(l' '-deoxy-1' '-p-D-fructopyranosyl)emetine (4.30), 2'-N-(l' '-deoxy-1' 
'-P-D-fructopyranosyl)cephaeline (4.31) and 2'-N-(l' '-deoxy-1' '-3-d- 
fructopyranosyl)neocephaeline (4.32) respectively (figure 4.3.5).
OMe
R1 = H, R2 = OMe (4.30)
R1 = H, R2 = OH (4.31)
R1 = OH, R2 = H (4.32)
Figure 4.3.5: Amadori products isolated from the Ipecac root
The isolation of the alkaloids from the Ipecac root involves extraction with hot 
methanol. Potentially Methanol can catalyse the Amadori rearrangement as 
already mentioned. It is therefore possible that the actual active compounds in the 
Ipecac root are not the rearranged compounds but compounds such as (4.33) 
(figure 4.3.6). There has been no literature evidence to suggest this.
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(4.33)
Figure 4.3.6: Potential products in the Ipecac route before methanol extraction 
Mutarotation and Hydrolysis
Mutarotation and hydrolysis are common pathways for glucuronosylamines and 
glycosylamines;24 this is dependent on the amine and the pH of the solution. There 
is an equilibrium between the closed sugar (4.34) and the ¡minium ion (4.28) where 
the nitrogen lone pair donates electron density into the electron deficient C l 
(scheme 4.3.2 p. 88). The hydroxyl group that has been released can then re-attack 
C l releasing the ¡minium ion. As this is not stereoselective and either face of the 
double bond can be attacked leading to mutarotation to give (4.35) (scheme 4.3.2) 
or (4.38) (scheme 4.3.7) (glucose and GA respectively). The second possibility is 
that an external nucleophile such as water can attack C l and subsequently on ring 
closure the amine is liberated to give the sugar (4.36) (scheme 4.3.2) or (4.39) 
(scheme 4.3.7), and the amine.
At low pH hydrolysis is slow due to the formation of the ammonium salt (4.37) 
hence reducing the formation of the iminium ion (scheme 4.3.7). The formation of 
the ammonium salt also depends on the basicity of the amine; if the amine is highly 
basic the ammonium salt will form readily. Simon et al.25 found that 3-D- 
glucosylpiperidine is stable in 2N HCI for 17 hours at 0°C due to the formation of the 
ammonium salt in preference to the formation of the iminium salt.
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Cx
HO,C H R- Weak acid HO,C f  R’ yk — u wr°i',!"
HO HO
Strong acid
HOiC R.
HO
HO
HO H
(4.37)
X
R
o
-I
CO,H
Mutarotation
HO'
HO-------/ I d
HO N ' RIK
(4.38)
HO
HO
CO,H
HO OH 
(4.39)
+  RR'NH2 
X '
Scheme 4.3.7: The product from the glucuronysylamine is pH dependent
Isbell et al.24 found that the rate of hydrolysis is very dependent on the pH of the 
solution. The maximum hydrolysis is obtained in weakly acidic solutions (graph 
4.3.8) and this is proposed to be due to the requirement of both an acid catalyst 
and a hydroxyl ion. The rate constant that they found (khydr0|) was calculated from 
the following equation:
khydroi -  1 / U2 - ti). log ((rti-roo)/(rt2-roo))
Where t2 and ti are times when a steady state has been obtained for the 
modifications of the amine in solution, rn and rt2 are the optical rotations observed 
at the respective times, and rM is the optical rotation of the solution once hydrolysis 
is complete.
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Graph 4.3.8: Values taken from Isbell et al.24 k hydroi vs pH of the solution which 
shows a maximum for hydrolysis.
Aniline derived /V-glucuronides are known to be more stable in general than alkyl N- 
glucuronides.26 As previously mentioned Baker27 suggests that if the proton on the 
nitrogen of tetra-0-(acetyl)glucopyranoside aniline is replaced with a methyl group, 
mutarotation is not induced even in the presence of concentrated hydrochloric 
acid; over time hydrolysis of the amine occurs. Baker states that this outcome 
suggests it must be the electrostatic interaction between the proton of the acid and 
the ring oxygen that induces mutarotation. This induction catalyses proton transfer 
of /V-glycosides that are derived from primary amines. Baker says that if the amine 
in the anomeric position is strongly basic, the proton from the acid co-ordinates to 
the nitrogen forming a salt, but this hydrolyses readily in a solution of alcohol. This 
suggests the ammonium salt formed from protonation is being displaced by the 
nucleophilic alcohol. Pigman28 in his review agrees that glycosylamines are unstable 
in weakly acidic solutions (pH 4-5), but are only slowly hydrolysed by stronger acids.
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4.4 Previous Synthesis of Neutral N-Glucosides and N-Giucuronides
Secondary amine glucosides have been synthesised previously. When Zsoldos-Mady 
et a!.29 synthesised Norfloxacin-ZV-glycoside (4.40), they were hoping to increase the 
solubility of the parent drug by addition of the sugar moiety to the antibacterial 
agent. They used (1.20) (l.le q ) and added more sugar portion wise (3 x O.leq) over 
4 days (scheme 4.4.1). They carried out this reaction under basic conditions by 
adding solid potassium hydrogen carbonate. They do not state why they used basic 
conditions but this is probably to ensure removal of hydrobromic acid generated in 
situ that could form the hydrobromide of norfloxacin and render it unreactive, or 
potentially catalyse hydrolysis of the desired product.
( 1.20)
(4.40)
Scheme 4.4.1: Conditions for the synthesis of Norfloxacin-/V-Glycoside
Some Ciprofloxacin derivatives have been synthesised previously by Jung et al.30 
(scheme 4.4.2). They took the ciprofloxacin derivative in ethanol and heated it with 
glucose under reflux for 48hrs, and were able to filter the product from the reaction 
with some methanol washes.
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Scheme 4.4.2: Reaction of Ciprofloxacin derivative with glucose carried out by Jung
et a l30
Rebeccamycin (4.41) is an antitumour antibiotic that possesses an indolocarbazole 
framework onto which is attached via a 3-/V-glycosidic bond, a 4-O-methoxyglucose 
(figure 4.4.3). Rebeccamycin's activity as an antitumour agent is due to its ability to 
inhibit topoisomerase I by forming a ternary DNA topoisomerase l-drug complex31. 
Messaoudi et al.32 synthesised a 7-aza staurosporine analogue (4.42) (figure 4.4.3) 
which is related to Rebeccamycin and has exhibited high selectivity towards tumour 
cell lines tested.
Rebeccamycin (4.41) 7-aza staurosporine (4.42)
Figure 4.4.3
Synthesis of 7-aza staurosporine was achieved by coupling (4.43) with the aglycone 
(4.44) in the presence of KOH and the phase transfer catalyst tris[2-(2- 
methoxyethoxy)ethyl]amine (TDA-1) (scheme 4.4.4). The next step was reaction 
with NaN3 in DMF which leads to the bridged compound. The final compound
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(4.45) was then isolated in the final step on subsequent deprotection of the benzyl 
ethers (scheme 4.4.4).
Scheme 4.4.4: Reaction conditions to synthesis a 7-aza staurosporine analogue
Gallopamil and Verapamil are two related drugs used to treat coronary heart 
disease. Several metabolites are formed, amongst these are the demethylated 
compounds Norgallopamil (4.46) and Norverapamil (4.47), which have both been 
found to be excreted as their respective /V-glucuronides. Mutlib et al.33 dosed rats 
with Gallopamil and Verapamil and isolated the /V-glucuronides of Norgallopamil 
and Norverapamil. They compared these in vivo samples to synthesised samples of 
the two /V-glucuronides. The chemical samples were synthesised from the acid 
catalysed reaction of the secondary amine (4.46 or 4.47) and the anomeric ester 
(4.48) (scheme 4.4.5). The compounds were isolated in 15-20 % yield.
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CO,Me
AcO
AcO OAc
AcO
(4.48)
Norgallopamil
or
Norverapamil
TsOH, DCM 
50°C
R" = OMe Norgallopamil (4.46)
R" = H Norverapamil (4.47)
Scheme 4.4.5
4.5 Previous Synthesis of Quaternary Ammonium ht-Glucuronides and ht- 
Glucosides
Attempts to make A/+-glucuronides in the past have resulted in low yields and 
difficulties in isolation. Luo et al.15 claimed to have synthesised a variety of aliphatic 
tertiary amine-containing A/+-glucuronides in a bi-phasic system (figure 4.5.1). Luo 
et al. concluded that once the A/+-glucuronide was formed it inhibited further 
production of the desired product when the reaction was carried out in an organic 
solvent such as DCM. They then designed a two phase system of water and 
benzene utilising NaHC03 as a phase transfer catalyst. Acetobromo-a-D-glucuronic 
acid methyl ester (1.6) is the glycosyl donor, which along with the tertiary amine is 
present in the benzene phase. They then proposed that once the ammonium- 
linked glucuronide metabolite is formed that this will pass into the aqueous phase 
and be deprotected to an extent by NaHC03.
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+ Other deprotected products
Figure 4.5.1: Bi-phase system used by Luo et al.
Tamoxifen /V+-Glucuronide (4.48) was synthesised in a direct substitution reaction 
between (1.6) and tamoxifen (4.49). The intermediate was then deprotected 
immediately with sodium hydroxide. The overall yield for this reaction was 6.7 % 
(scheme 4.5.2).
Tamoxifen ^-Glucuronide 
6.7 % overall yield
Scheme 4.5.2
Kaku et al.3i used human liver microsomes fortified with UDP-glucuronic acid and 
TAM and were able to identify TAM A/+-glucuronide (4.48) by comparing it to the 
synthetic sample by high-performance liquid chromatography-electrospray 
ionization-mass spectrometry.
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Tamoxifen (4.49) is a nonsterodial antiestrogen and is widely used for 
chemotherapy treatment of hormone dependent breast cancer in women. It is 
believed that TAM /V+-Glucuronide (4.48) (scheme 4.5.2) is also an active species 
itself and does not merely act as a detoxification agent34.
It should be noted that others have tried the conditions of Luo et al. with very 
limited success. As already discussed, Calligaro et al.14 tried the direct 
quaternisation of Olanzapine with (1.6) and found the reaction to be very low 
yielding, giving only 1-2 % product with a purity of 60 % (scheme 4.2.5).
fS^-(-)-Cotinine /V+-glucuronide was syntheised by Caldwell et al.17 from (1.6) and (S)- 
(-)-cotinine (4.50) by heating them together at 60°C for 3days (scheme 4.5.3), the 
yield after purification was 75 %.
Scheme 4.5.3: Nucleophilic substitution of (^-(-J-cotinine with bromo-sugar
Pyridinium W+-Glucuronides appear to form more readily chemically than 
alkylamines during an SN2 reaction with bromine. This is due to pyridine being less 
basic compared to aliphatic amines therefore inhibiting the E2 mechanism from 
taking place.
Dalgaard et al.35 isolated substituted and unsubstituted Pyridinium /V+-Glucuronides 
(figure 4.5.4) with yields of 58-73 %. They reacted pyridine derivatives and (1.6) in 
the absence of solvent and isolated the product by re-crystallisation from diethyl 
ether.
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R = H,Nle
Scheme 4.5.4: Pyridinium N+-Glucuronide isolated by Dalgaard et al.
They found that the pyridinium compounds were stable in the solid state and in 
solutions below pH 10; in strongly basic solutions hydrolysis slowly occurred. They 
found that a 0.1M solution of pyridinium A/+-glucuronide is cleaved at a rate of 
0.15mM/min at 38°C at pH 7.
Skorupwa et al,36 carried out a reaction between 2,3,4,6-tetra-O-acetyl-a-D- 
glucopyranosyl bromide (1.20) and a 30 % ethanolic solution of trimethylamine 
(scheme 4.5.5) following the same procedure as Karrer and Smirnoff37. They were 
able to isolate the compound (4.51) in 30 % yield after re-crystallisation from 
ethanol.
Scheme 4.5.5: Synthesis of the quaternary ammonium salt (4.51)
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4.6 Results and Discussion part I: The Synthesis of N*-Glucuronides and Glucosides
-Reaction of Anomeric halides in the GA series with tertiary amines.
Our initial approach to synthesise N+-Glucuronides involved using halide sugars, 
namely bromo-sugar (1.6) and iodo-sugar (4.53). Reactions were carried out under 
similar conditions as Luo et ai.15 replacing benzene with toluene. A solution of 
toluene, (1.6) or (4.53) and Amitriptyline (4.54) was added to the aqueous sodium 
bicarbonate (pH 8.4). Analysis of this reaction by NMR showed that the product 
present in the toluene phase was actually the glucal (4.55), (anomeric proton, 
singlet @ ~6.8ppm) and the aqueous phase contained the protonated amitriptyline 
(scheme 4.7.1). This suggested that (1.6) had undergone an elimination reaction in 
preference to the desired substitution reaction, showing that Amitriptyline (4.54) 
was basic enough to deprotonate the 2-H in an E2 reaction. We found the iodo- 
sugar (4.53) eliminated more readily than the bromo-sugar (1.6) during the 
reaction. There is precedence for this type of elimination reaction to occur with 
amines; the more basic the amine the more likely the elimination.
X= Br (1.6) 
X = I (4.53) COJVIe
AcO'
AcO3ÎAAcO IX
Organic Phase
Aqueous Phase H
\ \ N
I
R
I
Scheme 4.7.1: Bi-phase reaction and the products formed
The evidence suggests that under basic conditions (1.6) does undergo elimination. 
A reaction carried out by Kaji et al.3S to give the eliminated product (4.55) used 
diethylamine and tetrabutylammonium bromide (1.5:1.0 eq) in DMF. Lergenmuller
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and Lichtenthaler39 formed the glucal (4.55), from (1.6) using dimethylamine in the 
presence of tetrabutylammonium bromide in DMF.
Our next approach was to carry out the direct nucleophilic substitution reaction 
using solvents of varying polarity as it is known that increasing the polarity of the 
reaction solvent can favour Sn2 over E240. The solvents that we tried were, ethanol, 
dimethylformamide, acetone, isopropanol, tetrahydrofuran and dioxane, but 
changing the solvent had no effect, and we still saw no evidence by NMR of any SN2 
reaction.
We also looked at reactions with no solvent. We heated the bromosugar (1.6) and 
Amitriptyline (4.54) to 60°C to form a 'melt', but we only saw degradation from this 
reaction.
-Reaction of anomeric bromine in the glucose series with tertiary amines
The reaction was then carried out on the corresponding glucose derivatives to see if 
the electronics of the ring system would influence the nucleophilic substitution. If 
the reaction went via an SN1 mechanism this would mean that the oxonium ion 
intermediate (4.56) would be more stable in the glucose series (scheme 4.7.2). This 
is due to increased electron withdrawing ability of the methyl ester in (4.57) which 
de-stabilises the oxonium ion.
Figure 4.7.2: Oxonium ion intermediate of both the glucose series (4.56) and
glucuronic acid series (4.57)
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If the reaction was successful in the glucose series, the glucose derivative could 
then be oxidised in the final step via a TEMPO oxidation reaction to give the 
corresponding glucuronic acid product.
Baisch et at.41 carried out this reaction on a and P-glucosides. They used TEMPO to 
catalyse the oxidation of the CH2 OH group in water containing the oxidant sodium 
hypochlorite (scheme 4.7.3).
A solution of (1.20) in acetone was used in the nucleophilic substitution reaction 
with amitriptyline (4.54); again elimination was preferred over substitution (scheme 
4.7.4). Changing the solvent to EtOH, as Skorupowa et al,36 (scheme 4.5.5) do in 
their reaction (pg 94) with trimethylamine was also tried, but this also gave 
elimination over substitution.
Scheme 4.7.3: Reaction conditions to oxidise C.6
AcO Solvent AcOBr
(1.20)
Solvents used: Acetone, DMF, THF, and EtOH
(4.58)
Scheme 4.7.2: Elimination reaction
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Summary for the halide activated sugars and tertiary amines
There are several possible mechanisms for the generation of the eliminated 
products (4.55) (scheme 4.7.1) and (4.58) (scheme 4.7.2). Amitriptyline may 
deprotonate the 2-position of the sugar with bromine leaving at the same time (E2) 
(scheme 4.7.3, route 2). Alternatively the mechanism could proceed via E l, in 
which case the bromine would leave first, creating a carbocation; this is a secondary 
carbocation that can be stabilised via the oxonium ion and neighbouring group 
participation of the acetate protecting group (scheme 4.7.3, route 1). Generally this 
type of intermediate is only formed in the presence of a promoter such as Ag (I) 
salts. This same carbocation would also be formed if the reaction were to proceed 
via SN1. There is a third possibility in which the desired product is formed via SN2, 
but in the presence of excess Amitriptyline (4.54) it could undergo another 
substitution reaction to give the a-anomer (4.59) which can then eliminate by 
Hofmann degradation (scheme 4.7.3, route 3). Recent experiments have ruled out 
the possibility for Hofmann degradation, as we see no elimination of the (3- 
quaternary product in the presence of the amine.
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Scheme 4.7.3: Possible mechanisms to form the elimination product: 1: E l, 2: E2, 3:
Hofmann degradation
Following these unsatisfactory early results, we decided it was necessary to look at 
the reaction of primary and secondary amines with the bromosugar in both the 
glucose (1.20) and glucuronic acid series (1.6). We hoped to arrive at a better 
understanding of the reactivity of amines with sugar electrophiles, and seek 
alternative ways of introducing nitrogen at the anomeric position.
Reaction of the Anomeric Bromide with Primary Amines
Bognar et al.26 synthesised various aniline substituted W-glycosides. They carried 
out the reaction of p-toluidine with (1.20) under basic conditions (sodium hydroxide 
10 % w/v) (scheme 4.7.4). They purified the material with several re-crystallisations 
which gave them an isolated yield of 10 %. They were able to separate the a and 3 
anomers during re-crystallisation, with the 3-anomer being the major component
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isolated (92 % 3-anomer and 8 % a-anomer). Aniline derivatives have a pKa of ~5, 
much weaker than the bases we have looked at. Therefore it is less likely that 
elimination would occur using aniline derivatives.
Scheme 4.7.4: Reaction conditions to form p-toluidine-W-glucoside
We carried out the same reaction in the glucuronic acid series and we were able to 
isolate the protected p-toluidine-ZV-glucuronide (4.60) in 71 % yield as a mixture of 
a and 3 anomers (scheme 4.7.5). We found that the material contained 0.7:1 a/3- 
anomers; unlike Bognar et at.26 we used silica gel column chromatography to purify 
the material. We would expect the initial reaction between the a-bromo-sugar 
(1.6) and toluidine to be SN2 and therefore give inversion at the anomeric centre. It 
is plausible that the acidic nature of the silica during purification was able to induce 
mutarotation. As discussed in the introduction, Baker et at.27 found that 
glycosylamines derived from primary amines undergo mutarotation in weakly acidic 
environments, catalysed by the protonation of the pyranose oxygen.
Recently during our investigations of A/+-Glucuronide synthesis we have found 
amines can undergo a condensation reaction with the hemiacetal form of the sugar. 
This suggests that a possible role of the NaOH in this reaction is actually to form the 
hemiacetal (4.61), which then undergoes a condensation reaction with the p- 
toluidine to give a mixture of anomers (scheme 4.7.5).
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Scheme 4.7.5: Reaction of toluidine with the bromo-sugar under basic conditions
Reaction of the Anomeric Bromide with Secondary Amines
Baker27 found that secondary amines react with (1.20) in an SN2 fashion. He 
isolated various p-substituted benzylmethylamine /V-glycosides. He used two 
equivalents of amine; one to undergo the substitution reaction and the second to 
form the HBr salt of the second equivalent of amine in situ.
We utilised this chemistry and carried out the same procedure with both (1.6) and 
(1.20) and methyl-N-benzylamine (scheme 4.7.6). The HBr salt of the amine is 
insoluble in diethyl ether and can be filtered off from the reaction mixture. The 
glucose derivative (4.62) was isolated by re-crystallisation in 29 % yield; the 
glucuronic acid derivative (4.63) proved more troublesome and re-crystallisation 
was not possible. Purification of the GA series could probably be achieved by
column chromatography, with some hydrolysis. Purification was not carried out
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due to stability worries at the time of carrying out these reactions. Both series gave 
only the P-product by NMR analysis, suggesting that the reaction proceeds via Sn2 
with no mutarotation.
Scheme 4.7.6: Reaction conditions from Baker27 to form tertiary anomeric amines in 
the glucose and glucuronic acid series
Drug Examples using Anomeric Bromide in the Glucose and Glucuronic Acid Series
Following the promising result using N-methlbenzylamine, we moved on to look at 
Nortriptyline (4.64) and Desipramine (4.65) (figure 4.7.7) (the des-methyl versions 
of Amitriptyline and Imipramine respectively). Our ultimate aim was to synthesise 
examples of drug A/+-glucuronides.
(4.64) (4.65) (4.66)
Figure 4.7.7: Nortriptyline, Desipramine and acetylated desipramine
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Most N-methylated tertiary amino drugs which we were interested in are 
commercially available as their des-methyl derivative, but demethylation can be 
achieved using the Olofson reaction42 (scheme 4.7.8).
Scheme 4.7.8: The Olofson reaction to form secondary amines from tertiary amines
with a simple alkyl group
Nortriptyline
The conditions used for the reaction of (1.6) and (1.20) with methyl-/\/-benzylamine 
(scheme 4.7.6) did not give product when using Nortriptyline (4.64) (scheme 4.7.9). 
LCMS and NMR analysis showed that elimination was taking place (scheme 4.7.9), 
but no substitution was observed. As Nortriptyline (4.64) is poorly soluble in 
diethylether, we were limited to using DCM as the solvent for the reaction. The 
reaction carried out using methyl-A/-benzylamine is favourable due to the 
insolubility of the methyl-/V-benzylamine.HBr, which drives the equilibrium of the 
reaction to the desired product.
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R = COzMe (1.6) or 
CH2OAc (1.20)
Scheme 4.7.9
Again, we had problems with the E2 side reaction due to the basic nature of 
nortriptyline.
We then tried similar conditions to those developed by Bognar et al.26 who added 
10 % w/v sodium hydroxide to the reaction mixture (scheme 4.7.4, pg 102). We 
used a mixture of acetone and DCM as solvent for solubility reasons. This improved 
the reaction and we were able to isolate the desired products (4.67) and (4.68) in 
15 % and 22 % yield (scheme 4.7.10). We looked at other bases such as 10 % w/v 
sodium bicarbonate and 10 % w/v sodium carbonate; the latter gave slightly 
improved yields in both the glucose and GA series. Column chromatography was 
used to purify the compounds, and we isolated products (4.67) and (4.68) in low 
yield (17 % for the GA series and 29 % for the glucose series).
NMR analysis of the crude reaction mixture suggested elimination of the bromine 
was occurring, as well as hydrolysis in both series. We also saw significant amounts 
of starting materials remaining in both reactions. We suspect that hydrolysis on the 
silica during column chromatography reduced our yields further.
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R = C 02Me (1.6)
R = CH2OAc (1.20)
(4.67) R = C 0 2Me, 17 % Yield
(4.68) R = CH2OAc, 29 % Yield 
Scheme 4.7.10
Desipramine
The reaction of desipramine (4.65) under neutral conditions with the bromo-sugar 
in the glucose series (1.20) gave some product but in low yields as shown by NMR of 
the reaction mixture. The major component of this reaction was the acetylated 
desipramine (4.66) (figure 4.7.7). The mechanism by which acetylation occurs is 
thought to be acid catalysed (scheme 4.7.11).
Scheme 4.7.11: Possible mechanism for the amide formation
The reaction was then carried out with 10 % w/v Na2C03(aq) added to the reaction;
this reduced the amount of acetylated desipramine (4.66) generated, giving the
product (4.69) in 16 % yield after purification (scheme 4.7.12) (preparative HPLC
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was required to remove the E2 by-product). This suggests that the hydrobromic 
acid from the initial substitution reaction was catalysing amide formation (scheme 
4.7.11) when no base was present.
(4.65)
10% w/v Na2COj 
DCM/Acetone
R = C 0 2Me (1.6)
R = CH2OAc (1.20)
Scheme 4.7.12
AcO
Br
(4.69) R = CH2OAc, 16 % Yield
The reaction of desipramine (4.65) and the glucuronic acid bromosugar, (1.6) 
showed little product (4.70) by LCMS, even when using 10 % w/v Na2C03(aq) in the 
reaction. The main component isolated from the reaction was the acetylated 
desipramine (4.66) (figure 4.7.11). This could be due to the slower reactivity of the 
glucuronic acid series compared to the glucose series; the glucose series is known to 
be more reactive at the anomeric position43.
To eliminate the amide formation we then looked at a more hindered protected 
sugar (4.71)44 (scheme 4.7.13). We chose isobutyrate ester protecting groups, as 
we believed that deprotection could still be achieved under mild conditions. 
Although amide formation was not observed during our investigations, our yields 
(~19 %) were not improved to any extent due to the other by-products (elimination, 
hydrolysis). It was also difficult to fully remove the eliminated by-product from the 
desired product.
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iPrCO.O
iPrCO.O
(4.71)
Br
10 % Na2C 03 (aq) 
Acetone/DCM
(35C)
iPrCO.O
iPrCO.O
(4.72) 19 % yield
Scheme 4.7.13
The labile nature of the intermediate products on silica gel (4.67) and (4.68) was 
shown by TLC. Samples of pure isolated product (4.67) and (4.68) were loaded onto 
a TLC plate that was left for one hour before running. This showed the parent 
nortriptyline (4.64) and the respective 1-hydroxy sugars (4.73) and (4.61) (figure 
4.7.14). We investigated the use of alumina for purification, but this proved to be 
unsuitable as the resolution was very poor.
Figure 4.7.14: Product from hydrolysis during the reaction and purification
The successful reaction of p-toluidine with bromo-glucose (1.20) and glucuronic acid 
derivative (1.6), compared to unsuccessful reactions with alkyl amines (Nortriptyline
(4.64) and Desipramine (4.65)) is thought to be due to p-toluidine being a weaker 
base, therefore reducing the elimination mechanism. Stability of the product is also 
a factor; it is generally believed that sugar-aniline derivatives are more stable again, 
due to the lower basicity of the nitrogen.45
(4.61) (4.73)
Summary
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Quaternisation of the Nitrogen to form Quaternary Ammonium Salts
Once the Nortriptylme-A/-Glucoside/glucuromde (4.67, 4.68) were isolated, reaction 
with a methyl electrophile was required to form the quaternary ammonium salt. 
Nortriptyline-ZV-glucoside (4.68) proved troublesome. We used methyl iodide as the 
electrophile and carried out the reaction in dry acetonitrile. The reaction was 
followed by LCMS and after 6 hours there were no signs of product, but the parent 
amine could be seen suggesting hydrolysis (scheme 4.7.15). It is probable that the 
methyl iodide used had catalytic traces of H+ and H2 O that could cause hydrolysis. 
We then distilled methyl iodide and carried out the reaction with this neutral source 
but found no reaction occurred (scheme 4.7.15).
Methyliodide was also used in the attempted quaternisation of Nortriptyline-W- 
glucuronide (4.67). There was no reaction and no hydrolysis seen, showing how 
much more robust to mild acidic conditions the glucuronide series is compared to 
the glucose series (scheme 4.7.15).
CH3NR = Nortriptyline (4.67)
Scheme 4.7.15: Reactions of (4.68) and (4.67) with mildly acidic methyl iodide
We then looked at the reaction of methyl triflate with the GA series intermediate
(4.67). The initial experiment was carried out at 40°C but the reaction proceeds just
as efficiently at room temperature (scheme 4.7.16). Attempted recrystallisation of
110
(4.73)
CH3NR = Nortriptyline (4.68)
Chapter Four: N-Glucuronides and N-Glucosides
the crude solid resulted in decomposition. The product (4.75) was isolated by 
column chromatography and eluted in 10 % IPA/DCM giving the product in 21 % 
yield.
Scheme 4.7.16: Conditions for quaternisation of (4.67) with methyltriflate
We wanted to probe the reactivity of the nitrogen to see if we could use a less 
reactive methyl electrophile than methyl triflate. We investigated methyl tosylate 
and methyl nosylate (figure 4.7.17) in an attempt to quaternise (4.67), but found 
that neither gave us the desired product.
O
II
, 0 - i i
\\ // -NO,
Methyl nosylate
Figure 4.7.17
As our yields were unsatisfactory during the investigations of anomeric bromides 
we wished to investigate alternative anomeric leaving groups with the aim of 
reducing or eliminating the undesired E2 reaction.
Anomeric Sulphonates and their Reaction with Tertiary Amines
We decided to investigate anomeric sulphonate leaving groups in the glucose series, 
hoping that the more reactive glucose series would give us direct quaternisation of 
a tertiary amine.
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Leaving groups can determine the mechanism of a reaction, and it is thought that 
tosylate leaving groups favour SN2 over E240. We first looked at the anomeric 
mesylate (4.76), in the glucose series. Our first attempts to synthesise the mesylate 
sugar employed pyridine as base and methanesulfonyl chloride (scheme 4.7.18).
(4.76) (4.77)
Scheme 4.7.18: Attempted synthesis of the mesylate sugar
This reaction proved unsuccessful; we reasoned that once the mesylate sugar was 
formed, pyridine acted as a nucleophile and generated the pyridinium-A/+- 
Glucuronide (4.77) (scheme 4.7.18). Mass spectrometry (MS) and NMR analysis 
suggested that the a-chlorosugar had also been isolated by column 
chromatography.
The synthesis of mesylate sugars has been carried out in the past by Leroux et o/.46 
who used the mesylate sugar (4.76) to generate the anomeric bromo-sugar in situ. 
They used 2,3,6-collidine as base, which is non-nucleophilic, and methanesulfonic 
anhydride, which does not generate any nucleophilic counter ions.
We were able to isolate both the tosylate (4.78) and mesylate sugars (4.76) as the 
pure a-anomer using the same reaction conditions as Leroux (scheme 4.7.19).
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R = (4.76) Ms, 29 % Yield 
(4.78) Ts, 22 % Yield
Scheme 4.7.19: Reaction conditions to synthesise the anomeric sulfonates
The mesylate sugar (4.76) was then reacted with Amitriptyline (4.54), in acetonitrile 
for 5d at room temperature. Analysis of the crude reaction by NMR showed that the 
mesylate sugar had hydrolysed to the hemiacetal (4.73) (figure 4.7.20).
The tosylate sugar (4.78) also hydrolysed and gave no desired product (scheme 
4.7.20). We saw no elimination of the sulphonate sugars as we had seen with the 
halide sugars which seemed promising.
Scheme 4.7.20
Since we looked at using anomeric sulphonates, Araya et a!.47 published their work 
on the synthesis of A/+-Glucuronides using 2,3,4-tri-O-benzoyl-l-methanesulfonyl-a- 
D-glucopyranuronate (4.79) (scheme 4.7.21).
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Scheme 4.7.21
Although they were successful In their synthesis when using pyridine derivatives, 
imidazole derivatives, isoquinoline and 1-methylbenzimidazole, they were 
unsuccessful when using primary, secondary and tertiary amines (figure 4.7.22). 
They state that the reaction gave complex mixtures, agreeing with our findings.
Figure 4.7.22: Amines used during the reaction with the mesylate sugar that gave
complex mixtures
1,2-An hydrosugars (epoxides) and their Reaction with Tertiary Amines.
Due to the labile nature of the sulfonate sugars we decided to look at 1,2- 
anhydrosugars. We knew that there was no possibility for elimination using an 
epoxide, and hoped that the strained epoxide ring would open readily when 
reacting with a tertiary amine.
Epoxides are known to react well in substitution reactions with nucleophiles, and 
using them should eradicate the problem of elimination. Halcomb and 
Danishefsky48 have used epoxides in their work predominately to make glycosides 
(scheme 4.7.23).
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Scheme 4.7.23: Reaction carried out by Halcomb and Danishefsky48 to synthesise
glycosides from epoxide sugars
The commercially available starting material, 3,4,6-tri-O-acetyl-D-glucal (4.80) and 
dimethyldioxirane were used to make the 1,2-anhydro sugar following the 
procedure of Cheshev et al.49. Dimethydioxirane (DMDO) was generated from 
acetone, water, NaHCC>3 and Oxone. The DMDO was then distilled from the reaction 
flask as a solution in acetone and then added to a solution of (4.80) in DCM, giving 
quantitative formation of (4.81) (scheme 4.7.24). The formation of the epoxide was 
followed by TLC, and was used without any purification.
0 —0
Scheme 4.7.24: Reaction conditions to make the 1,2-anhydro sugar
The epoxide (4.81) was then reacted with Amitriptyline (4.54) (2 eq) in the presence 
of ZnCI2 (1M in Et20) (leq). On analysis by NMR it appeared that the Amitriptyline 
had not reacted with the epoxide. We were only able to isolate the hydrolysed 
sugar (4.82) from the reaction (scheme 4.7.25) and we suspected the presence of 
polysaccharides from the initial NMR analysis.
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ZnCI2
Am itriptyline
DCM
Scheme 4.7.25
Changing protecting groups
We then decided to look again at the direct quaternisation of tertiary amines with 
anomeric halides, but with a change of protecting group. Up to this point we had 
only looked at ester protecting groups that are known to be electron withdrawing. 
We hoped that by changing to a more electron donating group that we would 
render the 2-H less acidic, and we could limit the elimination reaction. The other 
advantage of using more donating protecting groups is that they enhance the 
reactivity of C l in substitution reactions.
Nicolaou et al.50 used the benzyl protected glycosyl fluoride (4.83) in the SN2 
reaction with morpholine. They used MgBr2.Et20 , which they claim forms the more 
reactive glycosyl bromine (4.84) in situ (scheme 4.7.26). It is possible that the 
activated benzyl protected sugars are more susceptible to the SN2 reaction, and as 
they state, the bromosugar (4.84), if formed is extremely reactive in this series. 
Benzyl protected glucose are termed the 'armed' series, whereas acetylated sugars 
are termed the 'disarmed' series due to their electron donating or withdrawing 
effects respectively51.
Scheme 4.7.26: Proposed intermediate from the reaction carried out by Nicolaou et
al.
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From the commercially available 2,3,4,6-tetra-O-benzyl glucopyranoside (4.85) we 
synthesised the cholorosugar (4.86) and the mesylate sugar (4.87), (scheme 4.7.27) 
although the mesylate sugar seemed quite unstable. The bromosugar (4.84) in this 
series is so unstable that it cannot be isolated, but only reacted immediately.
(4.85)
2,3,6-Collidine
M s20 , DCM
(4.87)
Scheme 4.7.27
NMR analysis of the crude material before reaction suggested the presence of the 
a-mesylate sugar (4.87) (~60 % by NMR integration). We decided that due to the 
suspected instability of the mesylate sugar, we would use it immediately without 
purification in the reaction with morpholine. Analysis of the reaction by NMR was 
difficult to interpret due to overlap of protons. By TLC there appeared to be no 
reaction; knowing more about the nature of the compounds this could have been 
due to hydrolysis of the product on silica gel. We analysed the reaction by mass 
spectrometry, which gave no indication of product. We therefore decided that 
using the more stable chloro-sugar (4.86) would be a better option, as this could be 
easily isolated and characterised.
Reaction of the chlorosugar (4.86) with amines, morpholine and N- 
methylmorpholine, again resulted in no desired product being isolated from the 
reactions (scheme 4.7.28). Upon column chromatography, only the chlorosugar
(4.86) and hemiacetal (4.85) were isolated.
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Due to the literature evidence suggesting the labile nature of (4.88) under acidic 
conditions, we thought that it was possible that product (4.88) was forming, but 
hydrolysing in the presence of hydrochloric acid generated in situ. We then carried 
out the reaction with piperidine, but used two equivalents in the hope that the 
second equivalent would form piperidine.HCI (scheme 4.7.28). On analysis of the 
reaction by NMR we suspected that the desired product had formed. We saw no 
evidence for elimination during the reaction. Purification by column 
chromatography was avoided due to the suspected labile nature of the product. 
The crude reaction mixture was taken and reacted with methyl triflate to form the 
quaternary ammonium salt (4.89) (scheme 4.7.28). This was then purified by 
column chromatography and isolated in 38 % yield.
(4.86)
OBn
(4.88)
H-N,
1) 2 eq
DCM, RT
2) MeOTf, DCM RT
Scheme 4.7.28
We then decided to change our direction and look at introducing nitrogen to the 
anomeric position via azides which have been synthesised previously.
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Anomeric Azides
Azides are known in both the glucuronic acid52 and glucose series53,54. The 
azidosugar in the GA series can also be synthesised from the glucose series by 
oxidising the primary alcohol to the carboxylic acid using TEMPO catalysed 
oxidation55.
We found that using Tin (IV) chloride in catalytic amounts and azidotrimethylsilane 
as the azide donor, we could convert the anomeric ester to azide in both the 
glucuronic acid (4.90) and glucose series (4.91) (scheme 4.7.29). We also tried 
Titanium chloride as a milder Lewis acid but this gave no product.
R = CH2OAc (4.91) 98 %yield 
C 0 2Me (4.90) 67 % yield
Scheme 4.7.29: Mechanism in the synthesis of the 3-azidosugar
The glucose intermediate (4.91) can then be reduced using palladium catalysed 
hydrogenation56,57,58 (scheme 4.7.30). Parekh et al.59 used Pd/C, H2 with ethanol as 
solvent in the reduction of galactose azide. Esteves et al.60 carried out the 
reduction of the glycosyl azide (4.91) using ethyl acetate and methanol as solvent 
with no purification. We found that recrystallisation could be carried out using 
ethanol.
R
AcO
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The azidoglucuronide (4.90) can also be reduced to give the aminoglucuronide
(4.92) as has been previously reported by Pitt et al.52 (scheme 4.7.30). We modified 
their reaction slightly by using MeOH/ethyl acetate (as with the glucose series
(4.93) ) in place of THF.
R
AcO
n 3
Pd/C, H. 
EtOAc, MeOH
R = CH2OAc (4.91) 
C 0 2Me (4.90)
R = CH2OAc (4.93) 99 % yield 
COzMe (4.92) 35 % yield
Scheme 4.7.30: Reduction conditions
The next step in the sequence is a reductive /V-dimethylation. Initial reactions were 
performed using acidic conditions such as; Eschweiller-Clarke reductive amination 
using paraformaldehyde and acetic acid, Pd/C hydrogenation with formic acid and 
paraformaldehyde, and sodium cyanoborohydride under acidic conditions in the 
presence of paraformaldehyde. All of these reactions gave no dimethylamino sugar
(4.94), only hydrolysis. We tried NaCNBH3 under neutral conditions in the presence 
of 37 % aq formaldehyde, NMR and MS suggested that we had reduced the ¡mine 
formed in situ (scheme 4.7.31), yielding an acyclic amine (4.95).
Scheme 4.7.31: Possible mechanism of reaction with Sodium cyanoborohydride
We carried out the reductive amination under neutral conditions using, 37 % aq 
formaldehyde, Pd/C and H2 to give the dimethylamino sugar (4.94) in the glucose
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series (scheme 4.7.32). The yield was variable (40-92 %) due to hydrolysis on silica 
gel during purification. This reaction suggests that it was the acidic conditions in 
previous reactions that were not tolerated.
Scheme 4.7.32: Conditions used for the reductive A/-dimethylation in the glucose
series
These conditions did not work for the glucuronic acid series (4.92). None of the by­
products were isolated, and NMR was difficult to interpret. It could be due to the 
amino group being less reactive in the glucuronic acid series (4.92). The methyl 
ester, with its electron withdrawing properties may have reduced the ability of the 
amino group to react with the formaldehyde.
Quaternisation Reaction of Dimethylamino Sugar to form Quaternary Ammonium 
Salts.
Synthesis of quaternary ammonium salts via a quaternisation reaction of (4.94) with 
electrophiles was carried out. We were able to successfully quaternise (4.94) with 
methyl iodide, benzyl bromide and allyl bromide to give (4.96), (4.97), and (4.98) 
respectively (scheme 4.7.33).
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A*.
AcO
RX
MeCN, 50°C
(4.94)
1) Na2CO, 
MeOH
2) Amberlite 
H+-resin
RX = Mel
Benzyl bromide 
Allyl bromide
R = methyl (4.96) 51 % yield 
benzyl (4.97) 64 % yield 
allyl (4.98)
Scheme 4.7.33
We had concerns about the stability of the products during deprotection as it has 
been reported that such quaternary ammonium compounds are able to form 
anhydro sugars in the presence of strong base61. The acetate protecting groups 
were removed using sodium carbonate in methanol (scheme 4.7.33) to give (4.99), 
(4.100) and (4.101) with no degradation (scheme 4.7.34). A simple workup was 
required for the final step; we found amberlite H+ resin could be used to quench the 
reaction. The advantage of the resin was that it could be filtered off leaving just the 
product in solution.
Figure 4.7.34
This was enabling work to try to prepare Amitriptyline-A/+-Glucoside (4.102) and 
related drug like products, by quaternisation with the respective electrophile of the 
side chain (scheme 4.7.35). No success has been obtained with this pathway, 
despite trying several different leaving groups, side chain and solvents (table 4.7.36)
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(4.94) (4.102)
Scheme 4.7.35: Theoretical quaternisation step to form the protected Amitriptyline
A/+-Glucoside
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It appears that the nitrogen on the sugar is not reactive enough to form a 
quaternary salt with electrophiles which are less reactive than methyl iodide and 
benzyl bromide.
Our next step was to remove the electron withdrawing acetate protecting groups to 
try to improve the nucleophilicity of the nitrogen. Triethylamine in methanol was 
tried first, but this gave us no success. We next looked at sodium methoxide 
directly in methanol and this gave us the desired product (4.108) (scheme 4.7.37).
AcO
(4.94)
NaOMe
MeOH
(4.108)
Scheme 4.7.37
We made chlorpromazine (4.103) (table 4.7.36) a focus of the work, and we 
attempted to react the chloro-derivative (4.104) (table 4.7.36) (scheme 4.7.38). A 
Finkelstein reaction62 was used to generate the iodo in situ, as there were concerns 
on the stability of the iodo-derivative (4.106) (table 4.7.36) from previous reactions.
Scheme 4.7.38: Conditions for the in situ Finkelstein reaction and quaternisation
reaction
Again this reaction gave us no quaternary ammonium salt. The chlorpromazine 
derivative appeared to decompose under these conditions. There were also 
concerns about the stability of (4.108). The free hydroxy groups potentially mean
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that the Amadori rearrangement could occur (scheme 4.7.39). It is difficult to 
determine if the Amadori rearrangement had occurred due to the complicated NMR 
spectrum.
Scheme 4.7.39: Potential Amadori rearranged products
We decided that this route was not worth pursuing and moved on to look at the 
reaction of free sugars with primary and secondary amines.
Crystal Structure Data, and its relation to the Anomeric Effect
As discussed in the introduction (p 26), the anomeric effect is a well accepted 
phenomenon. On the other hand, the reverse anomeric effect is very much 
debated and its existence had been questioned.
During the synthesis of the trimethyl ammonium glucoside, we were able to 
crystallise both the protected (4.96) and deprotected (4.99) products, giving us 
information on the bond lengths of the two species (figure 4.7.40). The anomeric C- 
N+ bond length found in (4.96) is 1.523 A and the deprotected species (4.99) has a 
bond length of 1.522 A which are the same giving experimental error (± 0.005 A). 
These bond lengths are consistent with those found in a trimethyl ammonium 
group attached to a secondary carbon, with the substructure Me3N+-CHR2 (R = 
alkyl), where the N+-C bond is found to be 1.537 A (± 0.008 A).
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Figure 4.4.40: Crystal structures of (4.99) and (4.96)
The Me3N+ group can only act as an o-acceptor, so that n0-o*C-o donation can only 
affect the exocycllc bond. It Is believed that sterlcally It Is more favourable for such 
quaternary ammonium salts to adopt the 3-conflguration, and that this effect is 
predominant over the anomerlc effect.
Ideally a crystal structure of the a-trlmethylammonlum glucoside (figure 4.7.41) 
could give insight as to whether such compounds behave as expected, adhering to 
the anomeric effect. If we saw a lengthening of the exocyclic C-N+CH3 bond, this 
would suggest that the anomerlc effect exists with such compounds, and would give 
more evidence to the fact that the reverse anomeric effect does not exist.
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4.7 Results and Discussions Part II: the Synthesis of N*-Giucuronides and 
Glucosides
The Reaction of Secondary Amines with Glucose
It is known that a direct reaction of glucose with piperidine will give N- 
Glucosylpiperidine (4.111)20'63. We have confirmed this reaction, and conducted 
further investigations with other cyclic secondary amines; morpholine, N- 
methylpiperazine and pyrrolidine to give (4.112), (4.113) and (4.114) respectively 
(figure 4.9.1). There are many drugs that contain morpholine, piperidine, 
piperazine and pyrrolidine structural elements, and all are potential candidates for 
/V-glucuronidation.
Figure 4.9.1: Cyclic amine glycosides
An acetylation of the free hydroxyl groups was carried out on amines (4.111), 
(4.112) and (4.113) using acetic anhydride and pyridine as solvent. An attempted 
quaternisation reaction was carried out on the piperidine derivative (4.115) using 
methyl iodide. We found that this methyl iodide did not react with the 
intermediate (4.115). We then looked at using methyl triflate, and were able to 
successfully quaternise (4.115) (scheme 4.9.2). We then tried to quaternise the 
morpholine derivative (4.116), but found that methyl triflate did not react, showing 
the less reactive nature of the morpholine nitrogen.
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Scheme 4.9.2
A deprotection was then carried out on (4.116) using sodium methoxide (scheme 
4.9.3) to give (4.117). We found that using our previous method of Na2C03 and 
methanol gave no deprotection
NaOMe 
MeOH
(4.117)
Scheme 4.9.3
We also looked at the reaction of glucose with aqueous dimethylamine (scheme 
4.9.4). Once we had carried out the condensation reaction, NMR analysis showed 
the presence of some remaining glucose together with the P-anomeric product 
(4.118). We then acetylated any free hydroxyl groups using acetic anhydride and 
pyridine (scheme 4.9.4). This gave us the dimethylamino sugar (4.94) in 19 % yield, 
compared to the earlier azide route which gives a yield of 39 % over three steps.
AcO
(4.118) (4.94)
19 % overall yield
Scheme 4.9.4: Reaction conditions to form (4.94) in two steps
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Secondary Amine, Nortriptyline in the Reaction with the Hemiacetal 6-O-Trityl 
Glucose
We needed an organic soluble source of glucose to use in our reactions with more 
lipophilic secondary amines. We chose 6-O-trityl glucose (4.119) as a stable 
crystalline compound which is easy to prepare from glucose and trityl chloride in 
the presence of pyridine.
Initially we took trityl glucose (4.119) and Nortriptyline (4.64) and heated them 
together at 120°C in toluene. NMR analysis suggested that we had formed the 
Amadori rearranged product (4.120) (scheme 4.9.5). The pyranose ring 
characteristics were no longer present; there appears to be a mixture of isomers, 
giving rise to two sets of triplets at 5.7-5.8 ppm for the nortriptyline olefenic proton 
of each isomer. The spectrum also shows two singlets at 2.32 ppm and 2.33 ppm 
accounting for the NCH3  protons. In the desired product we see the NCH3 signal 
further downfield at 2.4 ppm. The NMR is complex due to the nature of 
nortriptyline (4.64) giving rise to broad signals, but all of these characteristics led us 
to believe the presence of (4.120).
Scheme 4.9.5: Amadori rearranged product (4.120) formed at 120°C and product
from Mel quaternisation (4.121)
Further confirmation that the rearranged species had formed was that the 
quaternisation reaction used methyl iodide which contained traces of acid and 
water. The desired product hydrolyses in the presence of acid, but the Amadori
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rearranged product (4.120) is able to react forming the quaternary ammonium salt 
(4.121).
Under milder conditions using DCM as solvent at room temperature, Nortriptyline
(4.64) undergoes the desired condensation reaction with 6-O-trityl glucose (4.119) 
to give pure 3-anomer (scheme 4.9.6). Column chromatography was used to purify 
this intermediate (4.122), but again we found significant hydrolysis occurred on the 
silica gel which lowered our yields to 49 % (from crude NMR analysis yield ~80 %). 
Quaternisation of (4.122) was not possible due to reaction of the 2,3,4-OH groups 
with methyl triflate. We then protected the hydroxy groups by acetylation to give 
(4.123) in 79 % yield, and were then able to quaternise (4.123) with methyl triflate. 
During this step we saw removal of the trityl group that we presume is via trace acid 
hydrolysis. Purification of (4.124) was carried out by rapid column chromatography, 
hydrolysis of the aglycone occurred during the process lowering our yields to 59 %.
-OTf
(4.123) (4.124)
CHjNHR = Nortriptyline (4.64)
Scheme 4.9.6: Reaction Conditions to form the quaternary ammonium salt (4.124)
Having removed the 6-O-trityl group, oxidation of the primary alcohol to the 
carboxylic acid would take us through to the glucuronic acid series (4.125) (scheme 
4.9.7). We looked at various conditions for this step and eventually found that 
BAIB, and TEMPO in MeCN/H20 gave us the desired product with some over­
oxidation of the amitriptyline portion (4.126) (scheme 4.9.7). Epp et al. used similar 
conditions to oxidise 5'-hydroxymethylene of nucleosides to 5'-carboxylates64.
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Previous attempts had involved the use of TEMPO and harsh oxidising reagents e.g. 
NaOCI, under basic conditions which we believe caused hydrolysis of the aglycone. 
We were limited in the oxidants we could use due to the double bond present in 
the aglycone (4.54).
1) BAIB, TEMPO 
MeCN/H20  (1:1)
2) 10 % w/v Na2C 03 
MeOH
Scheme 4.9.7: Oxidation then hydrolysis of (4.124) giving the desired product 
(4.125) plus by-products (4.126) and (4.127)
We were able to analyse the BAIB, TEMPO reaction by LCMS carried out by James 
Maggs from the Department of Pharmacology. He found that the reaction mixture 
contained both Amitriptyline /V+-Glucoside (4.127) (peak II m/z 440 LCMS 4.9.8) and 
Amitriptyline A/+-Glucuronide (4.125) (peak I m/z 454 LCMS 4.9.8) (scheme 4.9.7). 
There was evidence for the presence of a by-product due to over oxidation, 
presumably epoxidation of the double bond as well as oxidation of the primary 
alcohol (4.126) (peak A m/z 470 LCMS 4.9.8) (scheme 4.9.7).
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Amitrlp N-gluc LI47-G-1 acn[2Q-45%, 20min]-FA
LI47-5-1
U24
11-Sep-2008 
19:22:34
Scan ES+
Figure 4.9.8: LCMS trace and respective MS data collected by James Maggs of The 
University of Liverpool. Peak A, (4.126). Peak I, (4.125). Peak II, (4.127).
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Summary
We wanted to fully evaluate the condensation reaction in the glucose series, as we 
believed that the glucose series would be more reactive than the GA series during 
these reactions. This route gave us access to higher yields (scheme 4.9.6) (20 % 
over four steps) of quaternary ammonium salts of drug examples, which up until 
this point had not been achieved successfully using the nucleophilic substitution 
route (scheme 4.7.10 and scheme 4.7.12) (0.04 % over two steps). We wanted to 
find an oxidation method that would be compatible with Amitriptyline (4.54), but 
unfortunately we were not successful. This method would be suitable for a 
quaternary ammonium salt which contains no functional groups capable of being 
oxidised under the conditions used. It is still a viable means for the synthesis of N+- 
Glucuronides.
________Chapter_Four: N-Glucuronides and N-GIucosides
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The Reaction of Secondary Amines with Glucuronic Acid
The reaction of aliphatic primary amines and the sodium salt of glucuronic acid is 
known.19 Takitani et al.19 used the sodium salt of glucuronic acid in preference to 
glucuronic acid itself as they found that not only did the amine react at the 
anomeric centre, but it also formed a salt with the carboxylic acid moiety.
We reacted piperidine and glucuronic acid and obtained the desired 3-product 
(4.128.A). Measured by NMR intergration and elemental analysis it appeared that 
piperidine had undergone the condensation reaction and had also formed the salt 
at the carboxylic acid. By NMR analysis it appeared that there was another product 
which we suspected to be due to Amadori rearrangement (4.128.B). The glucose 
equivalent gives only the 3-W-glycosyl piperidine (4.111) (scheme 4.9.1). The NMR 
spectrum shows an integration of 50:50 3-pi'oduct and suspected rearranged 
product. The second product does not show the usual coupling pattern that a 
pyranose sugar generally gives, but we know that it also contains two piperidine 
molecules, and gives the same elemental analysis as the 3-product.
Reaction of glucuronic acid with morpholine and pyrrolidine proved to be very 
exothermic; NMR suggested that possible side reactions had occured. On standing 
for 16 hours in DMSO, the NMR spectrum showed an increase in the suspected 
rearranged product (4.128.B). The formation of the rearranged product is probably 
due to acid catalysation, by glucuronic acid.
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(4.128.B)
Scheme 4.9.9: Products formed during reaction of piperidine and Glucuronic acid
Secondary Amines in the Reaction with the Hemiacetal in the GA Series
To avoid having to carry out a separate oxidation step we show in this section that 
the same condensation reaction carried out with 6-O-trityl glucose (4.119) and 
Nortriptyline (4.64) can be applied to the glucuronic acid series (4.129) (scheme 
4.9.10).
The isobutyrate protected hemiacetal (4.129) is used as the sugar source. Starting 
from the commercially available glucurono-3,6-lactone the hemiacetal (4.129) can 
be synthesised in two steps with an overall yield of 45 % (scheme 4.9.10). It is a 
more stable intermediate than anomeric sugar halides and can be stored in a 
desiccator for at least 6 months without any decomposition. We chose the 
isobutyrate protecting groups as a result of our earlier investigations. When using 
the acetate protected bromosugar (1.6), we found that acetylation of the amine 
occurred (scheme 4.7.11, p. 107). We saw no evidence of the secondary amines 
used reacting with the methyl ester to form the amide.
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1) NEt3, MeOH
2) iPrCOCI, py, 
DCM, 40°C
iPrCO.O 
iPrCO.O
iPrCO.O
n 2h4.h 2o
AcOH, DMF
Scheme 4.9.10
iPrCO.O 
iPrCO.O
iPrCO.O C
(4.129)
Nortriptyline (4.64) and Desipramine (4.65) react readily with (4.129) (scheme 
4.9.11). This method gives selectively the 3-anomer, thought to be due to steric 
effects.
1) (4.64) or (4.65)
iPrCO.O
iPrCO.O
¡PirCO.O
(4.129)
C02Me 
O
nOH
Toluene, 50°C
2) Ac2 0, py
3) MeOTf, DCM
CO,Me
iPrCO.O 
iPrCO.OiPrCO.O
-OTf
(4.130) (CH3)2NR = Amitriptyline
(4.131) (CH3)2NR = Imipramine
Scheme 4.9.11
We then carry out an acetylation reaction of any remaining amine (4.64 or 4.65) 
and hemiacetal (4.129). Reaction of these two species with methyl triflate in the 
next step would generate triflic acid, which could potentially cause hydrolysis of the 
intermediate (4.132) (scheme 4.9.12).
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M eOTf
TfOH
M eOTf
CO,Me
¡PrCO.O 
¡PrCO.O
iPrCO.O OMe
CO,Me
iPrCO.O
iPrCO.O
iPrCO.O OH
TfOH
(4.132) (4.129)
Scheme 4.9.12: The side reactions that could occur in the presence of triflic acid
The quaternisation with methyl triflate is then carried out under the same 
conditions used in the glucose series (scheme 4.9.11). We were able to isolate the 
intermediates (4.130) and (4.131) (scheme 4.9.11) by filtering the crude reaction 
mixture through a pad of silica gel. This was carried out efficiently to avoid 
hydrolysis of the aglycone. At this stage the intermediates had a purity of ~80 %. 
The next step was to remove the O-isobutyryl and methyl ester protecting groups, 
this is achieved using 1M NaOH or 1M LiOH in MeOH to give (4.133) and (4.134) 
(scheme 4.9.13) (see later for a full discussion on the deprotection step).
CO,Me
¡PrCO.O 
iPrCO.O
iPrCO.O
V
-OTf
1M NaOH, or LiOH 
MeOH, -10°C
(CH3)2NR = Amitriptyline (4.130) 
Imipramine (4.131)
(CH3)2NR = Amitriptyline (4.133) 
Imipramine (4.134)
Scheme 4.9.13
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Formation of an l\P-Glucuronide currently being investigated by AstraZeneca
We looked at forming the /V+-Glucuronide of a drug currently being investigated by 
AstraZeneca. The suspected /V+-Glucuronide formation is via the N- 
methylpiperidine (4.135) (scheme 4.4.14). Our strategy to form the A/+-Glucuronide 
was to react the hemiacetal with the des-methyl derivative (4.136), then carry out 
the acetylation and quaternisation as previously done (scheme 4.9.14).
Scheme 4.9.14
We were able to form the intermediate (4.135) in 23 % yield. We then tried to 
deprotect the isobutyrate groups to form the final product. The conditions we tried 
are summarised in table 4.9.15. Unfortunately we were unable to remove the 
isobutyrate protecting groups, the reason for this is unclear.
Base Equivalents Solvent
10 % w/v Na2C03 (aq) 4 MeOH
1M NaOH 4 MeOH
1M NaOH 8 MeOH
Table 4.9.15
To overcome the problem we changed the O-isobutyryl groups to O-acetyl 
protecting groups (4.61) (scheme 4.9.16). We had avoided using acetate groups 
due to previous investigations where we saw significant acetylation of Desipramine 
(scheme 4.7.11).
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The condensation reaction was carried out and there was no evidence for 
acetylation of the amine. The protection of unreacted amine (4.136) and 
hemiacetal (4.61) was carried out by acetylation as in previous examples. 
Quaternisation of the piperidine nitrogen was done in the usual way with methyl 
triflate to give (4.137) (14 % yield) (scheme 4.9.16). The deprotection was 
unsuccessful in this series, using 10 % w/v Na2C03 (aq) in MeOH (scheme 4.9.14). 
We isolated from the reaction glucuronic acid and the parent drug, showing 
hydrolysis of the glycosidic bond during deprotection.
(4.138)
Scheme 4.9.16
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N-substituted Pyrrolidine N*-Giucuronide
We found that (4.129) reacts well with cyclic secondary amines such as pyrrolidine 
to give (4.139) (scheme 4.9.17). This is not surprising since it is known that 
secondary amines (e.g. piperidine) and primary amines react with glucose and 
glucuronic acid respectively to form the A/-Glucosides//V-Glucuronides. NMR 
analysis of this reaction shows 100 % yield of the product (4.139), and requires no 
further purification and no acetylation.
(4 -1 2 9 ) (4 .1 3 9 )
Scheme 4.9.17: i) Pyrrolidine 1.4eq, Toluene, 50°C, 100 % yield
We looked at quaternisation with (4.140), to show that the quaternisation step 
would work for electrophiles other than methyl. Reaction of (4.139) with (4.140) 
gave us the desired quaternary ammonium A/+-glucuronide (scheme 4.9.18). This 
was then deprotected as a crude mixture using 10 % w/v Na2C03(aq) giving (4.141) 
in a yield of 11 % after preparative HPLC (scheme 4.9.18).
iPrCO.O
CO,M e
iPrCO.O  
iPrCO.O
iPrCO.O OH
yield
Formation of (4.140) was achieved by taking the primary alcohol and reacting this 
with 2,3,6-collidine and trifluoromethanesulfonic anhydride at 0°C in DCM (scheme
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4.9.19). Due to high solubility of 2,3,6-collidine.HCI in DCM we used diethyl ether 
during extraction.
Scheme 4.9.19
Primary triflate (4.140) was used for optimisation studies for more complex 
compounds that we wished to look at later. We knew that the compounds had 
limited solubility, so we needed to avoid using 2,3,6-collidine that forms a salt 
soluble in DCM. We looked at alternatives; pyridine gave some product but in lower 
yield (27 % cf 37 %), due to the reaction of pyridine with the formed primary 
triflate. Another base used was 2,6-lutidine, but surprisingly this gave us very low 
yields (8 %).
Discussion of the Deprotection Step
The final step in the sequence is the deprotection of the methyl and isobutyrate 
esters to give the zwitterionic A/+-glucuronide. The conditions used are dependent 
on the stability of the aglycone under basic conditions. During base hydrolysis to 
remove the isobutyrate esters two by-products can form; the aglycone can be 
liberated (pathway B scheme 4.9.20) or elimination of the 4-isobutyrate can result 
(pathway A scheme 4.9.20).
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A
+
Scheme 4.9.20: A: 10 % w/v Na2C03, MeOH, B: 1M LiOH or NaOH, MeOH -10°C
We found that the conditions to minimise both by-products were dependent on the 
aglycone. For both (4.130) and (4.131) either 1M NaOH or 1M LiOH were used. 
Although we observed hydrolysis yielding the aglycone (~30 % hydrolysis) (pathway 
B, scheme 4.9.20), the elimination of the 4-isobutyrate was not observed during the 
course of the reaction. When we used 10 % w/v Na2C03; we found that the major 
by-product was from elimination of the 4-isobutyrate (4.142) accounting for ~30 % 
of the reaction mixture (pathway A scheme 4.9.20). This proved more difficult to 
remove from the final product.
The 1M NaOH or 1M LiOH conditions could not be used for (4.141), due to the 
enhanced lability of the glycosidic bond (scheme 4.9.21). Using such bases gave up 
to 80 % hydrolysis of the quaternary ammonium in preference to the protecting 
group ester hydrolysis.
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NaOH or LiOH
MeOH, -10°C
C 0 2Me
iPrCO.O
iPrCO.O
iPrCO.O OH
Scheme 4.9.21
The optimal conditions for deprotection of (4.141) were found when using 10 % w/v 
Na2C03 and methanol as solvent. The by-product formed from elimination of the 4- 
isobutyrate was (4.143) (~30 %) (figure 4.9.22), but hydrolysis of the glycosidic bond 
was completely avoided.
Figure 4.9.22: By-product formed during isobutyrate deprotection with 1M NaOH
The Reaction of Primary amines with the Hemiacetal in the GA Series
We also wanted to look at approaches that could form the pyrrolidine ring in an 
intramolecular fashion. To optimise this reaction we took benzylamine and the 
protected hemiacetal (4.129) under the same conditions as previously investigated 
(scheme 4.9.23). This reaction gave us the desired product (4.144) in 100 % yield, 
measured by NMR analysis.
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Ph
50°C
(4.129) (4.144) 100 % yield
Scheme 4.9.23: Reaction conditions for the condensation between benzylamine and
the hemiacetal.
We then wanted to bis-alkylate the nitrogen with 1,4-butane ditriflate (4.145), 
involving an intramolecular quaternisation.
Beard et al.65 have previously synthesised 1,4-butaneditriflate from THF and 
trifluoromethanesulfonic anhydride. We were able to isolate 1,4-butane ditriflate 
as a crystalline solid and use it in the proposed reaction (scheme 4.9.24).
CO,Me
iPrCO.O
iPrCO.O
H2N 'Ph CO,Me
iPrCO.O OH Toluene
iPrCO.O
iPrCO.O
iPrCO.O
Scheme 4.9.24: Reaction conditions for the alkylation followed by intramolecular
quaternisation
We carried out this reaction in the presence of 2,6-lutidine to neutralise the triflic 
acid generated in situ from the initial alkylation reaction. 2,6-Lutidine was chosen 
as it is a hindered, non-nucleophilic base and would therefore avoid any possible 
reaction with the 1,4-butaneditriflate (4.145). The reaction was heated to 50°C for 
24hrs. After removal of the solvent the residue was filtered through a pad of silica 
which was eluted with 100 % ethyl acetate, followed by 10 % Ethanol/DCM with the 
intermediate (4.146) eluting in the latter. NMR showed product present with some 
impurities (~ 20 %) remaining at this stage. Further purification was carried out 
using column chromatography, but the intermediate (4.146) hydrolysed during the 
process showing the labile and unstable nature of this compound.
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We then looked at replacing benzylamine with 2-phenylethylamine, we hoped that 
this would be more reactive. The same conditions for the condensation reaction 
were used to form (4.147) (scheme 4.9.25). We then carried out the alkylation and 
intramolecular quaternisation under the same conditions as with (4.144). The 
intermediate (4.148) was filtered through a pad of silica gel, at this stage the 
compound was ~ 70 % pure. The intermediate did not appear to be very stable so it 
was decided that deprotection would be carried out with no further purification.
CO,Me
iPrCO.O
iPrCO.O
H2N '
iPrCO.O OH
CO,M e
Toluene
50°C
iPrCO.O
iPrCO.O
iPrCO.O
(4.147) 100 % yield
Deprotection of the isobutyryl and methyl ester groups was achieved using 10 % 
w/v Na2 C0 3 (aq) (scheme 4.9.26). It was thought that the compound would be 
similar to the previous pyrrolidinium compound (4.141) with respect to lability. 
Analysis of the crude reaction mixture by NMR showed the presence of the 
eliminated by-product (4.149) (~20 %). The compound was purified by preparative 
TLC to give the product (4.150) in 10 % yield with purity of ~80 %.
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10 % Na2C 0 3(aq) 
MeOH
+
-  20 %
(4.149)
Scheme 4.9.26
4.8 Conclusions and future work
During our initial investigations we looked at various sugars activated at the 
anomeric position to directly quaternise the tertiary amine, Amitriptyline. We 
found that the substitution reaction did not proceed, but the E2 reaction was 
significant. Despite trying to drive the reaction to the substitution product we were 
unable to form the desired quaternary ammonium species. The use of secondary 
amines appeared more promising, but poor yields ensued.
We then looked at the formation of quaternary ammonium glucosides. We hoped 
to optimise our route, and potentially oxidise the glucose derivative to give the 
glucuronic acid derivative. We were able to form protected quaternary ammonium 
glucosides in three steps. We found that in general only a trifluoromethane 
sulfonate leaving group would suffice during the quaternisation step. The oxidation 
gave some desired product, but due to the nature of the aglycone, Amitriptyline, we 
were unable to selectively oxidise the primary alcohol.
We have now found a synthetic route into quaternary ammonium glucuronides via 
the condensation reaction between secondary or primary amines and the
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hemiacetal. As well as using methyl triflate we have been able to synthesise other 
primary triflates and use them in the quaternlsatlon reaction successfully.
Deprotection of O-acetyl groups was carried out using Na2 C0 3  in MeOH to give 
mainly the product. When deprotecting the 2,3,4-isobutyryl protected sugar, the 4- 
O-isobutyrate is able to act as a leaving group and undergoes an elimination 
reaction. Significant 4-O-isobutyryl elimination occurs when using Na2C0 3 . When 
using NaOH or LiOH we see no elimination, but we do see hydrolysis of the aglycone 
occurring.
We have been able to learn more about the reactivity and stability of /V+- 
glucuronides during synthesis. The stability of the compounds that have been 
investigated varies significantly with respect to both purification on silica gel and 
base deprotection. From my experience of the compounds the order of stability is 
depicted in figure 4.9.27.
Figure 4.9.27: Quaternary ammonium compounds in order of stability, starting with
the least stable
From previous investigations of quaternisation reactions with methyl iodide and 
methyl triflate, it would appear that for direct quaternisation of a tertiary amine 
anomeric triflate would be most suitable. Crich et al.66 have used anomeric triflates
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to synthesise 3-mannosylpyranosides. They designed experiments in order to form 
either ex-linked pyranosides or 3-linked pyranosides. To form the 3-glycosidic bond 
they took mannosyl sulfoxide and reacted it with Tf2 <D in the presence of 2 ,6 -di-tert- 
butyl-4-methylpyridine, then finally they add the reacting alcohol. This forms the a- 
triflate, which is then reacted with an alcohol to give a 3 -configured bond (scheme 
5.1.1). To form the more accessible a-manoside the reacting alcohol is added at the 
start of the reaction.
To form the anomeric triflate, the reactions must be carried out at -78°C in order 
for stability of the triflate intermediate. They also note the requirement for a non­
participating protecting group in the 2- and 3- positions.
Scheme 5.1.1: Reaction conditions used by Crich et al.66 to form anomeric triflate
intermediates.
This seems a promising route into quaternary ammonium glucuronides, and should 
be investigated in a future project.
OTf OR
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5.1 Experimental
Moisture sensitive reactions were carried out in anhydrous organic solvents, under 
a nitrogen atmosphere. For all glucuronide intermediates and products, vacuum 
rotary evaporation was carried out at <35°C.
1H NMR and 13C NMR were recorded on a Bruker AMX 400 (400 MHz- aH and 100 
MHz- 1 3 C) spectrometer. Chemical shifts (6 ) are quoted in ppm and coupling 
constants (J) are quoted in Hertz (Hz).
Mass spectrometry was carried out on a VG analytical 7070E machine and Fisons 
TRIO spectrometer, using electron ionisation (El) and chemical ionisation (Cl); a 
Micromass LCT spectrometer was used for HRMS in the electrospray mode, carried 
out by Mr. Alan Mills of The University of Liverpool.
Elemental analysis was performed by Mr. Steve Apter of The University of Liverpool 
using a Thermo Flash EA1112 analyzer, configured for automated elemental 
analysis.
Infrared spectra were recorded on a Perkin-Elmer 1000 spectrometer or a FTIR- 
4100 type A instrument in the range of 600-4000cm_1. Samples were prepared as a 
nujol mull onto NaCI discs and absorption peaks quoted in wavenumbers (cm 1) or 
prepared as neat solids on the FTIR-4100 instrument.
Melting points were recorded using a Bibby-Sterlin Stuart SMP3 melting point 
apparatus.
Thin layer chromatography was carried out using Merck 5x2 cm aluminium backed 
plates with a 0.2mm layer of Kieselgel 60 F2 5 4 . They were visualised by UV lamp 
(254nm) and anisaldehyde stain were appropriate. Flash column chromatography 
was carried out using ICN (230-400 mesh) silica gel. Reverse phase chromatography
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was carried out using LiChroprep RP-18 Ci8  silica gel prepared by washing with 
methanol then water. The solvent used to elute was an increasing gradient of 
acetonitrile in water.
Preparative HPLC was carried out on a Agilent Technologies 1200 Series Preparative 
HPLC System, fitted with a Waters XBridge Prep C18 5um (19 x 10mm Guard 
cartridge) and a Waters XBridge Prep C18 5um OBD (19 x 100mm) column using a 
neutral gradient of acetonitrile:water.
LCMS was carried out by James Maggs of the department of Pharmacology. LCMS 
was carried out at room temperature on a Beckman Ultrasphere 5-pm C18 column 
(250 x 4.6 mm i.d.; Beckman Coulter, High Wycombe, Buckinghamshire, U.K.) by 
gradient elution with acetonitrile (20-45%, v/v, over 20 min) in 0.1% (v/v) formic 
acid. The eluent flow rate was 0.9 mL/min. Solid materials were dissolved in 
acetonitrile-water (2 :1 , v/v) at room temperature, and aliquots of solutions ( 1 0  pi) 
were injected onto the HPLC column without further treatment. The LC system 
consists of two Jasco PU980 pumps (Jasco UK, Great Dunmow, Essex, UK) and a 
Jasco HG-980-30 mixing module. Eluted compounds were monitored at 254 nm 
with a Jasco UV-975 spectrophotometer. Eluate split-flow to the LC-MS interface 
was co. 40 pL/min. A Quattro II mass spectrometer (Waters Corp, Manchester, UK) 
fitted with the standard co-axial electrospray source was operated using nitrogen as 
the nebulizing and drying gas. The interface temperature was 80 °C; electrospray 
capillary voltage, 3.8 kV; standard cone voltage, 30 V; cone voltage for in-source 
fragmentation of analytes, 65 V. The instrument was set up for full-scanning 
acquisitions in the positive-ion mode as follows: m/z 50-1050 with a scan time of 5 s 
and an inter-scan delay of 100 ms. Instrument management and data processing 
were accomplished through MassLynx 3.5 software.
Optical rotations ([a]D) were carried out on a PerkinElmer polarimeter 343 at a 
wavelength of 598 nm at 20°C. Solvents and concentrations used are quoted.
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5.21-^-0-Acyl Glucuronides
-Synthesis of substituted benzyl ester glucuronates 
- Using the polymer bound fluoride
X= N 02 (2.44), MeO (2.49)
To a solution of Glucuronic acid (2g, 10.31 mmol) in DMF (20 ml) at RT under N2 was 
added the polymer bound fluoride (5.2g, 15.46 mmol) followed by the substituted 
benzyl bromide (11.34 mmol). The reaction was left for 24h at RT, after this time 
the polymer bound fluoride was filtered off and the DMF removed under high 
vacuum. Column chromatography was carried out eluting with 10-20 % EtOH/DCM.
p-Nitrobenzyl glucuronate (2.44)
Yield: 67 %. Mp: 125-126°C. [M+Na]+ m/z 352.0634; Ci3 Hi5 N09Na requires m/z 
352.0645.
1H NMR 6 h d6-Acetone (1:1 a/P mixture): 3.19-3.25 (1H, dd, 2p-H, J = 7.7, 9.2 Hz), 
3.39-3.48 (2H, dd, 2a-H J = 3.6, 9.1 Hz, t, 3a-H J = 9.1 Hz), 3.65-3.72 (3H, t, 4a-H J =
9.1 Hz, t, 4P-H, t, 33-H), 3.96-4.00 (1H, d, 5a-H, J = 9.8 Hz), 4.40-4.43 (1H, d, 53-H J =
9.4 Hz), 4.60-4.64 (1H, d, lp-H, J = 7.8 Hz), 5.19-5.22 (1H, d, la-H  J = 3.6 Hz), 5.38­
5.40 (4H, 2 x s, C0 2CtU), 7.71-7.74 (4H, dd, a/p-ArH), 8.24-8.27 (4H, dd, a/P-ArH). 
13C NMR 6 C d6 -Acetone: 66.0, 66.1, 70.2, 73.2, 73.3, 73.5, 73.7, 74.6, 76.3, 77.1, 
77.7, 78.8, 79.9, 84.8, 94.5, 99.2, 124.5, 124.7, 128.2, 129.6, 145.2, 170.7. m/z (ESI, 
+ve ion mode) 352 [MNa]+, 100 %.
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p-Methoxybenzyl glucuronate (2.49)
Yield: 58 %. Found: C, 51.9; H, 5.6 %; [M+Na]+ m/z, 337.0905. Ci 4 Hi 8 0 8. 0.5.H2O 
requires C, 52.0; H, 5.9 %; Ci4 Hi8 0 8Na requires m/z, 337.0899.
1H NMR 6 h d6-Acetone (1:1 a/P mixture): 3.22 (1 H, m, 2P-H), 3.35-3.45 (2 H, m, 2a- 
H, 3p-H), 3.65 (2 H, H-4 a and P, J = 9.0 Hz), 3.73 (1 H, t, 3a-H, J = 8.9 Hz), 3.86 (1 H, 
d, H-5p, J = 9.8 Hz), 4.31 (1 H, 5a-H, J = 9.3 Hz), 4.57 (1 H, d, H-lp, J = 7.7 Hz), 5.10­
5.20 (4 H, ArCH20 a and P), 5.17 (1 H, d, H-la, J = 3.1 Hz), 6.95 and 7.36 ( 8  H, 
approx, dd, ArH).
13C NMR 6 C de-Acetone: 56.0, 56.3, 67.2, 67.3, 73.2, 73.3, 73.6, 74.5, 76.2, 77.2, 
94.3, 99.0, 115.1, 115.7, 129.3, 129.4, 131.1, 131.2, 136.1, 161.1, 162.7, 170.2 and
171.0. m/z (ES, +ve ion mode) 337 [MNa]+, 100 %.
-Using tetra-n-butylammonium fluoride (TBAF)
OMe
A solution of Glucuronic acid (2g, 10.31 mmol) in DMF (20 ml) was stirred at RT 
under N2, TBAF (10.84 ml, 10.31 mmol) was added and the reaction left stirring for 
lh . To this was added p-methoxybenzyl bromide (1.56 ml, 11.34 mmol) to the 
reaction and the solution left for a further 16h. The DMF was then removed in 
vacuo. Column chromatography was carried out using 10-20 % IPA/DCM. The foam 
was re-crystallised from warmed DCM, with the addition of ether on cooling.
p-Methoxybenzyl glucuronate (2.49)
Yield: 72 %. data agrees with previous synthesis
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6.2.2 -General coupling method using HATU
To a solution of Glucuronate ester (2.44 or 2.49) (0.32 mmol) in acetonitrile (4 ml) 
was added, HATU (133 mg, 0.35 mmol), carboxylic acid (0.35 mmol) and NMM (0.07 
ml, 0.64 mmol), the reaction was then left stirred at RT under N2 for 3-4 hrs 
monitored by TLC. The reaction was then quenched with Amberlite IR-120 H+ ion­
exchange resin (337 mg, 0.64 mmol), until pH 6-7 was reached. The resin was then 
filtered off and the acetonitrile removed in vacuo. Column chromatography was 
used to purify, eluting with 5-10 % IPA/DCM.
p-Nitrobenzyl l-(a-methyl-4-isobutylphenyl)acetyl-$-D-glucopyranuronate (2.57)
Yield: 32%
Mp: 141-142°C. Found: C, 60.43, H, 6.09, N, 2.66 %; [M+Na]+ m/z, 540.1862. 
C2 6 H3 iNOio requires C, 60.34 H, 6.03, N, 2.71 %; C2 6 H3 iNOi0Na requires m/z 
540.1846
*H NMR 6 h d6  Acetone: 0.83-0.89 (6 H, d, CH(CH3)2), 1.43-1.47 (3H, d, CHCH3J = 7.2 
Hz), 1.75-1.89 (1H, m, CH(CH3)2), 2.4-2.6 (2H, d, CH2CH J = 7.2 Hz), 3.28-3.35 (1H, t,
2-H, J = 8.7, 8.3 Hz), 3.83-3.50 (1H, t, 3-H, J = 8.9 Hz), 3.51-3.59 (1H, t, 4-H, J = 9.1 
Hz), 3.65-3.75 (1H, q, CHCH3, J = 7.1 Hz), 3.98-4.10 (1H, d, 5-H J = 9.2 Hz), 5.20-5.25
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(2H, AB qt, C0 2CH2 J = 13.9 Hz), 5.48-5.53 (1H, d, 1-H J = 8.1 Hz), 7.05-7.16 (2H, d, 
ArH), 7.20-7.31 (2H, d, ArH), 7.59-7.66 (2H, d, ArH), 8.16-8.22 (2H, d, ArH)
13C NMR 6 C d6 -Acetone: 19.5, 19.8, 23.0, 45.8, 45.9, 66.2, 73.0, 73.9, 77.4, 77.6,
96.0, 124.9, 128.4, 129.5, 130.3, 138.9, 141.6, 144.9, 148.9, 169.2, 174.1; m/z (ES, 
+ve ion mode) 540 (M+Na+), 100 %.
p-Nitrobenzyl l-(4-chlorobenzoyl)-$-D-glucopyranuronate (2.46)
Yield: 44%
Found [M+Na]+ m/z 490.0517 C2oHi8 NOio35CINa requires m/z 490.0497 
XH NMR 6 h de-Acetone: 3.50-3.62 (2H, m, 2-H, 3-H), 3.63-3.71 (1H, m, 4-H), 4.10­
4.13 (1H, d, 5-H, J = 9.6 Hz), 4.53 (1H, broad s, OH), 4.62 (1H, broad s, OH), 4.76 (1H, 
broad s, OH), 5.21-5.25 (2H, d, C0 2 CH2), 5.70-5.74 (1H, d, 1-H, J=7.6 Hz), 7.40-7.44 
(2H, d, ArH), 7.53-7.58 (2H, d, ArH), 7.91-7.96 (2H, d, ArH), 8.04-8.09 (2H, d, ArH).
13C NMR 6 C de-Acetone: 66.3, 73.1, 73.9, 77.3, 77.5, 96.5,129.4,129.7, 130.1, 130.3,
132.7,132.8,144.8,149.0,165.1,169.3. m/z (ES, +ve ion mode) 490 [M+Na]+ 100 %
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p-Nitrobenzyl l-(4-methylbenzoyl)-$-D-glucopyranuronate (2.59)
Yield: 52 %. Found: [M+Na]+ m/z 470.1053; C, 56.2, H, 4.78, N, 3.09 %; C2 iH 2 iO10NNa 
requires m/z 470.1063; C2 i H2 i Oi 0N requires C, 56.4, H, 4.73, N, 3.13 %.
1H NMR 6 h ds-Acetone: 2.42 (3H, s, ArCH3), 3.64-3.73 (2H, t, 2-H, J = 7.9 Hz, t, 3-H, J 
= 8.9 Hz), 3.77-3.81 (1H, t, 4-H, J = 9.1 Hz), 4.24-4.26 (1H, d, 5-H, J = 9.6 Hz), 5.37­
5.39 (2H, AB qt, CH2Ar), 5.84-5.86 (1H, d, 1-H, J = 7.8 Hz), 7.32-7.37 (2H, d, ArH), 
7.69-7.72 (2H, d, ArH), 7.96-8.01 (2H, d, ArH), 8.20-8.23 (2H, d, ArH).
13C NMR 6 C d6 -Acetone: 20.8, 65.2, 71.9, 72.8, 76.3, 76.3, 95.0, 113.8, 123.5, 126.8,
128.4,129.7,130.0,143.7,144.6,164.7,168.1. m/z (ES +ve ion mode) 470 100 %.
p-Nitrobenzyl l-(a-methylphenyl)acetyl-(i-D-glucopyranuronate (2.60)
Yield: 50 %, Reaction started with ('S^-2-phenylpropanoic acid, racemisation occurs 
in situ; it is presumed that the major component is the fSj-isomer. 
Diastereoisomers not separated.
Found [M+Na]+ m/z 484.120; C2 2 H2 3 NOi0Na requires m/z 484.122.
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1H NMR 6 h d6 -Acetone ratio R/S-isomers 1:4:1.43-1.45 (3H, d, R-isomer CHiCFU), J =
7.1 Hz), 1.46-1.48 (3H, d, S-isomer CHiCHa), J = 7.1 Hz), 3.42-3.46 (1H, t, R and S- 
isomer 2-H, J = 8.7, 8.2 Hz), 3.58-3.62 (1H, t, R and S-isomer 3-H, J = 9.0 Hz), 3.64­
3.69 (1H, t, R and S-isomer 4-H, J = 9.0 Hz), 3.70-3.75 (1H, q, R-isomer CH(CH3)), 
3.83-3.88 (1H, q, S-isomer CH(CH3), J = 7.1 Hz), 4.11-4.14 (1H, d, R and S-isomer 5-H,
J = 9.4 Hz), 5.30-4.40 (2H, AB qt, R and S-isomer CH2Ar), 5.62-5.64 (1H, d, R and S- 
isomer 1-H, J = 8.2 Hz), 7.27-7.36 (5H, m, ArH), 7.65-7.67 (2H, d, ArH), 8.20-8.22 (2H, 
d, ArH).
13C NMR 6 C d6 -Acetone: 19.5, 19.7, 46.2, 46.3, 66.2, 73.0, 73.8, 77.4, 77.4, 95.9, 
124.7, 128.3, 129.8, 129.5, 129.8, 141.6, 144.9, 148.9, 169.2, 173.9. m/z (ES +ve ion 
mode) 484 100 %.
p-Methoxybenzyl l-(4-bromobenzoyl)-$-D-glucopyranuronate (2.61)
Yield: 45 %
Found: C, 50.55, H, 4.29 %; [M+Na]+ m/z 519.0259. C2 iH 2 i0 979Br requires C, 50.72, 
H, 4.25 %; C2 iH 2 iOg79BrNa requires m/z 519.0267.
*H NMR 6 h de-Acetone: 3.40-3.54 (2H, m, 2-H, 3-H), 3.56-3.62 (1H, m, 4-H), 3.61­
3.66 (3H, s, OCH3), 3.97-4.01 (1H, d, 5-H, J = 9.5 Hz), 4.96-5.01 (2H, AB qt, C0 2 CH2), 
5.65-5.69 (1H, d, 1-H, J=7.8 Hz), 6.73-6.78 (2H, m, ArH), 7.16-7.22 (2H, m, ArH), 
7.56-7.61 (2H, m, ArH), 7.83-7.88 (2H, m, ArH).
13C NMR 6 C de-Acetone: 55.1, 66.7, 72.2, 73.1, 76.5, 76.8, 95.6, 114.2, 128.2, 128.5,
129.0,130.4,131.9,132.3,145.2, 164.3, 168.5. m/z (ES, +ve ion mode) 519 [M+Na]+ 
100 %.
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p-Methoxybenzyl l-(4-chlorobenzoyl)-$-D-glucopyranuronate (2.62)
Yield: 55%
Mp: 182-183°C. Found: [M+Na]+ m/z 475.0755 C2 iH 2 i0 935ClNa requires m/z 
475.0772
XH NMR 6 h de-Acetone: 3.62-3.69 (2H, m, 2-H, 3-H), 3.73-3.78 (1H, m, 4-H), 3.79 (3H, 
s, 0CH3), 4.13-4.17 (1-H, d, 5-H, J = 9.5 Hz), 5.14 (2H, s, OCHz), 5.82-5.84 (1H, d, 1-H, 
J = 7.9 Hz), 6.89-6.93 (2H, m, ArH), 7.33-7.37 (2H, m, ArH), 7.58-7.61 (2H, m, ArH), 
8.08-8.11 (2H, m, ArH)
13C NMR 6 C de-Acetone: 55.9, 67.6, 73.0, 73.9, 77.3, 77.6, 96.1, 115.0, 115.7, 128.0,
129.1, 130.5, 131.1, 131.3, 135.9, 165.8, 169.5. m/z (ES +ve ion mode) 475 [M+Na]+ 
100 %.
p-Methoxybenzyl l-(4-methylbenzoyl)-$-D-glucopyranuronate (2.63)
Me
Yield: 45%
Found: C, 58.44 %, H, 5.54 %; [M+Na] m/z 455.133. C2 2 H2 4 0 9 .H20 requires C, 58.66 
%, H, 5.81 %, C2 2 H2 4 0 9Na requires m/z 455.132.
*H NMR 6 h d6 -Acetone: 2.39 (3H, s, CCH3), 3.47-3.52 (2H, m, 2-H, 3-H), 3.55-3.64 
(1H, m, 4-H), 3.74 (3H, s OCH3), 3.99-4.01 (1H, d, 5-H, J = 9.4 Hz), 4.97-5.00 (2H, AB
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qt, OCH2), 5.65-5.68 (1H, d, 1-H, J = 8.0 Hz), 6.74-6.78 (2H, d, ArH), 7.17-7.22 (4H, d, 
ArH), 7.81-7.84 (2H, d, ArH).
13C NMR 6 C de-DMSO: 21.5, 55.4, 66.5, 71.6, 72.4, 75.6, 76.3, 95.0, 114.2, 126.4, 
127.8, 129.7, 130.0, 130.3, 144.7, 159.6, 164.8, 168.7. m/z (ES +ve ion mode) 455 
[M+Na]+ 100 %.
p-Methoxybenzyl l-(2-phenyl)acetyl-$-D-glucopyranuronate (2.64)
Yield: 55 %.
Found: C, 60.35, H, 5.7 %; [M+Na]+ m/z, 455.1321. C2 2 H2 4 O9 .O.5 H2 O requires C, 59.9, 
H, 5.7 %; C2 2 H24 0 9Na requires m/z, 455.1318.
XH NMR 6 h ds-Acetone: 3.32 (1 H, t, 2-H, J = 8.5 Hz), 3.43 (1 H, t, 3-H, J = 9.0 Hz), 
3.54 (1 H, t, 4-H, J = 9.3 Hz), 3.60 (2 H, s, PhCH2 CO), 3.66 (3 H, s, CH3 0), 3.88 (1 H, d, 
5-H, J = 9.7 Hz), 5.10-5.18 (2 H, AB qt, ArCH2 0), 5.58-5.60 (1H, d, 1-H, J = 8.1 Hz), 
6.77 and 7.20 (4 H, dd, ArH of PMB ester) and 7.10-7.20 (5 H, m, ArH of PhCH2).
13C NMR 6 C d6 -Acetone: 41.5, 56.0, 67.6, 73.1, 73.9, 77.6 (x2), 96.0, 115.1, 128.2,
129.2, 129.6, 130.7, 131.2, 135.2, 161.1, 169.4, 171.1. m/z (ES +ve mode) 455 
[MNa]+, 100%.
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6.2.3 -Deprotection using hydrogenation of the PNB group under acidic conditions.
To a solution of p-nitrobenzyl protected AG ((2.46) or (2.47)) (0.3 mmol) In 
¡PrOH/THF (3 ml) (2:1) was added, Pd/C (64 mg, 20 mol %) and Amberlite IR-120 H+ 
ion exchange resin (631 mg, 1.2 mmol). The reaction was then left stirring for 30 
mins at RT under H2 (g). The Pd/C was then filtered off onto a pad of cellite and the 
solvent removed in vacuo. The residue was then triturated with DCM.
l-(4-chlorobenzoyl)-$-D-glucopyranuronic acid1
Yield: 94%
[a]25D = -25.00 (c = 0.008 gml' 1 in acetone). Found [M-H] m/z 331.0221 Ci 3 Hi 2 0 835CI 
requires m/z 331.0226
JH NMR 6 h de-Acetone: 3.61-3.76 (3H, m, 2-H, 3-H, 4-H), 4.07-4.12 (1H, d, 5-H, J =
9.5 Hz), 5.81-5.84 (1H, d, 1-H, J = 7.9 Hz), 7.72-7.76 (2H, m, ArH), 7.99-8.04 (2H, m, 
ArH).
13C NMR 6 C ds-Acetone: 72.9, 73.8, 77.1, 77.4, 96.4, 129.4, 129.9, 132.8, 133.2,
165.1,170.2. m/z (ES -ve ion mode) 331 [M-H]‘ 100 %.
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l-((S)-a-methyl-4-isobutylphenyl)acetyl-$-D-glucopyranuronic acid1 (2.54)
Yield: 78 %
Found [M-H]" m/z 381.1559 CigH^Og requires m/z 381.1549 
*H NMR 6 h de-Acetone: 0.85-0.91 (6 H, d, CH(CH3)2), 1.43-1.48 (3H, d, CHCHs, J= 7.0 
Hz), 1.77-1.90 (1H, m, CH(CH3)2), 2.43-2.47 (2H, d, CH2 CH, J =7.0 Hz), 3.41-3.48 (1H, 
t, 2-H, J = 8.3 Hz), 3.55-3.68 (2H, t, 3-H, J = 8.7 Hz, t, 4-H, J = 9.1 Hz), 3.78-3.85 (1H, 
q, CHCH3, J = 7.2 Hz), 3.94-3.99 (1H, d, 5-H J = 9.3 Hz), 5.58-5.61 (1H, d, 1-H, J = 8.0 
Hz), 7.08-7.13 (2H, d, ArH), 7.21-7.26 (2H, d, ArH).
13C NMR 6 c d6 -Acetone: 18.6, 21.9, 30.1, 38.2, 45.5, 71.8, 72.6, 75.9, 76.4, 94.7, 
125.2,127.4,129.3,137.8,140.4,172.9. m/z (ES -ve ion mode) 381 [M-H]" 100 %.
Deprotection of the PMB group using acid hydrolysis.
To the PMB ester (91 mg, 0.21 mmol) was added a solution of 10 % TFA (90 % in 
water) in DCM (0.91 ml) at 0°C, and the reaction left for 30mins to 3h depending on 
the AG (monitored by TLC). The reaction solvent was then removed in vacuo, and 
the residue triturated with DCM.
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l-(4-bromobenzoyl)-$-D-glucopyranuronic acid1 (2.57)
Yield: 52%
Found: C 41.70, H 3.63 %; [M-H] m/z 374.9723. Ci3 H1 3 0 8Br requires C 41.40, H 3.47 
%; C i3 Hi2 0 879Br requires m/z 374.9716
*H NMR 6 h de-Acetone: 3.60-3.76 (3H, m, 2-H, 3-H, 4-H), 4.08-4.13 (1H, d, 5-H J = 9.3 
Hz), 5.81-5.84 (1H, d, 1-H, J = 7.6 Hz), 7.72-7.77 (2H, d, ArH), 7.99-8.04 (2H, d, ArH). 
13C NMR 6 C d6 -Acetone: 72.9, 73.8, 77.1, 77.4, 96.4, 129.4, 129.9, 132.8, 133.1,
160.5,170.2. m/z (ES, -ve ion mode) 375, [M-H] 100 %.
l-(4-methylbenzoyl)-$-D-glucopyranuronic acid1 (2.53)
Yield: 90%
Mp: 168-169°C. Found: [M-H] m/z 311.0769; C, 53.63, H, 5.29 %. C1 4 Hi5 0 8  requires 
m/z 311.0767; Ci4 H1 60 8  requires C, 53.85, H, 5.16 %.
XH NMR 6 h de-Acetone: 2.42 (3H, s, ArCH3), 3.60-3.80 (3H, m, 2-H, 3-H, 4-H), 4.08­
3.97-4.11 (1H, d, 5-H, J = 9.5 Hz), 5.81-5.83 (1H, d, 1-H, J = 8.0 Hz), 7.18-7.22 (2H, d, 
ArH), 7.81-7.87 (2H, d, ArH).
13C NMR 6 C de-Acetone: 22.0, 73.0, 73.9, 77.1, 77.6, 96.1,126.4,128.1,130.9, 131.1, 
165.8,170.4. m/z (ES, -ve ion mode) 311 [M-H] 100 %.
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l-(2-phenyl)acetyl-$-D-glucopyranuronate2(2.55)
Yield: 82%
Found [M-H]" m/z 311.0767 Ci4 H1 5 0 8  requires m/z 311.0761.
XH NMR 6 h d6 -Acetone: 3.32-3.38 (1H, t, 2-H J = 9.1 Hz), 3.43-3.50 (1H, t, 3-H, J = 9.3 
Hz), 3.52-3.59 (1H, t, 4-H J = 9.5 Hz) 3.61 (2H, s, CH2), 3.83-3.88 (1H, d, 5-H, J = 9.5 
Hz), 5.45-5.51 (1H, d, 1-H, J = 8.0 Hz), 7.15-7.20 (5H, m, ArH).
13C NMR 6 C de-Acetone: 41.5, 72.9, 73.8, 77.1, 77.6, 95.9,128.2,129.5,130.8,135.2,
170.4,171.2. m/z (ES -ve ion mode) 311 [M-H]' 100 %.
6.2.4 -Other Coupling reagents 
-Pentafluorophenyl diphenylphosphinate (2.62)
F
F 
O
II
Ph^Vo
Ph
F
Diphenylphosphinic chloride (2.99 ml, 15.7 mmol) was added to a solution of 
pentafluorophenol (2.89 g, 15.7 mmol) in DCM (30ml). A solution of imidazole (1.07 
g, 15.7 mmol) in DCM was then added dropwise to the reaction at RT, the reaction 
was then left for lh. The imidazole salt was then filtered off and the filtrate 
concentrated in vacuo. A column was run using 20-40 % EtOAc/Hexane. The 
product was then stored in a desiccator for 2  weeks to give a white solid3.
31P {H} NMR d6 -Acetone: 37.528ppm
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The synthesis of acid fluorides
2-Phenylacetyl fluoride (2.77f
A solution of DCM (2ml) and phenyl acetic acid (48 mg, 0.35 mmol) was cooled to - 
20°C. Pyridine (0.032 ml, 0.39 mmol) was added to the stirring solution followed by 
cyanuric fluoride (0.1 ml, 0.78 mmol)5. The reaction was allowed to reach -10°C, 
and left stirring for 2h. The reaction was diluted with DCM (10 ml); this was then 
extracted with water (3 x 10 ml). The DCM layer was then dried over MgS04  and 
concentrated to ~2 ml.
IR vmax (cm 1) (nujol mull): 1844.8 (s, C=0 stretch), 1456 (s, aromatic C=C stretch),
1077.9 (s, C-0 stretch).
Coupling method using acid fluorides.
p-Methoxybenzyl l-(2-phenyl)acetyl-6-D-glucopyranuronate (2.64)
A solution of PMB glucuronate (100 mg, 0.32 mmol) in acetonitrile (2 ml) was 
cooled to -10°C and evacuated with N2. To this was added the NMM (0.035 ml, 0.32 
mmol), followed by the acid fluoride (0.93 ml, (0.35M in DCM) 0.32 mmol). The
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reaction was left for 6.5h at -10°C and then the solvent was removed in vacuo. 
Column chromatography was carried out using 5-10 % EtOH/DCM.
Yield 31 %, data as before with previous HATU coupling method (p. 172).
5.3 The synthesis of Acyl glucosides
-Coupling method using HATU
To a solution of 6 -O-trityl glucose6  (300 mg, 0.71 mmol) in MeCN ( 8  ml) was added 
HATU (298 mg, 0.78 mmol), and the respective carboxylic acid (0.78 mmol). The 
reaction was then flushed with N2 and the NMM (0.16 ml, 1.42 mmol) added whilst 
stirring at RT. After 4hrs of stirring at RT the reaction was quenched with the 
addition of Amberlite H+resin (747 mg, 1.42 mmol) for 30 mins. The resin was then 
filtered off and washed with MeCN. The solvent was then removed in vacuo and the 
residue purified by column chromatography using 5 % EtOH/DCM.
N.B. For the 2-phenyl propionoic acid derivative we used the racemic acid, and 
separated the diastereoisomers by chromatography. The a-dimethyl substituted 
carboxylic acid required a longer reaction time (16 hrs).
o
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6-O-Trityl l-(2-phenyl)-acetyl-(i-D-glucopyranose (3.14)
Yield: 55 %
Found: [M+Na]+m/z 563.205 C3 3 H3 2 0 7Na requires m/z 563.204.
XH NMR 6h CD3CN: 3.12-3.16 (1H, dd, 6-H, J = 10.2, 5.7 Hz), 3.22-3.25 (1H, dd, 6-H', J 
= 10.2, 2.0 Hz), 3.34-3.38 (2H, m, 2-H, 4-H), 3.53-3.55 (2H, m, 3-H, 5-H), 3.77 (2H, s, 
CH2Ph), 5.49-5.51 (1H, d, 1-H, J = 7.8 Hz), 7.22-7.34 (14H, m, ArH), 7.41-7.44 (6H, m, 
ArH).
13C NMR 6C CD3CN: 17.4, 40.1, 56.6, 62.8, 69.5, 72.2, 75.8, 76.2, 85.8, 95.3, 126.7, 
127.4,128.2,129.1,133.6,143.7,170.1. m/z (ES +ve ion mode) [M+Na]+ 100 %.
6-O-Trityl l-([(2R)-phenyl]propanoyl)-$-D-glucopyranose (3.15)
Yield: 53%
Found: C 70.6 %, H 6.58 %; [M+Na] m/z 577.220. C34H34O7.H2O requires C 71.31 %, H 
6.33 %; C3 4 H3 4 0 7Na m/z 577.220.
*H NMR 6h de-Acetone: 1.54-1.56 (3H, d, CH(CH3), J = 7.2 Hz), 3.24-3.28 (1H, dd, 6- 
H', J = 9.9, 4.2 Hz), 3.38-3.41 (1H, dd, 6-H, J = 9.9, 2.0 Hz), 3.42-3.50 (2H, m, 2-H, 4- 
H), 3.57-3.64 (2H, m, 3-H, 5-H), 3.87-3.93 (1H, q, CH(CH3)), 4.23 (1H, m, OH), 4.46 
(1H, d, OH), 4.49 (1H, m, OH), 5.58-5.59 (1H, d, 1-H, J = 7.8 Hz), 7.21-7.39 (12H, m, 
ArH), 7.40-7.41 (2H, m, ArH), 7.50-7.52 (6H, m, ArH).
13C NMR 6C d6-Acetone: 19.9, 46.5, 64.7, 71.7, 74.2, 77.7, 78.7, 87.4, 96.2, 128.2,
128.2, 128.9, 128.9, 129.8, 130.1, 141.8, 145.6, 174.2. m/z (ES +ve ion mode) 
[M+Na]+ 100%
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6-O-Trityl l-([(2S)-phenyl]propanoyl)-$-D-glucopyranose (3.16)
Yield: 53%
*H NMR 6 h de-Acetone: 1.49-1.50 (3H, d, CH(CH3) J = 7.1 Hz), 3.16-3.20 (1H, dd, 6 -H', 
J = 9.9, 5.9 Hz), 3.34-3.37 (1H, dd, 6 -H, J = 9.9, 2.0 Hz), 3.38-3.50 (2H, m, 2-H, 4-H), 
3.55-3.62 (2H, m, 3-H, 5-H), 3.88-3.94 (1H, q, CH(CH3)), 5.60-5.62 (1H, d, 1-H, J = 7.8 
Hz), 7.20-7.38 (12H, m, ArH), 7.40-7.41 (2H, m, ArH), 7.50-7.52 (6 H, m, ArH).
13C NMR 6 C d6 -Acetone: 20.1, 46.4, 64.6, 71.6, 74.2, 77.7, 78.6, 87.3, 96.2, 128.1, 
128.2,128.8,128.9,129.9,130.0, 142.0,145.6, 174.1.
6-O-Trityl l-(2,2-dimethylphenyl)acetyl-$-D-glucopyranose (3.17)
Yield: 49%
Found: [M+Na]+ m/z 591.283. C3 5 H3 6 0 7Na requires m/z 591.236.
XH NMR 6 h CD3CN: 1.58 (3H, s, C(CH3)), 1.64 (3H, s, C(CH3)), 3.0-3.14 (1H, dd, 6 -H),
3.21-3.38 (3H, m, 6 -H', 2-H, 4-H), 3.51-3.56 (2H, m, 3-H, 5-H), 5.51-5.53 (1H, d, 1-H, J 
= 8.1 Hz), 7.22-7.32 (14H, m ArH), 7.40-7.45 (6 H, m, ArH).
13C NMR 6 C CD3 CN: 25.1, 26.3, 46.3, 62.7, 69.7, 72.1, 75.7, 76.3, 85.8, 94.3, 125.4, 
126.5, 126.7, 127.5, 128.1, 128.3, 143.7, 144.1, 174.9. m/z (ES +ve ion mode) 
[M+Na]+ 100 %.
172
Chapter Five: Experimental
Deprotection of the 6-O-trityi group by acid hydrolysis
To a solution of the trityl protected compound (0.4 mmol) in DCM (4 ml) was added 
water (0.014 ml, 0.8 mmol) followed by TFA (0.029 ml, 0.4 mmol) with vigorous 
stirring at RT. The reactions were monitored by TLC and showed completion in ~30 
mins. The solvent was removed in vacuo and the residue purified by column 
chromatography using 10-20 % EtOH/DCM.
1 -(2-phenyl)acetyl-$-D-glucopyranose (3.18)
Yield: 92%
Found: C, 56.27 %, H, 6.11 %; [M+Na]+ m/z 321.095. Ci 4 Hi 8 0 7 requires C, 56.37 %, H,
6.08 %; Ci4 Hi8 0 7Na requires m/z 321.095.
[ot]D293K = +1.81° (c = 0.0105 gml'1, MeOH)
XH NMR 6 h CD3 CN: 3.26-3.31 (2H, m, 2-H, 4-H), 3.33-3.41 (2H, m, 3-H, 5-H), 3.56­
3.60 (1H, dd, 6 -H, J = 12.0, 5.2 Hz), 3.70-3.74 (1H, dd, 6 -H', J = 12.0, 2.5 Hz) 3.74 (2H, 
s, CH2 Ph), 5.45-4.47 (1H, d, 1-H, J = 8.1 Hz), 7.29-7.37 (5H, m, ArH).
13C NMR 6 C CD3 CN: 40.0, 61.0, 69.5, 72.2, 75.9, 76.8, 94.1, 126.8, 128.2, 129.2,
133.6,170.2. m/z (ES +ve ion mode) [M+Na]+ 100 %.
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l-([(2S)-phenyl]propanoyl)-$-D-glucopyranose (3.20)
Yield: 8 8 %
Found: [M+Na]+ m/z 335.111; Ci5 H2o07Na requires m/z 335.1107.
NMR 6 h de-acetone: 1.48-1.49 (3H, d, CH(CH3), J = 7.15 Hz), 3.36-3.41 (2H, m, 2- 
H, 3-H), 3.43-3.48 (1H, m, 5-H), 3.52-3.57 (1H, t, 4-H, J = 8.95 Hz), 3.62-3.66 (1H, dd, 
6 -H, J = 12.1, 5.2 Hz), 3.78-3.81 (1H, dd, 6 -H', J = 12.1, 2.3 Hz), 3.88-3.92 (1H, q, 
CH(CH3), J = 7.1 Hz), 5.51-5.53 (1H, d, 1-H, J = 8.1 Hz), 7.27-7.39 (5H, m, ArH).
13C NMR 6 C d6-acetone: 19.7, 46.3, 62.3, 70.9, 73.7, 77.6, 78.6, 96.0,128.4,128.9, 
129.9,141.6, 174.9.
l-([(2R)-phenyl]propanoyl)-$-D-glucopyranose (3.19)
Yield: 90%
Found: [M+Na]+ m/z 335.1095; Ci5 H2o07Na requires m/z 335.1107.
[a]D293K = -7.18° (c = 0.017 gm l1, MeOH)
*H NMR 6 h de-acetone: 1.47-1.49 (3H, d, CH(CH3), J = 7.2 Hz), 3.32-3.36 (1H, t, 2-H, J 
= 8 . 6  Hz), 3.44-3.53 (3H, m, 3-, 4-, 5-H), 3.69-3.73 (1H, dd, 6 -H, J = 11.8, 4.4 Hz), 
3.80-3.86 (2H, m, 6 -H, CH(CH3)), 5.51-5.53 (1H, d, 1-H, J = 8.2 Hz), 7.25-7.30 (5H, m, 
ArH).
13C NMR 6 C de-acetone: 19.7, 46.4, 62.8, 71.5, 74.2, 78.4, 78.8, 96.0,128.2,128.9, 
129.7,141.8,174.1. m/z (ES +ve ion mode) 335 [M+Na]+ 100 %
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l- (2 ,2 -dimethylphenyl)acetyl-$-D-glucopyranose (3.21)
Yield: 89 %
Found C, 58.71 %, H, 6 . 8 6  %; m/z [M+Na]+ 349.1266; Ci6 H2 2 0 7  requires C, 58.89 %, H 
6.79 %, C i6 H2 2 0 7Na requires m/z 349.1263.
[a]D293K = +9.17° (c = 0.006 gml'\ MeOH)
*H NMR 6h d6 -Acetone: 1.55 (3H, s, C(CH3)), 1.59 (3H, s, C(CH3)), 3.29-3.34 (1H, m, 2- 
H), 3.38-3.42 (2H, m, 4-H, 5-H), 3.48-3.52 (1H, m, 3-H), 3.67-3.72 (1H, m, 6 -H), 3.80­
3.83 (1H, m, 6 '-H), 5.54-5.56 (1H, d, 1-H, J = 8.1 Hz), 7.21-7.25 (1H, m, ArH), 7.30­
7.35 (2H, m, ArH), 7.39-7.42 (2H, m, ArH).
13C NMR 6 C d6 -Acetone: 27.2, 27.8, 47.9, 63.0, 71.7, 74.2, 78.4, 78.8, 96.3, 127.1, 
127.8,129.5,146.0,176.2. m/z (ES +ve ion node) 349 [M+Na]+100 %.
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5.3 Synthesis of N-Glucuronides and Glucosides 
Methyl 1,2,3,4-tetra-0-acetyl-$-D-glucopyranuronate7
AcO
A solution of Glucurono-3,6 -lactone (2 g, 11.36 mmol) in MeOH (28 ml) was 
evacuated with N2 . Triethylamine (0.06 ml) was added to the reaction which was 
left for lh . Acetic acid (0.02 ml) was then added to quench the reaction and left 
stirring for 30 mins. The methanol was then removed in vacuo. The product was 
then dissolved in pyridine (5.66 ml) and cooled to 0°C. The acetic anhydride (8.5 ml) 
was added drop wise to the reaction mixture (~15mins for addition) and the 
reaction left stirring for 3 hrs. The pyridine was removed in vacuo. Over ice, EtOAc 
( 1 0 0  ml) and water ( 1 0 0  ml) was added to the residue followed by saturated 
NaHC03 ( 6  ml) until the solution was at neutral pH. The Organic layers were then 
separated and the aqueous layer extracted with EtOAc (2 x 60 ml). The organic 
layers were combined and dried using MgS04, and solvent removed in vacuo. A re­
crystallisation was carried out using hot EtOAc and cold Hexane.
Yield: 78%
*H NMR 6 h de-Acetone: 1.98-2.10 (6 H, 2xOAc), 2.07-2.10 (6 H, 2xOAc), 3.71 (3H, s, 
CH3 ), 4.51-4.56 (1H, d, 5-H), 5.03-5.14 (1H, dd, 2-H), 5.12-5.22 (1H, t, 3-H), 5.42-5.53 
(1H, t, 4-H), 5.94-5.99 (1H, d, 1-H, J = 8.1 Hz)
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Methyl (1,2,3,4-tetra-0-isobutyryl)-$-D-glucopyranuronate8
CO,Me
iPrCO.O
iPrCO.O
iPrCO.O
iPr
To a solution of Glucurono-3,6-lactone (22.2g, 0.12 mol) in MeOH (140 ml) was 
added triethylamine (0.4 ml) at RT. The reaction was then left for 4 hrs at which 
point the glucuronolactone had dissolved. The reaction was then neutralised with 
acetic acid (0.4 ml) and left stirring for a further 30 mins. The methanol was 
removed in vacuo and the residue dissolved in pyridine (60 ml) and DCM (60 ml). A 
solution of Isobutyryl chloride (100 ml) and DCM (100 ml) was added to the stirring 
reaction mixture dropwise via a pressure equalising dropping funnel at RT. After 
addition was complete the reaction was heated to 40°C for 3 hrs, and then allowed 
to cool to RT. The reaction was diluted with diethylether (150 ml) and water (150 
ml) and the organic layer separated. The aqueous layer was extracted further with 
diethylether (2 x 150 ml) and the organic fractions combined. The combined 
organic extracts were successively washed with 3N HCI (100 ml), sat. NaHCC>3 (100 
ml), brine (100 ml), water (100 ml) and then dried over MgS04. The solvent was 
removed and a re-crystallisation carried out using hexane.
Yield: 59%. Mp: 127-128°C
*H NMR 6h CDCI3: 1.13-1.17 (24H, m, CHfChUh), 2.45-2.63 (4H, m CH(CH3)2), 3.73 
(2H, s, COzCHj), 4.18-4.20 (1H, d, 5-H, J = 9.9 Hz), 5.21-5.27 (2H, m, 2-H, 4-H), 5.37­
5.42 (1H, t, 3-H, J = 9.5 Hz), 5.77-5.79 (1H, d, 1-H, J = 8.2 Hz)
13C NMR 6C CDCI3: 18.6, 19.1,19.2, 19.3, 34.1, 34.2, 34.3, 34.5, 53.2, 69.2, 70.0, 
71.8, 73.6, 91.8,167.1,175.3,175.4, 175.7,176.1.
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Methyl (2,3,4-tri-0-acetyl)-a-D-glucopyranuronate bromide (1.6)7
CO,Me
To a solution of starting material (1 g, 2.52 mmol) in DCM ( 6  ml) at 0°C was added 
drop wise, HBr in AcOH (45 w/v %) (5.3 ml, 27.7 mmol). The reaction was then 
allowed to reach RT after addition and left stirring for 3hrs. The acid was then 
quenched with saturated NaHC03 (30 ml) and the organic layer separated. The 
Aqueous layer was then extracted further with DCM (3 X 50 ml). The organic layers 
were combined and washed with water (2 x 40 ml). The DCM was then dried over 
MgS04, and evaporated to dryness. A re-crystallisation was then carried out using 
diethyl ether which gave a white crystalline solid
52% yield
1H NMR 6 h CDCI3: 2.01-2.13 (9H, 3xs, 3xOAc), 3.72 (3H, s, C0 2CH3), 4.54-4.61 (1H, d, 
5-H, J = 10.3 Hz), 4.80-4.91 (1H, dd, 2-H), 5.18-5.32 (1H, t, 4-H, J = 10.2 Hz), 5.56­
5.69 (1H, t, 3-H, J = 9.6 Hz), 6.62-6.69 (1H, d, 1-H, J = 4.0 Hz).
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Methyl (2,3,4-tri-0-acetyl)-a-D-glucopyranuronate iodide (4.53)
A solution of starting material (500 mg, 1.33 mmol) in acetonitrile (2 ml) was 
evacuated with N2. TMSI (0.28 ml, 2 mmol) was added to the stirring solution and 
the reaction heated to 50°C for 2 h. The reaction was then allowed to cool and 
acetonitrile removed in vacuo. The residue was re-dissolved in ethyl acetate (15 ml) 
and extracted with Na2 S2 C>3 (10 % w/v) (15 ml) followed by NaHCC>3 (10 ml) and 
water (10 ml). The ethyl acetate layer was extracted further with water (2 x 10 ml). 
The organic layer was then dried over MgSCU and evaporated to dryness. The 
residue was then re-crystallised from ethanol9.
Yield: 85%
Mp: 103-105°C. Found: CiaH^OglNa [M+Na]+ m/z 466.9815 requires 466.98089 
XH NMR 6 h CDCI3 2.01-2.15 (9H, 3x s, 3xOAc), 3.77 (3H, s, OCH3), 3.20-3.25 (1H, dd,
2-H, J = 9.8, 4.4 Hz), 4.31-4.39 (1H, d, 5-H, J = 10.2 Hz), 5.20-5.29 (1H, t, 4-H, J = 9.5 
Hz), 5.49-5.58 (1H, t, 3-H, J = 9.7 Hz), 7.0-7.04 (1H, d, 1-H, J = 4.3Hz).
13C NMR 6 C CDCI3: 20.8, 20.9, 21.1, 53.4, 6 8 .6 , 70.4, 71.3, 71.4, 75.1, 166.9, 169.7, 
169.8,169.9. m/z (ES +ve ion mode) 467 [M+Na]+ 100 %.
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2,3,4,6-(tetra-0-benzyl)-a-D-glucopyranose chloride (4.86)
BriPnO
BnO
OBn
Cl
To a solution of tetra-O-benzyl glucopyranose (579 mg, 1.07 mmol) in DCE ( 6  ml) 
was added SOCI2  (1 ml, 13.7 mmol) and DMF (0.05 ml). The reaction was left 
stirring at RT for 17 hrs. The reaction was then quenched over ice carefully with 
water (~10 ml drop wise), then sat.NaHC03 (~5 ml) until neutralised. The solution 
was then diluted with DCM (30 ml) and the organic layer collected. The organic 
layer was then washed with brine (20 ml) and water (20 ml) and dried over Na2 S04. 
The solvent was removed in vacuo to give the product as a viscous oil. 1 0 ,1 1
Yield: 98 %
Found: [M+Na]+ m/z 581.207 C3 4 H3 5 0 535ClNa requires m/z 581.202 
*H NMR 6 h CDCI3: 3.51-3.57 (1H, dd, CH2 OBn), 3.61-3.71 (3H, m, CH2 OBn, 2-H, 4-H), 
3.92-4.03 (2H, m, 3-H, 5-H), 4.32-4.50 (3H, 3 x d, 3 x CF^Ar), 4.61 (2H, s, CH2 OCH2- 
Ar), 4.70-4.78 (2H, 2 x d, CH2Ar), 4.85-4.91 (1H, d, CH2Ar), 5.97-6.0 (1H, d, 1-H, J =
3.7 Hz), 7.02-7.06 (2H, m, ArH), 7.15-7.28 (18H, m, ArH).
13C NMR 6 C CDCI3: 68.2, 73.4, 73.8, 73.9, 75.7, 76.3, 76.8, 80.2, 81.8, 94.0, 128.2, 
128.3, 128.4, 128.4,128.5,128.5, 128.6,129.0, 137.9,138.1, 138.5, 138.9.
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-General procedure for the selective deprotection of the anomeric ester
To a solution of anomeric ester protected sugar (5.13 mmol) in DMF (15 ml) at - 
10°C was added AcOH (0.43 ml, 7.18 mmol). Hydrazine monohydrate (0.34 ml, 7.18 
mmol) was then added to the reaction mixture which was kept at -10°C for 4 hrs. 
The reaction was then diluted with DCM (50 ml) and then neutralised with sat. 
NaHC03 (~ 10 ml) at 0°C. The organic layer was then separated and the aqueous 
layer extracted with DCM (3 x 30 ml). The organic layers were then combined and 
washed with brine (100 ml), and water (3 x 50 ml). The DCM was then dried over 
Na2 S0 4  and evaporated to dryness. The residue was purified by column 
chromatography, eluting with 30-70 % EtOAc/hexane.
Methyl (2,3,4-tetra-0-acetyl)-a,$-D-glucopyranuronate (4.61)12
XH NMR 6h CDCI3 a/3 ratio 8:1: 2.0-2.12 (18H, 6 x s, a and 3 OAc), 3.75 (3H, s, a-C02- 
CH3), 3 . 7 6  (3H, s, 3-C02CH3), 4.13-4.16 (1H, m, 3 5-H), 4.58-4.61 (1H, d, 5-H, J = 10.6 
Hz), 4.88-4.95 (2H, m, a-2-H, 3-1-H, J = 7.8 Hz), 5.15-5.32 (4H, m, a-4-H, 3-2-H, 3-H, 
4-H), 5.54-5.60 (2H, d and t, 1-H, J = 3.9 Hz, 3-H, J = 9.5 Hz).
13C NMR 6C CDCI3: 20.9, 20.9, 20.9, 21.1, 21.4, 53.3, 53.4, 60.9, 68.4, 69.5, 69.8, 
69.9, 71.1, 71.9, 72.9, 73.2, 90.6, 95.8, 167.9, 168.8, 169.9, 170.1, 170.4, 170.5, 
170.9,171.8.
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Methyl (2,3,4-tri-0-isobutyryl)-a,$-D-glucopyranuronate (4.129f
OH
Column chromatography carried out using 30-45 % EtOAc/Hexane 
Yield: 74 % 0.3:1 3/a ratio
XH NMR 6 h CDCI3: 1.08-1.16 (18H, m, CH(CH3)2), 2.47-2.58 (3H, m, CH(CH3)2), 3.57­
3.58 (1H, dd, a-OH), 3.72 (3H, s, aC0 2 CH3) 3.74 (3H, s, PCOzCHs), 4.10-4.13 (1H, d, 
35-H, J = 9.9 Hz), 4.59-4.61 (1H, d, a5-H, J = 10.2 Hz), 4.77-4.81 (1H, dd, pi-H, J = 8.3 
Hz), 4.90-4.97 (2H, m, a2-H, 32-H), 5.17-5.26 (2H, m, a4-H, 34-H), 5.36-5.41 (1H, t, 
33-H, J = 9.6 Hz), 5.54-5.56 (1H, dd, al-H , J = 3.8 Hz), 5.62-5.67 (1H, t, a3-H, J = 9.9 
Hz)
13C NMR 6 C CDCI3: 19.0, 19.1, 19.2 (x 2), 19.3,19.3, 34.1, 34.2, 34.3, 34.4, 53.1, 53.3, 
68.5, 69.0, 69.5, 69.6, 70.9, 71.3, 73.1, 73.2, 90.7, 96.1, 167.8, 168.8, 175.8, 175.9, 
176.1,176.5,177.3.
2,3,4,6-(tetra-0-acetyl)-a,6-D-glucopyranose (4.73)13
CO„Me
iPrCO.O 
iPrCO.O
iPrCO.O
Found: [M+Na]+ m/z 371.095 Ci4 H2 0 Oi0Na requires m/z 371.095 
XH NMR 6 h CDCI3: 2.01-2.03 (12H, s, a and 3 4 x OAc), 2.09-2.10 (12H, s, a and 3 4 x 
OAc), 3.73-3.77 (1H, m, 35-H), 4.11-4.17 (2H, 36-H, a 6 -H), 4.22-4.29 (3H, 36'-H, a 6 '- 
H, a5-H), 4.73-4.75 (1H, d, 31-H, J = 8.0 Hz), 4.88-4.92 (2H, m, a2-H, 32-H), 5.05-5.08 
(2H, 2 x t, a4-H, 34-H), 5.10-5.25 (2H, t, 33-H), 5.46-5.47 (1H, d, al-H , J = 3.6 Hz), 
5.51-5.56 (1H, t, a3-H).
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-General synthesis of anomeric sulfonate sugars
Ar.O
AcO"
AcO
AcO OR
R = Msor Ts
To a solution of starting material (0.57 mmol) and DCM (3 ml) was added collidine 
(0.22ml, 1.72 mmol) at RT under N2. The sulfonic anhydride (0.86 mmol) was added 
to the reaction mixture as a solution in DCM (1 ml). The reaction was left stirring 
for 3 h. The reaction was then diluted with DCM (15 ml) and successively washed 
with 1M HCI (20 ml), 1M NaHC03 (20 ml) and water (2 x 20 ml). The DCM was then 
dried over MgS04  and evaporated to dryness. Column chromatography was carried 
out using EtOAc/Hex (60:40).
2,3,4,6-Tetra-0-acetyl-l-0-(methylsulfonyl)-a-D-glucopyranose (4.76)14
Yield: 29%
Mp: 109-112°C. Lit. 108-110°C14. Found: [M+Na]+ m/z 449.0714 Ci5 H2 2 0 i 2SNa 
requires m/z 449.0730
AcO
OMs
^  NMR 6 h CDCI3: 2.0-2.11 (12H, 4 x s, 4 x CCH3 ), 3.09 (3H, s, 0 S0 2 CH3), 4.09-4.32 
(3 H, m, 5-H, CH2), 5.01-5.08 (1H, dd, 2-H, J = 10.3, 3.7 Hz), 5.10-5.18 (1H, t, 4-H, J =
9.6 Hz), 5.44-5.51 (1H, t, 3-H, J = 10.1 Hz), 6.06-6.08 (1H, d, 1-H, J = 3.7 Hz)
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13C NMR 6 C CDCI3: 20.8, 20.8, 20.9, 20.9, 39.8, 61.8, 68.0, 69.4, 69.5, 70.6, 96.3,
169.7,170.1,170.2,170.7. m/z (ES +ve ion mode) 449 [M+Na]+ 100 %.
2,3,4,6-Tetra-0-acetyl-l-0-(toluenesulfonyl)-a-D-glucopyranose (4.78)14
AcO
OTs
Yield: 22 %
Found: [M+Na]+ m/z 525.1055 C2 iH 2 6 0 i 2SNa requires m/z 525.1043 
*H NMR 6 h CDCIb 250 MHz: 1.96 (3H, s, OAc), 2.01 (6 H, s, 2x OAc), 2.05 (3H, s, OAc), 
2.46 (3H, s, ArCH3), 3.65-3.73 (1H, dd, 6 -H, J = 12.7, 2.2 Hz) 3.87-3.96 (1H, m, 5-H) 
4.08-4.16 (1H, dd, 6 -H', J = 12.5, 3.6 Hz), 4.92-4.99 (1H, dd, 2-H, J = 10.3, 3.6 Hz), 
5.05-5.14 (1H, t, 4-H, J = 9.4 Hz), 5.39-5.49 (1H, t, 3-H, J = 9.4 Hz), 6.01-6.04 (1H, d, 
1-H, J = 3.6 Hz).
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Reactions of secondary and primary amines with the anomeric bromo sugar
2,3,4,6-Tetra-0-(acetyl)-l-N-methylbenzyl-$-glucopyranose (4.62)15
2,3,4,6-Tetra-O-acetyl glucopyranosyl bromide (616mg, 1.5 mmol) and benzyl-A/- 
methylamine (0.36 ml, 3 mmol) were warmed together at 35°C in diethylether (5 
ml) until most of the ether had evaporated to a 1ml concentration. The mixture 
was then left at RT for 1.5 hrs, with the HBr salt of benzyl-/V-methylamine beginning 
to precipitate on cooling. The reaction was then filtered and washed through with 
diethylether. The filtrate was then extracted with 10 % w/v aq citric acid (2 x 10 ml) 
and the ether dried over Na2 S04, filtered and evaporated to dryness. A re­
crystallisation was carried out using iso-hexane and a few drops of ether on cooling 
to bring on crystallisation. 15
Yield: 29 %
Found: C2 2 H3 0 O9 N [M+H]+ m/z 452.1917
!H NMR 6 h CDCI3: 1.99 (3H, s, OAc), 2.01 (3H, s, OAc), 2.06 (3H, s, OAc), 2.10 (3H, s, 
OAc), 2.37 (3H, s, NCH3 ), 3.53-3.58 (1H, m, 5-H), 3.74-3.79 (1H, d, CH2Ar, J = 13.8 
Hz), 3.85-3.89 (1H, d, CH2Ar, J = 13.8 Hz), 4.04-4.11 (1H, d, 1-H, J = 8 . 8  Hz), 4.13-4.17 
(1H, dd, 6 '-H, J = 12.0, 2.5 Hz), 4.22-4.26 (1H, dd, 6 -H, J = 12.3, 5.0 Hz), 4.99-5.04 
(1H, t, 4-H, J = 9.5 Hz), 5.13-5.18 (1H, t, 2-H, 9.3 Hz), 5.19-5.24 (1H, t, 3-H, J = 9.0 Hz),
7.22-7.32 (5H, m, ArH).
13C NMR 6 C CDCI3 : 20.6, 20.6, 20.7, 35.2, 57.9, 61.0, 62.4, 66.4, 68.2, 69.0, 72.9,
74.1, 91.9, 127.2, 128.3, 128.5, 138.7, 139.3, 169.5, 169.5, 170.2, 170.6. m/z (ES +ve 
ion mode) 452 [M+H]+ 100 %.
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Methyl-(2,3,4-Tri-0-acetyl)-l-(4-methylphenyl)amino-a,fl-glucopyranuronate
(4.60)
To a solution of bromo-sugar (1.6) (250 mg, 0.63 mmol) in acetone (3 ml) under 
nitrogen was added p-toluidine (50 mg, 0.47 mmol) in acetone (1 ml); the solution 
turned brown on addition. Then 10 % w/v NaOH (0.25 ml, 0.63 mmol) was added to 
the reaction mixture and the brown colour intensified. The reaction was left stirring 
at room temperature for 5 days. The solvent was then removed in vacuo and the 
oily residue taken up in DCM (10 ml). The DCM was extracted with water (2 x 30 
ml) and the DCM dried over MgS04. Column chromatography was carried out using 
40-50 % EtOAc/Hexane. The fractions containing product were collected and 
solvent removed, a recrystallisation was carried out using diethylether/hexane 
which gave a white crystalline solid.
Yield: 71%
Found: C2oH2 5 NOgNa [M+Na]+ m/z 446.1427, requires m/z 446.1440 
1:3 a/3 Ratio, 1H NMR 6 H P-anomer d6 -Acetone: 1.96 (3H, s, OAc), 1.97(3H, s, OAc), 
1.98 (3H, s OAc), 2.19 (3H, s, ArCH3), 3.65 (3H, s, C0 2CH3), 4.43-4.46 (1H, d, 5-H, J =
10.1 Hz), 5.03-5.06 (1H, d, 1-H, J = 8.5 Hz), 5.10-5.15 (1H, t, 4-H, J = 9.3 Hz), 5.20­
5.26 (1H, dd, 2-H, J = 9.1 Hz), 5.40-5.46 (1H, t, 3-H, J = 9.5 Hz), 6.71-6.75 (1H, m, 
ArH), 6.87-6.91 (1H, m, ArH), 6.95-7.00 (2H, m, ArH).
*H NMR 6 h a-anomer d6 -Acetone: 2.01 (3H, s, OAc), 2.02 (3H, s, OAc), 2.05 (3H, s, 
OAc), 2.21 (3H, s, ArCH3), 3.70 (3H, s, C0 2 CH3), 4.45-4.47 (1H, d, 5-H, J = 10 Hz), 
4.99-5.04 (1H, t 2-H, J = 8  Hz), 5.14-5.19 (1H, t, 3-H, 8  Hz), 5.46-5.50 (1H, t, 4-H, J = 
8.5 Hz), 5.55-5.59 (1H, dd, 1-H, J = 7.0, 4.5 Hz), 5.89-5.94 (1H, d, NH, J = 7.0 Hz), 
6.71-6.75 (1H, m, ArH), 6.87-6.91 (1H, m, ArH), 6.95-7.00 (2H, m, ArH)
13C NMR 6 C d6-Acetone (a and p): 20.7, 20.8, 20.8, 20.9, 21.0, 29.6, 53.0, 53.1, 69.9,
70.1, 70.4, 70.4, 70.5, 71.2, 72.2, 73.6, 73.9, 74.1, 80.2, 84.8, 115.6, 115.7, 129.2,
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129.2, 130.7, 144.4, 144.5, 144.5, 168.8, 169.7, 170.2, 170.2, 170.3, 170.6, 170.6, 
170.8. m/z (ES +ve ion mode) 446 [M+Na]+ 100 %.
- Reaction of the anomeric bromo sugar with drug like amines
AcO
R= CH2OAc, C02Me
To a solution of bromosugar (1.6) or (1.20) (0.75 mmol) in acetone ( 6  ml) was added 
the secondary amine (1.5 mmol) in a solution of DCM ( 6  ml), followed by 10 % w/v 
sodium carbonate (0.75 mmol). The reaction was heated with stirring to 45°C for 4 
hrs without a condenser to allow some solvent to evaporate. The remaining solvent 
was then removed in vacuo. Column chromatography was then carried out using 
10-30 % EtOAc/lsohexane.
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N-(Methyl (2,3,4-tri-0-acetyl)-$-D-glucopyranuronate)-N-methyl-3-(10,11-dihydro- 
5H-dibenzo[a,d]cycloheptan-5-ylidene)-l-propanamine (4.67)
Yield: 17%
Found: C, 66.70, H, 6.77, N, 2.15; [M+H] m/z 580.254. Caz^gOgN requires C, 66.31, 
H, 6.43, N, 2.42 % C3 2 HB9 O9 N requires m/z, 580.256
aH NMR 6 h CDCI3: 1.74 (3H, s, OAc), 1.98-2.01 (6 H, 2s, OAc), 2.2-2.28 (2H, broad m, 
CH2 CH2 CH), 2.29 (3H, s, NCH3 ), 2.65-2.74 (1H, m, NCH2), 2.75-2.88 (2H, broad s, 
ArCH2 CH2, m, NCH2), 2.90-3.02 (1H, broad s, CH2 CH2Ar), 3.22-3.47 (2H, broad s, 
ArCH2 CH2Ar), 3.72 (3H, s, C0 2CH3), 3.78-3.90 (1H, broad s, 5-H), 4.05-4.13 (1H, s, 1- 
H), 5.07-5.17 (2H, t, 4-H, J = 9.5 Hz, broad peak, 2-H), 5.17-5.24 (1H, t, 3-H, J = 9.3 
Hz), 5.76-5.82 (1H, t, CH2 CH, J = 7.3 Hz), 6.99-7.04 (1H, ArH), 7.09-7.27 (7H, ArH).
13C NMR 6 C CDCI3: 20.3, 20.5, 20.6, 28.0, 32.0, 33.8, 34.4, 35.3, 52.6, 53.2, 53.9,
67.7, 69.9, 73.3, 73.9, 125.6, 125.9, 127.0, 127.4, 128.0, 128.2, 128.5, 129.9, 137.1, 
139.4, 140.0, 141.3, 143.6, 167.7, 169.3, 170.0, 171.1. m/z (ES +ve ion mode) 580 
[M+H]+ 100 %
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N(2,3,4,6-Tetra-(O-acetyl)-$-D-glucopyranosyl)-N-methyl-3-(10,ll-dihydro-5H- 
dibenzo[a,d]cyclohepten-5-ylidene)-l-propanamine (4.68)
Yield: 29%
Found [M+H] m/z 594.27002 C33H40O9N requires m/z 594.269 
*H NMR 6 h CDCI3: 1.76 (3H, s, OAc), 1.98 (3H, s, OAc), 2.01 (3H, s, OAc), 2.05 (3H, s, 
OAc), 2.21-2.27 (2H, broad s, CHCH2), 2.25-2.29 (3H, s, NCH3), 2.64-2.72 (1H, m, 
NCH2), 2.73-2.84 (1H, broad s, ArCH2 CH2), 2.76-2.85 (1H, m, NCH2), 2.88-3.02 (1H, 
broad s, ArCH2 CH2), 3.22-3.55 (2H, 2 x broad s, ArCH2 CH2Ar), 3.45-3.50 (1H, broad s, 
5-H), 4.01-4.07 (2H, dd, 6 -H', J = 12.0, 2.3 Hz, underneath 6 -H' broad s 1-H), 4.16­
4.21 (1H, dd, 6 -H, J = 12.0, 4.8 Hz), 4.91-4.99 (1H, t, 4-H, J = 9.5 Hz), 5.07-5.19 (2H, 
broad m, 2-H, t, 3-H, J = 9.3 Hz), 5.77-5.83 (1H, t, CH2 CH, J = 7.5 Hz), 6.99-7.04 (1H, 
m, ArH), 7.09-7.27 (7H, m, ArH)
13C NMR 6 C CDCI3: 20.4, 20.6, 20.7, 28.0, 32.1, 33.8, 60.3, 62.4, 68.1, 68.9, 72.9,
74.1, 125.7, 126.0, 127.0, 127.4, 128.1, 128.3, 128.5, 129.3, 129.9, 137.1, 139.4,
140.1,141.3,143.6,169.5,170.2,170.7. m/z (ES +ve ion mode) 594 [M+H]+ 100 %
189
N(2,3,4,6-Tetra-(O-acetyl)-$-D-glucopyranosyl)-N-methyl-3-(10,ll-dihydro-5H-
dibenzo[b,f]azepin-5-yl)-l-propanamine (4.69)
Yield: 16 %. After column chromatography the material required further 
purification using preparative HPLC to remove the E2 product (see experimental 
introduction for specifications). The column was eluted with an increased gradient 
of MeCN/H20 under neutral conditions.
Found: [M+H]+ m/z, 597.281, C3 2 H4 i 0 9 N2 requires m/z 597.285 
XH NMR 6 h CDCI3: 1.64-1.72 (2H, m, CH2CH2 CH2), 1.86 (3H, s, OAc), 1.99 (3H, s, OAc),
2.01 (3H, s, OAc), 2.05 (3H, s, OAc), 2.28 (3H, s, NCH3), 2.64-2.76 (2H, m, NCH2CH2- 
CH2), 3.16 (4H, s, CH2CH2), 3.44-3.50 (1H, m, 5-H), 3.69-3.73 (2H, t, CH2 CH2 CH2, J =
6 . 8  Hz), 3.99-4.01 (1H, d, 1-H, J = 9.0 Hz), 4.02-4.06 (1H, dd, 6 -H', J = 12.3, 2.5 Hz), 
4.15-4.20 (1H, dd, 6 -H, J = 12.1, 4.8 Hz), 4.93-4.98 (1H, t, 4-H, J = 9.3 Hz), 5.05-5.10
(1H, t, 2-H, J = 9.3 Hz), 5.12-5.17 (1H, t, 3-H, J = 9.3 Hz), 6.88-6.93 (2H, m, ArH), 7.03-
7.13 (4H, m, ArH).
13C NMR 6 C CDCI3: 20.5, 20.6, 20.7, 26.3, 32.2, 34.7, 48.0, 51.8, 62.4, 68.2, 68.9,
72.8, 74.1, 91.6, 93.1, 119.9, 122.5, 126.4, 129.8, 134.2, 148.4, 169.5, 170.7. m/z
(ES, +ve ion mode) 597 [M+H]+ 100 %
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Method for the quaternisation using methyl triflate
N-(Methyl-(2,3,4-tri-O-acetyl)-$-D-glucopyranuronate)-N,N-dimethyl-3-(10,ll-
dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-l-propanammonium
trifluoromethane sulfonate (4.75)
To a solution of starting material (4.67) (35 mg, 0.06 mmol) in DCM (4 ml) under 
nitrogen, was added methyltriflate (0.014 ml, 0.12 mmol) at room temperature. 
The solution was left stirring for 2 h. The DCM was removed in vacuo and column 
chromatography used to purify, the eluting solvent being 10% IPA/DCM.
Yield: 21 %
Found: [M+H] m/z 594.2718 C33H40O9N requires 594.270
1H NMR 6 h d6DMSO and d4-acetic acid @373K: 1.99 (3H, s, OAc), 2.08 (3H, s, OAc), 
2.15 (3H, s, OAc), 2.61-2.78 (2H, m, CH2 CH), 3.00-3.12 (4H, m, CH2 CH2), 3.12 (3H, s, 
NCH3), 3.18 (3H, s, NCH3), 3.63-3.69 (2H, m, NCH2), 3.79 (3H, s, C0 2CH3), 5.1 (1H, s, 
5-H), 5.19-5.25 (4H, m, 1-H, 2-H, 3-H, 4-H), 5.75-5.79 (1H, t, CH2 CH), 7.06-7.28 (8 H, 
m, ArH)
13C NMR 6 C ds-DMSO: 19.9, 20.1, 20.4, 22.7, 31.1, 32.6, 46.9, 48.3, 52.5, 62.3, 63.2,
64.2, 64.7, 75.5, 86.7, 124.0,125.5, 125.7,127.1, 127.5, 127.6,128.1, 129.5,136.5,
138.4,138.5,140.0,145.2,166.9,167.0,168.2,168.4. m/z (ES +ve ion mode) 594 
[M+H]+ 100 %.
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The Azide Route
- General method for the preparation of the anomeric azide
R
AcO
R= CH2OAc , COzMe
To a solution of 1-O-acetyl sugar (30 mmol) in DCM (20 ml) under a nitrogen 
atmosphere was added Tin (IV) Chloride (1.05 ml, 9 mmol), followed by 
trimethylsilyl azide (5.57 ml, 42 mmol). The reaction was left stirring at room 
temperature for 24 h. The reaction was then diluted with DCM (100 ml) and 
carefully quenched with saturated Na2 C0 3  (50 ml) at 0°C. The Tin residues were 
then filtered off, and the filtrate collected and extracted with Na2C0 3 (1 X 50 ml) 
and water (2 x 50 ml). The DCM layer was then dried over MgS04  and evaporated 
to dryness. The off white solid was then recrystalised from ethanol to give a 
crystalline white solid.
Methyl (2,3,4-tri-0-acetyl)-$-D-glucopyranuronate azide (4.90)16
r n  M o
AcO
Yield: 67%
Mp: 151-152°C. Found: [M+H]+ m/z, 382.0847; C, 43.22, H, 4.74, N, 11.38 %. C1 3 H1 7 - 
0 9 N3 Na requires m/z 382.0862; C1 3 H1 7 O9 N3 requires C, 43.47, H, 4.77, N, 11.70 %.
XH NMR 6 h CDCI3: 2.02-2.03 (6 H, 2s, OAc), 2.07 (3H, s, OAc), 3.78 (3H, s, C0 2 CH3), 
4.10-4.14 (1H, d, 5-H, J = 9.5 Hz), 4.69-4.73 (1H, d, 1-H, J = 8.7 Hz), 4.93-4.99 (1H, t,
3-H, J = 8.7 Hz), 5.21-5.31 (2H, m, 2-H, 4-H).
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13C NMR 6 C CDCI3: 20.8, 20.9, 53.4, 69.4, 70.9, 72.3, 74.7, 88.5, 118.1, 166.9, 169.4,
169.9,170.3
2,3,4,6-Tetra-O-acetyl-fi-D-glucopyranosyl azide (4.91)17
n3
Yield: 98%
Mp: 128-129°C. lit: 127°C Found: [M+NH3]+ m/z 391.145; C, 44.91, H, 5.10, N, 11.30 
%. Ci 4 H2 3 0 9 N4  requires m/z 391.146. Ci4 HigOgN3 requires C, 45.04, H, 5.13, N, 11.26 
%.
*H NMR 6 h CDCI3: 2.01-2.03 (6 H, 2s, OAc), 2.09-2.14 (6 H 2s, OAc), 3.76-3.86 (1H, m, 
5-H), 4.11-4.22 (1H, dd, 6 -H', J = 12.4, 2.3 Hz), 4.25-4.34 (1H, dd, 6 -H, J = 12.4, 4.8 
Hz), 4.62-4.69 (1H, d, 1-H, J = 8 . 8  Hz), 4.91-5.01 (1H, t, 2-H, J = 9.3 Hz), 5.08-5.13 
(1H, t, 4-H, J = 9.8 Hz), 5.19-5.24 (1H, t, 3-H, J = 9.5 Hz).
13C NMR 6 C CDCI3: 20.9, 21.0, 62.1, 68.3, 71.1, 73.0, 74.4, 88.3, 169.5, 169.6, 170.4, 
170.9. m/z (Cl +ve ion mode) [M+NH3] 391 100 %.
- General method for the reduction of the Azidosugar
R
AcO
R= CH2OAc, C0 2Me
To a solution of azidosugar (4.90 or 4.91) (7 mmol) in ethyl acetate (20 ml) was
added Pd/C (1.48 g, 20 mol %). The residual Pd/C was washed down into the flask
with methanol (20 ml), and a vacuum applied to the flask. A positive pressure of
hydrogen was applied to the reaction which was magnetically stirred at room
temperature for 4 hrs. The Pd/C was filtered onto cellite and ethyl acetate used to
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wash the celite pad. The solvent was removed in vacuo. A re-crystallisation was 
carried out on using hot ethanol, on cooling addition of hexane or diethyl ether 
slowly brought on crystallisation.
Methyl-(2,3,4-tri-0-acetyl)-l-N-amino-$-D-glucopyranuronate (4.92)1S
AcO
Yield: 35%
Mp: 140-142°C. Found: C, 46.63, H, 5.74 N, 4.17 %; [M+H]+ m/z 334.1142. C1 3 H1 9 O9 - 
N requires C, 46.85, H, 5.74, N, 4.20 %; C1 3 H2 0 O9 N requires m/z 334.1138 
1H NMR 6 h CDCI3: 2.01-2.05 (6 H, s, 2 x OAc), 2.08 (3H, s, OAc), 3.77 (3H, s, C0 2 CH3), 
4.02-4.08 (1H, d, 5-H, J = 10.0 Hz), 4.21-4.25 (1H, d, 1-H, J = 9.0 Hz), 4.81-4.87 (1H, t,
2-H, J = 9.5 Hz), 5.11-5.22 (1H, t, 3-H, J = 9.5 Hz), 5.27-5.38 (1H, t, 4-H, J = 9.6 Hz).
13C NMR 6 C CDCI3: 20.8, 20.9, 21.0, 6 8 .8 , 70.3, 72.1, 72.8, 73.9, 85.7, 168.0,169.8, 
170.3,170.4. m/z (Cl +ve ion mode) 334 [M+H]+ 100 %.
(Tetra-2,3,4,6-0-acetyl)-l-N-amino-$-D-glucopyranuronate (4.93)19
NH2
AcO
Yield: 99%
Mp: 161-162°C. Lit: 163-164°C19. Found Ci4 H2 iN 0 9Na [M+Na]+ m/z 370.1114 CMH. 
2 1 N09Na requires 370.1128
XH NMR 6 h CDCI3: 2.01 (3H, s, OAc), 2.02 (3H, s, OAc), 2.07 (3H, s, OAc), 2.09 (3H, s, 
OAc), 3.66-3.72 (1H, m, 5-H), 4.09-4.14 (1H, dd, 6 -H', J = 12.3, 2.3 Hz), 4.16-4.21 (1H, 
broad d, 1-H), 4.20-4.26 (1H, dd, 6 -H, J = 12.3, 4.9 Hz), 4.79-4.86 (1H, t, 2-H, J = 9.6 
Hz), 5.01-5.07 (1H, t, 3-H, 9.6 Hz), 5.21-5.27 (1H, t, 4-H, J = 9.6 Hz)
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13C NMR 6 C CDCI3: 21.0, 21.1, 21.2, 62.7, 69.3, 72.5, 73.2, 73.6, 85.4, 118.1, 169.9,
170.5,171.0. m/z (ES +ve ion mode) [M+Na]+ 370 100 %.
N,N-Dimethylation of the aminosugar
2,3,4,6-Tetra-0-acetyl-$-D-glucopyranosyl-N,N-dimethylamine (4.94)
AcO
To a solution of (4.93) (400 mg, 1.15 mmol) In THF (15 ml) was added Pd/C (245 mg, 
20 mol %) and IPA (15ml), followed by the addition of a 37% aqueous solution of 
formaldehyde (0.93 ml, 11.50 mmol). The flask was then placed under vacuum 
before purging with hydrogen. The reaction was stirred at room temperature under 
a positive pressure of hydrogen for 5 hrs. The solution was filtered through a pad of 
celite, and washed with ethyl acetate. The solvent was removed in vacuo and 
column chromatography carried out using 3:7 EtOAc/Hexane, 5:5 EtOAc/Hexane, 
7:3 EtOAc/Hexane.
Yield: 40-92% (yield is variable due to hydrolysis on silica gel during purification) 
Found: Cie^sNOgNa [M+Na]+ m/z 398.1427 requires 398.1424 
XH NMR 6 h CDCI3: 2.00 (3H, s, OAc), 2.02 (3H, s, OAc), 2.04 (3H, s, OAc), 2.07 (3H, s, 
OAc), 2.40 (6 H, s, N(CH3)2)J, 3.57-3.62 (1H, m, 5-H), 4.03-4.07 (1H, d, 1-H, J = 9.3 Hz), 
4.10-4.15 (1H, dd, 6 -H', J = 12.1, 2.6 Hz), 4.20-4.26 (1H, dd, 6 -H, J = 12.1, 4.9 Hz), 
4.97-5.04 (1H, t, 4-H, J = 9.5 Hz), 5.08-5.15 (1H, t, 2-H, J = 9.4 Hz), 5.17-5.23 (1H, t, 3- 
H, J = 9.3 Hz).
13C NMR 6 C CDCI3: 20.9, 21.1, 21.2, 39.9, 62.9, 68.7, 69.4, 73.3, 74.5, 93.7, 169.9, 
169.9,170.6,175.9,178.4. m/z (ES +ve ion mode) 398 [M+Na]+ 100 %.
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General quaternisation reaction of dimethylamino glucose (4.94)
To a solution of (4.94) (49 mg, 0.13 mmol) in acetonitrile (1 ml) under argon was 
added the alkylhalide (0.08 ml, 1.33 mmol). The reaction was heated to 50°C for 
5hrs. The acetonitrile was removed in vacuo and a re-crystallisation carried out 
using ethanol.
2,3,4,6-Tetra-O-acetyi-P-D-glucopyranosylftrimethylammonium) iodide (4.96)
Yield: 51%
Found: C, 39.2; H, 5.5; N, 2.6 % [M+HV m/z 390.1764 Ci7 H2 8 N09  requires C, 39.5; H, 
5.4; N, 2.7 %; C1 7 H2 9 NO9  requires m/z 390.1765
*H NMR 6 h D2 0: 2.20 (3H, s, OAc), 2.22 (3H, s, OAc), 2.23 (3H, s, OAc), 2.28 (3H, s, 
OAc), 3.32 (9H, s, N+(CH3)3), 4.38-4.42 (1H, m, 5-H), 4.48-4.52 (2H, m, 6 -H', 6 -H), 
5.28-5.30 (1H, d, 1-H, J = 8 . 8  Hz), 5.34-5.38 (1H, t, 4-H, J = 9.2 Hz), 5.56-5.60 (1H, t,
3-H, J = 8.4 Hz), 5.73-5.77 (1H, t, 2-H, 8 . 6  Hz)
13C NMR 6 C D2 0: 20.5, 20.6, 20.7, 20.8, 51.7, 62.1, 67.5, 68.4, 74.2, 75.2, 93.7, 172.2,
173.0,173.2,174.2. m/z (ES +ve ion mode) 390 [M+H]+ 100 %.
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2,3,4,6-Tetra-0-acetyl-$-D-glucopyranosyl(benzyldimethylammonium) bromide 
(4.97)
The recrystallisation was carried out using ethyl acetate/hexane.
Yield: 64%
Mp: 160-162°C. C2 3 HB2 NO9  Found [M+H]+ m/z 466.2077 requires 466.2072.
XH NMR 6 h D2 0: 2.17 (3H, s, OAc), 2.22 (6 H, s, 2 x OAc), 2.28 (3H, s, OAc), 3.20 (3H, 
s, NCH3), 3.32 (3H, s, NCH3), 4.43 (1H, m, 5-H), 4.56 (2H, d, NCH2), 4.64-4.71 (1H, dd, 
6 -H), 4.89-4.96 (1H, dd, 6 -H'), 5.08-5.12 (1H, d, 1-H, J = 8.7 Hz), 5.32-5.40 (1H, t, 4-H,
9.3 Hz), 5.46-5.51 (1H, t, 3-H, J = 8.4 Hz), 5.73-5.82 (1H, t, 2-H, J = 8.4 Hz), 7.66-7.74 
(5H, m, ArH).
13C NMR 6 C D2 0: 20.5, 20.6, 20.7, 21.1, 47.6, 49.1, 62.4, 67.5, 68.0, 6 8 .8 , 74.2, 74.9, 
91.1, 126.6, 130.1, 131.9, 133.4, 172.2, 173.0, 173.2, 174.2. m/z (ES +ve ion mode) 
466 [M+H]+ 100%.
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Deprotection of the dimethylamino sugar (4.94) 
$-D-glucopyranosyl-N,N-dimethylamine- (4.108)
HO
A solution of (4.94) (187 mg, 0.5 mmol) in MeOH (3 ml) was evacuated and flushed 
with nitrogen. NaOMe (5.4 mg, 0.1 mmol) was added to the reaction in MeOH (1 
ml). The reaction was then left stirring at room temperature for 2hrs. Amberlite IR- 
120H ion exchange resin was then added to quench the reaction, and filtered off. 
The methanol was removed in vacuo to yield a clear, viscous oil.
Yield: 100%
Found [M+H] m/z 208.11803 for C8 Hi8 0 5N
*H NMR 6 h de-DMSO: 2.31-2.33 (6 H, s, N(CH3)2), 2.96-3.04 (2H, m, 5-H, 3-H), 3.10­
3.17 (2H, m, 4-H, 2-H), 3.40-3.46 (1H, m, 6 -H") 3.62-3.68 (2H, m, 6 -H', 1-H).
13C NMR 6 C d6 -DMSO: 48.9, 61.8, 70.5, 70.9, 78.1, 78.5, 94.7 (anomeric)
General deprotection procedure for the quaternary ammonium salts
HO
X
To a solution of quaternary ammonium salt (0.06 mmol) in MeOH (1 ml) under 
argon was added solid Na2C0 3 (18 mg, 0.17 mmol) at room temperature, and was 
left stirring at room temperature for 3 hrs. The reaction was quenched with 
Amberlite H+ resin (57 mg, 0.17 mmol) until the reaction was ~pH 7. The resin was 
filtered off and washed with methanol. The solvent was removed in vacuo and a 
recrystallisation carried out using ethanol and a few drops of ether on cooling.
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fl-D-Glucopyranosyl(trimethylammonium) iodide (4.99)
Yield: 87%, white crystalline solid
Found: C, 30.88, H, 5.78, N, 4.00 [M]+ m/z, 222.1349. C9 H2 0 NO5 I requires C, 30.94, H, 
5.78, N, 4.01 %, C9 H2 0 NO5 requires m/z, 222.1341; *H NMR: 6 H d6 -DMSO: 3.11 (9H, s, 
(CH3 )3 N+), 3.10-3.40 (3H, m, 2-H, 3-H, 4-H), 3.48 (2H, m, 6 -H, 6 -H'), 3.71 (1H, m, 5- 
H) and 4.54 (1H, d, J = 8.9 Hz, 1-H).
13C NMR: 6 C d6 -DMS0: 50.7, 60.8, 69.2, 70.5, 77.3, 80.6 and 95.4; m/z (ES +ve mode) 
222 cation [M]+, 100%.
$-D-Glucopyranosyl(benzyldimethylammonium) bromide (4.100)
Once the methanol was removed in vacuo, the residue was triturated with ethyl 
acetate to leave an amorphous glass.
Yield: 72%
Found [M]+ m/z 298.1654 C1 5 H2 4 NO5 requires 298.1660
XH NMR 6 h de-DMSO: 3.09 (3H, s, NCH3 ) 3.12 (3H, s, NCH3), 3.13-3.19 (1H, t, 4-H, J =
9.3 Hz), 3.25-3.31 (1H, t, 3-H, J = 8.5 Hz), 3.36-3.42 (1H, m, 5-H), 3.52-3.59 (1H, dd, 
6 -H', J = 12.3, 6 . 6  Hz), 3.62-3.69 (1H, t, 2-H, J = 8.7 Hz), 3.81-3.87 (1H, dd, 6 -H, J = 
12.3, 1.7 Hz), 4.21-4.26 (1H, d, 1-H, J = 8.9 Hz), 4.54-4.60 (1H, d, CHzPh, J = 12.5 Hz), 
4.84-4.91 (1H, d, CH2 Ph, J = 12.5 Hz), 7.49-7.57 (3H, m, ArH), 7.62-7.66 (2H, m, ArH)
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13C NMR 6 C dg-Acetone: 46.9, 48.2, 61.1, 66.1, 69.2, 70.1, 77.2, 80.5, 92.9, 127.9, 
129.4,130.8,133.4. m/z (ES + ion mode) [M]+ 298 100 %.
$-D-Glucopyranosyl(dimethyl-2-propenyl)ammonium bromide (4.101)
Yield: 98 %. (the starting material (4.98) was made by Chandrakala Pidathala)
Found: C, 38.1; H, 6.9; N, 3.4 %; [M]+ m/z, 248.1492. C1 1 H2 2 NO5 .H2 O requires C, 
38.15; H, 6.9; N, 4.0 %; C1 1 H2 2 NO5 requires m/z, 248.1498.
XH NMR: 6 h [(CD3 )2SO]: 2.97, 3.02 ( 6  H, 2s, 2xCH3 N+), 3.16 (1 H, t, J = 9.4 Hz, 4-H), 
3.32 (1 H, t, J = 8.7 Hz, 3-H), 3.30-3.40 (1 H, m, 5-H), 3.49 (1 H, dd, J = 12.4 and 6.1 
Hz, 6 -H), 3.56 (1 H, t, J = 8 . 8  Hz, 2-H), 3.72 (1 H, dd, J = 12.4 and 1.9 Hz, 6 '-H), 3.90 (1 
H, dd, J = 12.9, 7.2 Hz, one of CHCFUN*), 4.16 (1 H, dd, J = 12.8, 7.7 Hz, one of 
CHCH2 N+), 4.39 (1 H, d, J = 8.9 Hz, 1-H), 5.62 (1 H, dd, J = 10.0 and 1.5 Hz, CH=CH2 
cis- olefinic H), 5.66 (1 H, dd, J = 17.2 and 1.5 Hz, CH=CH2 trans- olefinic H), and 5.95 
(1 H, m, CH2 CH=CH2).
13C NMR 6c [(CD3 )2SO]: 47.1, 48.3, 60.5, 65.9, 68.9, 70.1, 76.9, 80.1, 93.3,125.4 and 
129.0; m/z (ES +ve mode) 248 cation [M]+ 100 %.
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The reaction of free sugars and secondary amines
- Glucuronic acid derivatives
Piperidinium carboxylate-N-(piperidin-l-yl)-$-D-glucopyranuronate (4.128)
Glucuronic acid (1.94 g, 10 mmol) and piperidine (3.95 ml, 40 mmol) were heated 
together at 60°C for lhr with magnetic and manual stirring with a spatula. Acetone 
(25 ml) was added to the paste while the mixture was still warm and the acetone 
solution then filtered to remove any insoluble solid. The acetone solution was then 
allowed to cool to room temperature before storing the solution in the refrigerator 
(4°C) overnight. During this time a white solid had precipitated which was 
collected.
Yield: 87%. 50:50 3 and re-arranged product
Found [M+H]+ m/z 262.128 for Ci i H2 0 O6 N, C 54.91, N 8 .8 6 , 8.07 %, Ci 6 H3 oN206 
requires C 55.49, H 8.67 N 8.09 %, CuH2o06N requires m/z 262.128.
*H NMR 6 h d6-DMSO 3-anomer: 1.32-1.51 (6 H, m, NCH2 (CH2 ) 3 of the aglycone), 
1.56-1.67 (6 H, m, H2 N+CH2 (CH2)3of the salt), 2.50 (under DMSO) (2H, m, CH2 NCH2 of 
the aglycone), 2.63-2.71 (1H, m, CH2 NCH2 of the aglycone), 2.76-2.84 (1H, m, CH2- 
NCH2 of the aglycone), 2.95-3.01 (4H, m, H2 N+(CH2 ) 2  of the salt), 3.05-3.12 (1H, t, 5- 
H, J = 9.29 Hz), 3.10-3.16 (1H, t, 4-H, J = 8.3 Hz), 3.18-3.27 (2H, m, 3-H, 2-H), 3.60­
3.64 (1H, d, 1-H J = 8 . 8  Hz).
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piperidinium(2S,3S,4S)-3,4,5-trihydroxy-5-(piperidin-l-ylmethyl)tetrahydrofuran-2-
carboxylate
1H NMR 6 h d6-DMSO a and 3 re-arranged product: 1.32-1.51 (6 H, m, NCH2 (CH2 ) 3 of 
the aglycone), 1.56-1.67 (6 H, m, H2 N+CH2 (CH2 ) 3 of the salt), 2.50 (under DMSO) (2H, 
m, CH2 NCH2 of the aglycone), 2.63-2.71 (1H, m, CH2 NCH2 of the aglycone), 2.76-2.84 
(1H, m, CH2 NCH2 of the aglycone), 2.95-3.01 (4H, m, H2 N+(CH2 ) 2 of the salt), 3.26­
3.31 (0.5H, d, CH2 N, J = 19 Hz), 3.39-3.43 (0.5H, d, CH2 N, J = 19 Hz) 3.65-3.69 (1H, 
dd, 4.8, 1.8 Hz), 3.51-3.53 (0.5H, d, CH2 N, J = 7.6 Hz), 3.58-3.60 (0.5H, d, CH2 N), 3.66­
3.67 (0.5H, dd, 2-H, J = 4.8, 1.6 Hz) 3.69-3.71 (1H, dd, 2-H, 4.0, 1.6 Hz), 3.8 (0.5H, d,
4-H, 1.3 Hz), 3.93-3.96 (0.5H, dd, 3-H, 4.8, 1.2 Hz), 4.02-4.03 (0.5H, d, 3-H, J = 4.0 
Hz), 4.11-4.12 (0.5H, d, 4-H, J = 1.3 Hz).
13C NMR 6 C d6-DMSO re-arranged product and 3-product: 22.4, 22.9, 24.7, 24.9, 
25.8, 26.2, 26.2, 44.1, 48.6, 49.0, 54.4, 69.5, 70.8, 72.8, 76.6, 77.4, 78.1, 79.1, 81.2, 
95.4, 102.1,174.1,174.1
-Glucose derivatives
Glucose (1.8 g, 10 mmol) and secondary amine (20 mmol) were heated together 
(60°C for morpholine, piperidine and N-methylpiperazine, 40°C for pyrrolidine) for 
lh r with magnetic and manual stirring with a spatula. Acetone (25ml) and 
methanol (2.5ml) were added to the paste while the mixture was still warm and the 
acetone solution then filtered to remove any insoluble solid. The acetone solution
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was then allowed to cool to room temperature before storing the solution in the
refridgerator (4°C) overnight. Iso-hexane was added to the solution if no
20precipitation had occurred, until the solution was cloudy throughout.
P-D-(glucopyranosyl) piperidine(4.Ill)20
Mp: 123-125°C. Found: C, 53.30, H, 8.58, N, 5.65 %, [M+H]+ m/z 248.149. Ci i H2 i 0 5N 
requires C, 53.43, H, 8.55, N, 5.66 % m/z [M+H]+ 248.148
XH NMR 6 h de-DMSO: 1.34-1.42 (2H, m, aglycone CH2 CH2 CH2), 1.44-1.52 (4H, m, CH_ 
2 CH2 CH2), 2.46-2.55 under DMSO peak (2H, m, CH2 NCH2), 2.78-2.86 (2H, m, CH2 NCH_ 
2), 2.93-3.03 (2H, m, 4-H, 6 -H), 3.09-3.16 (1H, t, 3-H, J = 7.8 Hz), 3.18-3.25 (1H, t, 2- 
H, J = 8 . 8  Hz), 3.36-3.44 (1H, m, 5-H), 3.60-3.68 (1H, d, 1H, J = 8 . 8  Hz, m, 6 -H')
13C NMR 6 C de-DMSO: 24.91, 26.22, 48.47, 61.82, 69.54, 70.90, 78.26, 78.76, 95.51 
(anomeric). m/z (ES +ve ion mode) 248 [M+H]+ 100 %.
P-D-(glucopyranosyl) morpholine (4.112)
Yield: 79%
Found: [M+H]+ m/z 250.128 Ci 0 Hi 9 O6N requires m/z 250.129 
XH NMR 6 h d6 -DMSO: 2.52-2.58 (2H, m, CHzNCHz), 2.79-2.86 (2H, m, CH2 NCH2), 
2.95-3.04 (2H, m, 4-H, 5-H), 3.12-3.17 (1H, t, 3-H, J = 8.5 Hz), 3.18-3.24 (1H, t, 2-H, 
8.5 Hz) 3.39-3.45 (1H, dd, 6 -H, J = 11.8, 5.5 Hz), 3.52-3.59 (4H, t, CFbOCHz, J = 4.8 
Hz)) 3.62-3.68 (2H, m, 6 -H', 1-H, J = 8 .8 Hz)
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13C NMR 6 C d6 -DMSO: 48.95 (morpholine), 61.6 (C6 ), 61.8 (morpholine), 67.7 (C4), 
69.2 (C3), 70.8 (C2), 78.1 (C5), 94.6 (C l anomeric). m/z (ES +ve ion mode) 250 
[M+H]+ 100 %.
P-D-(glucopyranosyl) pyrrolidine(4.114)
Yield: 8 6 %
Found [M+H]+ m/z 234.133 C10H2o05N requires m/z 234.133
*H NMR 6 h de-DMSO: 1.65-1.70 (4H, m, CH2CH2), 2.70-2.77 (2H, m, CFhNCHz), 2.85­
2.92 (2H, m CH2 NCH2), 2.97-3.05 (2H, m, 3-H, 5-H), 3.09-3.14 (2H, m, 2-H, 4-H), 3.38­
3.44 (1H, dd, 6 -H, J = 11.8, 4.5 Hz), 3.63-3.69 (1H, d, 6 -H', J = 11 Hz), 3.86-3.90 (1H,
d, l-H,J=8.5Hz)
13C NMR 6 C d6 -DMSO: 24.2 (pyrroidine), 46.0 (pyrrolidine), 61.8 (C6 ), 71.0 (C3), 72.0 
(C2), 78.1 (C4), 78.2 (C5), 90.9 (Cl), m/z (ES +ve ion mode) 234 [M+H]+ 100 %.
P-D-(glucopyranosyl) N-l-methyl piperazine (4.113)
Yield: 100%
Found: C 48.03, H, 8.25, N, 9.79 % [M+H]+ m/z 263.1607. CnH 2 2 0 5 N2 .H20 requires C, 
47.13, H, 8.62, N, 9.99 %, CiiH 2 3 0 5 N2 requires m/z 263.1610
*H NMR 6 h D2 0: 2.31 (NCHs), 2.78-2.81 (4H, m, MeNiCFUh), 3.01-3.10 (4H, m, 
MeN(CF(2)2), 3.38-3.43 (2H, m, 4-H, 5-H), 3.5-3.58 (1-H, m, 3-H), 3.58-3.67 (1H, t, 2- 
H), 3.75-3.81 (1H, m, 6 -H), 3.91-3.99 (1H, m, 6 -H), 4.00-4.07 (1H, d, 1-H, J = 8.9 Hz)
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13C NMR 6 C D2 0: 44.5, 44.9, 54.5, 61.5, 69.4, 70.5, 77.7, 77.8, 93.8. m/z (ES +ve ion 
mode) 263 [M+H]+ 100 %.
-Alterantive route for the synthesis of the acetylated dimethylamino glucose
2,3,4,6-Tetra-0-acetyl-6-D-glucopyranosyl-N, N-dimethylamine (4.94)
AcO
Glucose (1.8 g, 10 mmol) and 40 % w/v aqueous dimethylamine (20 mmol) were 
heated together at 40°C for lhr. The water and excess dimethylamine was 
removed in vacuo and NMR showed a mixture of product and glucose (2:1). The 
material was then dissolved in Pyridine (15 ml) and cooled to 0°C. Acetic anhydride 
(4.16 ml, 44 mmol) was then added and the reaction left at 0°C for 4 hrs. The 
reaction was then neutralised with NaHC0 3  (~ 20 ml) and diluted with DCM (50 ml). 
The aqueous phase was extracted twice more with DCM (50 ml) and the combined 
DCM layers washed with water (100 ml) and brine (100 ml). The DCM was then 
dried over Na2S0 4  and the solvent removed in vacuo. Column chromatography was 
carried out using 40-70 % EtOAc/Hexane.
Yield: 23 %
Data as before when using the reductive amination method.
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- Acetylation of the cyclic amino sugars
AcO
To a solution of aminosugar ((4.111)/(4.112)/(4.113)) (2.77 mmol) in pyridine (2 ml) 
at 0°C was slowly added acetic anhydride (1.93 ml, 20.4 mmol). On full addition of 
the acetic anhydride the reaction was allowed to reach room temperature and was 
left stirring at for 4-5hrs. The pyridine was then removed under vacuum. DCM (20 
ml) was added to the residue and the reaction quenched over ice with saturated 
NaHC03 (~20 ml) and water (~20 ml) until pH 7-8 was obtained. The DCM layer was 
collected and the aqueous phase extracted with DCM (3 x 20 ml). The DCM 
fractions were combined and washed with water (1 x 50 ml). The DCM was then 
dried over MgS04  and then removed in vacuo. A recrystallisation was carried out 
using hot ethanol, on cooling ether was added which brought on the formation of 
white crystals.
2,3,4,6-Tetra-0-acetyl-$-D-glucopyranosyl piperidine (4.115)20
Found: C, 55.1, H, 7.12, N, 3.24 %, [M+Na]+ m/z 438.171. C1 9 H2 9 O9 N requires C, 
54.94, H, 7.04, N, 3.37 %, Cig^gOgNNa requires m/z 438.174 
XH NMR 6 h CDCI3: 1.38-1.56 (6 H, m, CH2 CH2 CH2 ) 2.0-2.08 (12H, 4 x s, OCOCH3), 2.5­
2.53 (2H, m, CH2 NCH2), 2.88-2.93 (2H, m, CH2 NCH2), 3.56-3.6 (1H, m ,5-H), 3.96-3.98 
(1H, d, 1-H, J = 8.9 Hz), 4.09-4.12 (1H, dd, 6 -H, J = 12.1, 2.6 Hz), 4.21-4.25 (1H, dd, 6 -
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H', J = 12.1, 4.8 Hz), 4.96-5.01 (1H, t, 4-H, J = 9.2 Hz), 5.13-5.17 (1H, t, 2-H, J = 9.4 
Hz), 5.18-5.23 (1H, t, 3-H, J = 9.4 Hz)
13C NMR 6C CDCI3: 21.0, 21.1, 21.2, 24.9, 26.7, 49.4, 62.8, 67.9, 69.4, 73.4, 74.3, 
94.8, 169.9, 170.0, 170.7, 171.1
2,3,4,6-Tetra-O-acetyl-fi-D-glucopyranosyl morpholine (4.116)
Yield: 68%
Found: C, 51.53, H, 6.44, N, 3.33 %, [M+Na]+ m/z 440.1523 Ci 8H27 Oi 0N requires C, 
51.80, H, 6.47, N, 3.36 %, Ci8H27Oi0NNa requires m/z 440.1523 
*H NMR 6h CDCI3: 2.02 (3H, s, OAc), 2.03 (3H, s, OAc), 2.08 (3H, s, OAc), 2.11 (3H, s, 
OAc), 2.58-2.63 (2H, m, CH2NCH2), 2.93-3.01 (2H, m CH2NCH2), 3.53-3.66 (5H, m, CH_ 
2OCH2 5-H), 3.96-4.01 (1H, d, 1-H, J = 9.3 Hz), 4.95-5.02 (1H, t, 4-H, J = 9.6 Hz), 5.10­
5.17 (1H, t, 2-H, J = 9.4 Hz), 5.21-5.28 (1H, t, 3-H, J = 9.4 Hz).
13C NMR 6C CDCI3: 20.7, 20.8, 20.8, 20.9, 47.0, 61.8, 67.5, 69.3, 73.0, 73.1, 73.4, 
93.8,169.9,170.3,170.4,170.8. m/z (ES +ve ion mode) 440 [M+Na]+ 100 %.
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2,3,4,6-Tetra-O-acetyl-fl-D-glucopyranosyl N-l-methyl piperazine
AcO AcO
AcO
Yield: 26%
Found: [M+H]+ m/z 431.2030. C1 9 H3 1 O9 N2 requires m/z 431.2017.
*H NMR 6 h CDCI3: 2.02 (3H, s, OAc), 2.03 (3H, s, OAc), 2.08 (3H, s, OAc), 2.11 (3H, s, 
OAc), 2.26 (3H, s, NCH3), 2.29-2.43 (4H, m, MeNfCHzh), 2.09-2.18 (2H, m, CH2 NCH2 ), 
2.97-3.05 (2H, m, CH2 NCH2 ), 3.61-3.68 (1H, m, 5-H), 3.99-4.03 (1H, d, 1-H, J = 9.3 
Hz), 4.08-4.14 (1H, dd, 6 -H', J = 12.1, 2.6 Hz), 4.19-4.22 (1H, dd, 6 -H, J = 12.1, 5.2 
Hz), 4.95-5.00 (1H, t, 4-H, J = 9.5 Hz), 5.09-5.13 (1H, t, 2-H, J = 9.5 Hz), 5.20-5.25 (1H, 
t, 3-H, J = 9.4 Hz)
13C NMR 6 C CDCI3: 20.7, 20.8, 20.9, 20.9, 21.0, 46.2, 55.6, 62.7, 68.3, 68.7, 73.3, 
74.1, 93.6,169.9,170.4,170.5,170.9. m/z (ES +ve ion mode) 431 [M+H]+ 100 %.
-Quaternisation of the piperidine derivative
(N-(2,3,4,6-Tetra-0-acetyl-$-D-glucopyranosyl)-N-methyl)piperidinium 
trifluoromethanesulfonate (4.116)
To a solution of (4.115) (100 mg, 0.24 mmol) in DCM (2 ml) under nitrogen was 
added MeOTf (0.054 ml, 0.48 mmol). The reaction was then left stirring for 4 hrs at 
room temperature. The DCM was removed in vacuo. Column chromatography was 
carried out using 100 % EtOAc, 50:50 Ethanol/DCM. The ethanol/DCM fractions 
were combined and solvent removed to give the desired product.
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N.B. The product is undetectable by anisaldehyde stain when diluted i.e. product 
can not been seen when diluted in the eluting solvent of the column, evaporation of 
the solvent showed product present.
Yield: 62 %
Found: m/z, 430.2064. C2 0 H3 2 NO9 requires m/z, 430.2077;
*H NMR 6 h CDCI3: 1.70-1.80 (3H, m, CCH2 C), 1.98, 2.03, 2.05 and 2.12 (12 H, 4s, 
4xCH3 CO), 2.00-2.10 (3 H, m, CCH2 C), 3.30 (3 H, s, CH3 N+), 3.60-3.95 (4 H, 2m, 
2xCH2 N+), 4.27 (1 H, dd, 6 -H, J = 12.6, 5.9 Hz), 4.36-4.44 (2 H, m, 6 -H', 5-H), 5.23 (1 
H, t, 4-H, J = 9.7 Hz), 5.49 (1 H, dd, 3-H, J = 9.4, 8.3 Hz), 5.69-5.78 (2 H, m, 1-H, 2-H). 
13C NMR: 6 C CDCI3: 20.7, 20.9, 21.0 (x 2), 21.3, 21.8, 61.8, 62.2, 62.6, 68.4, 68.9,
74.6, 76.5, 90.9; 117.7,120.9,124.1,127.3 (CFs, q), 170.5 (x 2), 170.6 and 171.3; 
m/z (ES +ve ion mode) 430 cation [M]+ 100 %.
-Deprotection of the quaternary ammonium salt
(N-(fl-D-glucopyranosyl)-N-methyl)piperidinium trifluoromethanesulfonate(4.117)
TfO-
To a solution of (4.116) (394 mg, 0.92 mmol) in MeOH ( 6  ml) was added NaOMe 
(2.3 mg, 0.046 mmol). The reaction was left stirring at room temperature for 5 hrs. 
The reaction was then quenched with Amberlite H+ resin to reach pH 7. The resin 
was then filtered off and washed with methanol. The solvent was then removed in 
vacuo.
Yield: 100%
Found: m/z 262.1661. C1 2 H2 4 NO5  requires m/z, 262.1654.
XH NMR: 6 h d6 -Acetone: 1.69-1.78,1.91-2.03, 2.05-2.12 ( 6  H, 3m, CCH2 C), 3.27 (3 H,
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s, CH3 N+), 3.48 (1 H, t, J = 9.5 Hz, 4-H), 3.45-3.75 (2 H, m, CH2 N+), 3.65-3.75 (2 H, m, 
2x6-H), 3.67 (1 H, t, J = 9.3 Hz, 3-H), 3.87-3.98 (2 H, m, CH2 N+), 3.90 (1 H, t, J = 8 . 8  
Hz, 2-H), 4.12 (1 H, m, 5-H) and 5.00 (1 H, d, J = 8 . 8  Hz, 1-H).
13C NMR: 6 C d6 -Acetone: 20.7, 20.8, 22.0, 45.5, 61.1, 61.8, 61.9, 70.2, 71.6, 78.7,
81.7, 93.5,118.3 (CF3), 121.5 (CF3) N.B. only two peaks from the CF3 signal can be 
assigned due to weak spectrum, m/z (ES +ve mode) 262 cation [M]+ 100 %.
-Formation of the benzyl protected piperidinium sugar
(N-(2,3,4,6-tetra-0-benzyl)-$-D-glucopyranosyl)-N-methyl)piperidinium 
trifluoromethanesulfonate (4.89)
BnO -OTf
To a solution of (4.86) (598 mg, 1.07 mmol) in DCM (5 ml) was added piperidine 
(0.21 ml, 2.14 mmol). The reaction was left stirring at RT for 17 hrs. The precipitate 
was then filtered off, and the solvent then removed in vacuo. The residue was then 
taken up in a solution of DCM (5 ml) and MeOTf (0.24 ml, 2.14 mmol) was added to 
the solution. The solution was left stirring at RT for 17 hrs. The reaction was then 
quenched with water (10 ml) followed by sat.NaHC03 (aq) (2 ml) and diluted with 
DCM (20 ml). The organic layer was separated and the aqueous layer extracted 
with DCM (2 x 20 ml). The combined organic layers were then extracted with water 
(2 x 20 ml), dried over Na2 S0 4  and concentrated in vacuo. Column chromatography 
was then carried out using 10-20 % EtOH/DCM.
Yield: 38%
Found: [M]+ m/z 622.353. C4oH4805N requires m/z 622.353
*H NMR 6 h de-acetone: 1.62-1.77 (2 H, m, CHzCH^CHz), 1.79-2.08 (4H, m, CH2CH2 CHr
), 3.25 (3H, s, C0 2 CH2), 3.5-3.66 (2H, m, CH2 NCH2), 3.81-3.92 (3H, m, CH2 NCH2 , 4-H),
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4.08- 4.12 (1H, m 5-H), 4.15-4.19 (1H, t, 3-H, J = 7.8 Hz), 4.31-4.36 (1H, t, 2-H, J = 7.3 
Hz), 4.58-4.66 (2H, 2 x d, CH2 OBn, J = 12.1 Hz), 4.68-4.72 (1H, d, CH2 Bn, J = 11.3 Hz),
4.8- 4.84 (1H, d, CH2 Bn, J = 11.2 Hz), 4.86-5.01 (3H, 3 x d, CH2 Bn, J = 11.3 Hz), 5.07­
5.12 (1H, d, CH2 Bn, J = 11.3 Hz), 5.28-5.32 (1H, d, 1-H, J = 8.2 Hz), 7.28-7.46 (20H, m , 
ArHj. ES (+ve ion mode) [M]+ 622 100 %
13C NMR 6 C dg-acetone: 20.8 (x 2), 21.9, 45.6, 61.3, 61.5, 69.9, 74.1, 74.5, 75.1, 75.8, 
77.5, 78.0, 79.6, 85.2, 93.3, 117.9, 121.2, 124.4, 127.6 (q for CF3), 128.8, 128.9, 
129.0,129.1,129.2 (x 2), 129.6 (x 2), 129.8, 138.7, 139.5, 139.6, 139.8.
The 6-O-trityl glucose series
6-0-Trityl-a.,$-D-glucopyranose (4.119f 1
To a solution of Glucose (5 g, 27.78 mmol) in pyridine (50 ml) at 0°C was added 
Tritylchloride (8.5 g, 30.55 mmol) and the reaction left stirring at 0°C for 7 hours. 
The reaction was then diluted with ethyl acetate (100 ml) and water (100 ml). The 
water layer was then extracted with ethyl acetate (3 x 100 ml). The combined ethyl 
acetate layers were then washed with brine ( 1 0 0  ml) and water ( 1 0 0  ml), and then 
dried over Na2S04. The solvent was then removed in vacuo. Column 
chromatography was carried out using 5-10% EtOH in DCM to give a white solid.
Yield 85%
Found: [M+Na] m/z 445.163. C2 5 H2 6 0 6Na requires m/z 445.1627.
*H NMR 6 h d3-Acetonitrile ratio a/3 1:1: 3.06-3.57 (9H, m, a and 3 3-H, 4-H, 6 -H, 6 '- 
H, 1 x 5-H), 3.84-3.89 (1H, m, 5-H), 4.44-4.47 (2H, m, a and 3 2-H), 4.76-4.77 (1H, d, 
31-H, J = 6 . 6  Hz), 5.10-5.12 (1H, dd, al-H , J = 3.9 Hz), 7.22-7.27 (6 H, m, a and 3- 
ArH), 7.29-7.34 (12H, m, a and 3‘ArH), 7.46-7.50 (12H, m, a and 3-ArH).
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13C NMR 6 C CDCI3: 70.7, 71.6, 71.8, 72.4, 73.8, 74.8, 76.6, 87.2, 87.5, 92.7, 96.8,
127.4, 127.5, 128.2,128.3,129.1, 143.9,144.1.
- General procedure for the condensation reaction
R
To a solution of 6 -O-trityl glucose (1.2 g, 2.83 mmol) in DCM (15 ml) under nitrogen 
was added the secondary amine (2.83 mmol). The reactants were stirred at RT for 
24 hrs. The DCM was then removed in vacuo. Column Chromatography was carried 
out using 100 % EtOAc.
(N-(6-O-Trityl)-$-D-glucopyranosyl))-N-methyl-3-(10,ll-dihydro-5H- 
dibenzo[a,d]cyclohepten-5-ylidene)-l-propanamine (4.122)
Yield 49%
Found: Mp: 91-92°C. m/z, 668.3407. C4 4 H4 6 NO5 requires m/z, 668.3376.
*H NMR 6 h (CD3CN + ~2 % D2 0) @343K: 2.40-2.47 (2 H, m, ^CHCHz), 2.40 (3 H, s, 
NCH3), 2.92 (2 H, m, NCH2 CH2), 2.95-3.15 (4 H, br m, ArCH2 CH2Ar), 3.15-3.2 (1 H, dd, 
6 -H, J = 10.0 and 5.5 Hz), 3.25-3.32 (3 H, m, 4-H, 5-H, 6 '-H), 3.31-3.35 (1 H, t, 3-H, J =
8 . 6  Hz), 3.38-3.42 (1 H, t, 2-H J = 8.5 Hz), 3.89-3.92 (1 H, d, 1-H, J = 8 . 8  Hz), 5.91-5.97 
(1 H, t, J = 7.6 Hz, C=CHCH2), 7.05-7.35 (17 H, m, ArH) and 7.49-7.54 (7 H, m, ArH). 
13C NMR 6 C (CD3 CN): 27.6, 31.2, 33.0, 34.3, 53.3, 63.4, 69.5, 70.1, 76.1, 77.4, 85.7,
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93.6, 125.4,125.5,126.7, 126.8, 127.1, 127.4, 127.6, 127.7,128.0,128.3, 129.0, 
129.7,136.6,139.1,139.8,140.8, 143.1,144.0; m/z (ES +ve mode) 6 6 8  [MH]+ 100 %.
(N-(6-O-Trityl)-$-D-glucopyranosyl))-N-methyl-3-(10,ll-dihydro-5H-
dibenzo[b,f]azepin-5-yl)-l-propanamine
Yield 29%
Found: [M+H] m/z 671.3503; C4 3 H4 7 N2 O5 requires m/z 671.3485.
*H NMR 6 h CD3 CN: 1.75-1.83 (2H, m, CH2 CH2 CH2, J = 6.9 Hz), 2.37 (3H, s, NCH3), 
2.77-2.90 (2H, m, NCH2 CH2), 3.02-3.07 (1H, dd, 6 -H, J = 9.9, 6.1 Hz), 3.07 (4H, s, 
ArCJi-ChhAr), 3.11-3.24 (4H, m, 6 '-H, 4-H, 3-H, 5-H), 3.25-3.3 (lH,t, 2-H, J = 8 . 6  Hz) 
3.76-3.82 (3H, t and d, CH2 N, J = 6.7 Hz, 1-H, J = 8 . 8  Hz), 6.87-6.92 (2H, m, ArH),
7.06-7.13 (6 H, m, ArH), 7.20-7.31 (9H, m, ArH), 7.46-7.50 (6 H, m, ArH).
13C NMR 6 C CD3 CN: 25.7, 31.5, 34.6, 47.5, 51.0, 63.5, 69.6, 70.2, 76.1, 77.6, 85.6,
93.8, 119.5, 122.1, 126.0, 126.6, 127.4, 128.3, 129.4, 133.8, 144.0, 148.1. m/z (ES 
+ve ion mode) [M+H]+ 671 100 %.
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-Acetylation of the free hydroxyl groups
(N-[(6-O-Trityl)-2,3,4-tri-O-acetyl)-$-D-glucopyranosyl))-N-methyl-3-(10,ll- 
dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-l-propanamine (4.123)
To a solution of (4.122) (1 g, 1.5 mmol) in pyridine (15 ml) at 0°C under nitrogen was 
added acetic anhydride (0.85 ml, 9 mmol). The reaction was allowed to reach room 
temperature on addition of the acetic anhydride and left stirring for 4 hrs. The 
reaction was then basified using sat. NaHC03 until pH 7 was reached. The reaction 
was then diluted with DCM (60 ml). The aqueous layer was then extracted with 
DCM (3 x 50 ml). The combined DCM layers were then washed with brine, (100 ml), 
water (100 ml) and dried over Na2 S04.
Yield: 79%
Found: m/z, 794.371. C5 0 H5 2 NO8  requires m/z, 794.3693.
XH NMR: 6 h (CD3 CN): 1.73,1.77 and 1.95 (9 H, 3s, 3 x CH3 CO), 2.39 (5 H, m, =CHCH2  
+ NCH3), 2.75-3.20 ( 6  H, m, ArCH2 CH2Ar + NCH2 CH2), 3.25-3.60 (3 H, m, 2 x 6 -H, 5-H), 
4.15-4.35 (1 H, br d, 1-H), 5.10-5.25 (3 H, br m, 2-H, 3-H, 4-H), 5.87 (1 H, t, =CHCH2), 
7.00-7.35 (15 H, m, ArH), 7.47 ( 6  H, approx d, ArH); the 1H NMR spectrum showed 
very broad signals and meaningful coupling constants cannot be quoted.
13C NMR 6 C (CD3 CN): 19.4,19.6, 22.0, 27.4, 31.0, 31.3, 33.0, 33.4, 61.6, 67.9, 68.1,
73.4, 73.6, 85.7, 92.2, 125.3, 125.7,126.7, 127.1, 127.5, 127.7, 128.1, 128.2, 129.2, 
129.7,136.7,139.1,139.8,141.0,142.9,143.6,168.6,169.0 and 169.6. m/z (ES +ve 
mode) 794 [MH]+ 100%.
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-Quaternisation, and subsequent 6-0- trityl deprotection
(N-(2,3,4-tri-0-acetyl)-(i-D-glucopyranosyl))-N, N-dimethyl-3-(10,ll-dihydro-5H- 
dibenzo[a,d]cyclohepten-5-ylidene)-l-propanammonium) 
trifluoromethanesulfonate (4.124)
To a solution of (4.123) (300 mg, 0.38 mmol) in DCM ( 8  ml) under nitrogen was 
added MeOTf (0.086 ml, 0.76 mmol). The reaction was left stirring at room 
temperature for 17 hrs. The DCM was removed in vacuo and column 
chromatography carried out using 100 % EtOAc, 20 % EtOH/DCM.
Yield: 59%
Found: m/z, 566.2470. Cb2 H4 oN08  requires m/z, 566.2754; vmax (diamond) cm"13347 
(s, br), 1751,1604,1520 and 1452.
*H NMR: 6  (CD3 CN): 2.01, 2.03 and 2.09 (9 H, 3d, 3 x CH3 CO; fluxional effects), 2.64 
(2 H, m, =CHCH2), 3.02, 3.04 ( 6  H, 2d, 2 x CH3 N+), 2.95-3.30 (5H, br m, ArCH2 CH2Ar, 
NCH2), 3.30-3.45 (1 H, br m, 6 -H), 3.50-3.70 (3 H, br m, 6 -H', 5-H, NCH2), 4.86 (1 H, 
approx, d, 1-H, J = 6.5 Hz), 5.08 (1 H, approx, t, 4-H, J = 9 Hz), 5.26 (1 H, approx, t,
3-H, J = 9 Hz), 5.41 (1 H, dd, 2-H, J = 9.2 and 6.5 Hz), 5.79 (1 H, d, =CHCH2, J = 6.4 Hz) 
and 7.05-7.45 (8 H, m, ArH).
13C NMR: 6 C (CD3 CN): 19.5,19.6, 19.8, 22.5, 31.2, 32.9, 48.3, 59.2, 63.6, 66.3, 67.0,
72.8, 77.5, 91.0,118.9 (CF3), 122.8 (CF3), 125.9, 127.1,127.4, 127.7, 128.1, 130.0,
136.9,138.6,139.1,169.3,169.6 and 169.8. N.B. only signals 118.9 and 122.8 could 
be assigned for the CF3 quartet due to weak spectrum, m/z (ES +ve mode) 566 
cation [M]+, 100 %.
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Using the hemiacetal in the glucuronic acid series
The condensation reaction of the hemiacetal with secondary amines
Methyl ((2,3,4-tri-0-isobutyryl)-$-D-l-N-methylbenzylamine)-glucopyranuronate
To a solution of hemiacetal (4.129) (300 mg, 0.72 mmol) in toluene (3 ml) under N2 
was added N-methylbenzylamine (0.18 ml, 1.43 mmol). The reaction was heated to 
50°C for 5 hrs and the solvent then removed in vacuo. The residue was 
recrystallised from hexane/ether (9:1).
Yield: 29%
Found: C, 62.27, H, 7.61, N, 2.72, [M+Na]+ m/z 544.2512. C27H39O9N requires C, 
62.18, H, 7.53, N, 2.69; C2 7 H3 9 0 9NNa requires m/z 544.2523.
*H NMR 6 h CDCI3: 1.06-1.21 (18H, m, CHiCH^h), 2.39 (3H, s, NCHs), 2.45-2.55 (3H, m, 
CH(CH3)2), 3.74 (3H, s, C0 2 CH^), 3.77-3.81 (1H, d, CH2Ar, J = 13.7 Hz), 3.87-3.94 (2H,
2 x d, CH2 Ar, J = 13.7 Hz, 5-H, J = 9.9 Hz), 4.18-4.20 (1H, d, 1-H, J = 9.23 Hz), 5.17­
5.20 (1H, t, 4-H, J = 9.8 Hz), 5.27-5.29 (2H, m, 2-H, 3-H), 7.21-7.31 (5H, m, ArH).
13C NMR 6 C CDCI3: 19.1, 19.2,19.2, 19.3, 19.3, 34.2, 34.3, 34.3, 35.6, 53.0, 58.2,
67.8, 69.9, 73.2, 74.5, 92.9,127.5, 128.6,128.9, 138.9, 168.3, 175.7, 175.8, 176.3. 
m/z (ES +ve ion mode) 544 [M+Na]+ 100 %.
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- Condensation reaction followed by acetylation and quaternisation using drug 
examples.
To a solution of (4.129) (498 mg, 1.19 mmol) in toluene (5 ml) at 50°C was added 
Nortriptyline, Desipramine or the desmethyl AZ compound, (4.136) (1.19 mmol) in a 
solution of toluene (5 ml). The reaction was heated to 50°C under a nitrogen 
atmosphere for 24 hrs. The toluene was then removed in vacuo and the residue 
taken up in a solution of Pyridine (15 ml). The solution was cooled to 0°C and 
placed under nitrogen. Acetic anhydride (0.24 ml, 2.39 mmol) was then added 
slowly to the reaction mixture. The solution was then left stirring at 0°C for 4 hrs. 
The reaction was then quenched with NaHC03 until pH 7-8 was achieved. The 
solution was then diluted with DCM (20 ml) and the organic layer collected. The 
aqueous phase was then extracted with DCM (3 x 50 ml) and the organic layers 
combined. The combined organic layers were then washed with brine (50 ml) and 
water (2 x 50 ml) and then dried over Na2S04. The organic solvent was then 
removed in vacuo with the pyridine residues being removed under high vacuum. 
The residue was then dissolved in dry DCM ( 8  ml) and evacuated with nitrogen. 
Methyl triflate (0.27 ml, 2.39 mmol) was then added to the stirred solution. On 
complete addition the reaction was left stirring for 17 hrs at RT. The DCM was then 
removed in vacuo and column chromatography carried out using, 100 % EtOAc, 
10:90 IPA/DCM.
C 0 2Me
iPrCO.O
-OTf
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Methyl(N-(2,3,4-tri-0-isobutyryl)-$-D-glucopyranuronate))-N, N-dimethyl-3- 
(10,ll-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-l-propanammonium 
trifluoromethanesulfonate (4.130)
Yield: 18 %. Found: C 57.78, H 6.38, N 1.44 %, [M]+ m/z 678.3660; C4 0 H5 2 O1 2 NSF3 
requires C 58.03, H 6.33, N 1.69 % [C39H5209N]+ requires m/z 678.3642 
*H NMR 6 Hd6 -DMSO: 1.00-1.06 (18H, m, C0 2 CH(CH3)2), 2.40-2.49 (3H, m, C0 2 CH(CH_ 
3)2), 2.50-2.58 (2H, broad s, CHCjH2CH2 N+), 2.73-2.92 (2H, broad s, CH2 CH2), 2.98-3.09 
(6 H, 2 x d, N+(CH3 )2), 3.2-3.31 (2H, broad s, CH2 CH2), 3.34 (3H, s, C0 2CH3), 3.62-3.71 
(2H, m, CHCH2CH2 N+), 4.5-4.52 (1H, m, 5-H), 5.14-5.30 (1H, m, 3-H), 5.3-5.4 (1H, m,
4-H), 5.5-5.51 (1H, t, 2-H, J = 9.2 Hz), 5.7-5.84 (2H, t, CHCH2 CH2 N+ J = 7.2 Hz and, 
broad m, 1-H), 7.08-7.3 (8 H, m, ArH).
13C NMR 6 C CDCI3: 14.3, 18.2, 18.6, 18.7, 18.8, 18.9, 22.4, 23.0, 31.6, 33.4, 33.5,
33.5, 33.6, 48.8, 48.9, 53.2, 67.0, 67.7, 72.2, 72.7, 126.3, 126.4,127.6, 127.9,128.3,
128.5, 128.6, 128.7,130.5,137.0, 139.0, 139.3, 140.4, 174.7, 175.1, 175.4 (x2). m/z 
(ES +ve ion mode) 678 [M]+ 100 %.
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Methyl(N-(2,3,4-tri-0-isobutyryl)-$-D-glucopyranuronate))-N, N-dimethyl-3- 
(10,ll-dihydro-5H-dibenzo[b,f]azepin-5-yl)-l-propanammonium trifluoromethane 
sulfonate (4.131)
Yield: 16 %. Found: [M]+ m/z 681.376, C3 8 H5 3 O9 N2 requires m/z 681.375 
*H NMR 6 h CDCI3: 1.05-1.08 (18H, m, COzCHlCH^h), 2.1-2.2 (2H, m, NCH2 CH2 CH2 ), 
2.35-2.6 (3H, m, C0 2 CH(CH3)2), 2.95 (3H, s, NCH^), 3.08 (3H, s, NCHj), 3.18 (4H, s, C K  
2 CH2 ), 3.4-3.5 (1 H, m, NCH2 CH2 CH2 ), 3.55-3.65 (1 H, m, NCH2 CH2 CH2), 3.76 (3H, s, CO_ 
2 CH3 ), 3.8-3.98 (2H, m, NCHzCHzCH^), 4.5-4.53 (1H, d, 5-H, J = 9.5 Hz), 5.09-5.18 (1H, 
t, 4-H, J = 9.3 Hz), 5.3-5.5 (2H, 2 x t, 2-H, J = 8.4 Hz, 3-H, J = 8.4 Hz), 5.6-5.65 (1H, d, 
1-H, J = 8 . 6  Hz), 6.9-7.23 (8 H, m, ArH).
13C NMR 6 C CDCI3: 18.5, 18.8,18.9, 21.1, 32.4, 34.1, 34.2, 34.3, 46.7, 48.2, 48.9,
53.4, 60.9, 67.4 (4-C), 68.2 (3-C), 72.8 (2-C), 74.0 (5-C), 93.6 (1-C), 120.0, 123.9, 
127.2,130.6,134.6,147.2,166.3,175.0,175.9 (x2). m/z (ES +ve ion mode) 681 [M]+ 
100 %.
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AZ N+-Glucuronide (4.135)
OR
Yield: 23%
Found: [M]+ m/z 877.294, C4 iH 5 3 0 iiN 4 81BrF requires m/z 877.285 
*H NMR 6 h d6 -acetone: 1.04-1.21 (18H, m, CH(CH3)2), 1.23-1.42 (4H, m, CH2CHCH2), 
1.76-1.9 (1H, m, CHCH2 OR), 2.42-2.53 (3H, m, CH(CH3)2), 2.87-2.93 (3H, m, CH2 NCH2- 
), 3.21-3.3 (1H, m, CH2 NCH2), 3.68 (3H, s, NCH3), 3.72 (3H, s, C0 2CH3), 3.92 (3H, s, 
aglycone), 4.24-4.38 (1H, d, 5-H, J = 10 Hz), 4.43-4.46 (1H, d, 1-H, J = 9.4 Hz), 5.08­
5.13 (1H, t, 4-H, J = 9.8 Hz), 5.17-5.24 (1H, t, 2-H, J = 9.7 Hz), 5.37-5.42 (1H, t, 3-H, J =
9.6 Hz), 7.0-7. 8  (6 H, aglycone).
13C NMR 6 C de-acetone: 19.4, 19.6, 19.7, 34.9, 35.0, 35.1, 37.3, 37.7, 45.1, 53.1,
56.8, 68.2, 71.0, 73.7, 74.8, 75.0, 95.0, 100.9, 104.2, 108.5, 113.7, 114.1, 119.5,
127.6, 127.9, 135.4, 135.8, 149.8, 150.7, 154.5, 154.9, 155.7, 157.6, 169.1, 176.1, 
176.2,176.4.
-Using the acetate protected hemiacetal 
Protected AZ N+-Glucuronide (4.137)
OR
The method is as above replacing (4.129) for (4.61).
Yield: 14%
Found: [M]+ m/z 791.190 C3 5 H4 1 OiiN 4 79BrF requires m/z 791.193
*H NMR 6 h de-acetone: 1.08-1.44 (4H, m, CHzCHCHz), 1.8-1.97 (1H, m, CHCH2 OR),
1.9-2.05 (9H, 3 x s, COCHs), 2.45-2.52 (1H, m CH2 NCH2), 2.86-2.95 (2H, m, CHzNCHz),
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3.24-3.3 (1H, m, CH2 NCH2), 3.71 (3H, s, C0 2 CH3), 4.02-4.19 (8 H, 2 x s ,  m, aglycone),
4.22-4.25 (1H, d, 5-H, J = 10 Hz), 4.4-4.45 (1H, d, 1-H, J = 9.4 Hz), 5.03-5.08 (1H, t, 4- 
H, J = 9.7 Hz), 5.16-5.21 (1H, t, 2-H, J = 9.5 Hz), 5.32-5.38 (1H, t, 3-H, J = 9.6 Hz), 
7.35-8.5 (6 H, aglycone)
13C NMR 6 C d6-acetone: 14.9, 20.9, 21.1, 21.3, 37.1, 39.6, 45.1, 52.8, 53.2, 57.4,
60.9, 6 8 .6 , 71.3, 73.9, 74.8, 75.3, 94.9, 100.3, 106.2, 110.7, 120.3, 120.6, 128.8, 
129.8, 137.1, 151.7, 152.0, 156.4, 157.2, 158.6, 169.1, 170.3, 170.5. ES (+ve ion 
mode) m/z [M]+ 791 100 %.
Deprotection of the isobutyryl groups
$-D-Glucopyranuronate-(N, N-dimethyl-3-(10,ll-dihydro-5H- 
dibenzo[a,d]cyclohepten-5-ylidene)-l-propanammonium) (4.133)
To a solution of (4.130) (115 mg, 0.14 mmol) in MeOH (2 ml) was added 1M NaOH 
(0.42 ml, 0.42 mmol) at -10°C. The reaction was left stirring at -10°C for 3hrs at 
which time TLC (5:3:2 EtOAc/IPA/H2 0) showed completion. The reaction was then 
quenched with Amberlite IR-120 H+ resin (140 mg, 0.42 mmol) till pH 7 was reached. 
The resin was then filtered and washed with methanol, and the methanol removed 
in vacuo. The residue was then partitioned between DCM (30 ml) and water (30 
ml). The aqueous phase was separated and extracted with more DCM (3 x 30 ml) 
and then the water removed in vacuo to yield an amphorous glass (yield 76 %). The 
residue was then purified further using reverse phase Ci8  silica gel, eluting with 1 0 0  
% H2 0 , 10 % MeCN/H20 to 25 % MeCN/H2 0.
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Yield: 16%
Found: [M]+ m/z 454.2227, C26H3206N [M]+ requires m/z 454.2230 
*H NMR 6 h MeOD 600 MHz @ 323K: 2.57-2.72 (2H, m, NCHzCJHjCH), 2.78-3.0 (2H, 
broad m, ArCH2 CH2Ar), 3.15 (3H, s, NCH3 ), 3.19 (3H, s, NCH3 ), 3.40-3.47 (3H, m, 3-H, 
N CJi, ArCH2 CH2Ar), 3.51-3.62 (2H, broad s, NCH2, ArCH2 CH2 Ar), 3.69-3.74 (2H, m, 2- 
H, 4-H), 3.88-3.98 (1H, broad s, 5-H), 4.3-4.51 (1H, broad s, 1-H), 5.73-5.82 (1H, t, 
=CHCH2), 7.04-7.31 (8 H, m, ArH).
13C NMR 6 C MeOD @323K: 24.4, 33.2, 34.9, 64.2, 64.8, 71.5, 71.6, 77.8, 78.7, 79.0,
79.1, 94.7, 95.2,124.9, 125.2,127.3,127.7,128.8, 131.1, 131.4, 138.5, 140.7, 140.8,
141.6.148.5.175.1.
$-D-glucopyranuronate-(N, N-dimethyl-3-(10,ll-dihydro-5H-dibenzo[b,f]azepin-5- 
yl)-l-propanammmonium) (4.134)
To a solution of (4.131) (116 mg, 0.14 mmol) in MeOH (2 ml) was added 1M LiOH 
(0.42 ml, 0.42 mmol) at -10°C. The reaction was left stirring at -10°C for 2hrs at 
which time TLC (100 % EtOAc) showed completion. The reaction was then 
quenched with Amberlite H+ resin (142 mg, 0.42 mmol) till pH 7 was reached. The 
resin was then filtered and washed with methanol, and the methanol removed in 
vacuo. The residue was then partitioned between DCM (30 ml) and water (30 ml). 
The aqueous phase was separated and extracted with more DCM (3 x 30 ml) and 
then the water removed in vacuo to yield an amorphous glass (yield 82 %). The 
residue was then purified further using preparative HPLC using neutral MeCN/H2 0.
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Yield: 57 %
[a ] 2 9 3  = -18.25 (2 gm l1 in MeOH). Found: C, 60.97, H, 6.98, N, 5.37, [M]+ m/z 
457.2343. C25H3206N2.2H20 requires C, 60.96, H, 7.36, N, 5.68 %; C2 5 H3 3 O6 N2 
requires m/z 457.2339
aH NMR 6 h MeOD: 2.0-2.16 (2H, m, N+CH2 CH2 CH2), 3.05 (3H, s, NCH3 ), 3.09 (3H, s, 
NCH3 ), 3.18 (4H, s, CH2 CH2 ), 3.37-3.54 (3H, m, 3-H, N+CH2 CH2CH2 ), 3.69-3.71 (2H, m, 
2-H, 4-H), 3.73-3.84 (2H, m, 5-H, N+CH2CH2 CH2), 3.88-3.98 (1H, m, N+CH2 CH2CH2), 
4.51-4.55 (1H, d, 1-H, J = 8.9 Hz), 6.92-6.97 (2H, m, ArH), 7.11-7.20 (6 H, m, ArH).
13C NMR 6 c MeOD: 22.4, 33.6, (3 x peaks suspected to be amongst MeOD 48.6­
50.1), 63.8, 71.9, 73.1, 78.9, 79.5, 95.8, 121.1, 124.5, 128.1, 131.5,136.0, 149.5, 
175.3. m/z (ES +ve ion mode) 457 [M]+ 100 %.
Model compound
Methyl(N-(2,3,4-tri-0-isobutyryl)-$-D-glucopyranuronate)-pyrrolidine (4.139)
To a solution of (4.129) (1.09 g, 2.6 mmol) in toluene ( 8  ml) under a nitrogen 
atmosphere was added pyrrolidine (0.24 ml, 3.12 mmol). The reaction was heated 
to 50°C for 6  hrs. The toluene and excess pyrrolidine were removed in vacuo.
Yield: 100%
Found [M+H]+ m/z 472.256 C2 3 H3 8 O9 N requires m/z 472.255 
*H NMR 6 h CDCI3: 0.98-1.2 (18H, m, C0 2 CH(CH3 )2), 1.6-1.61 (4H, m, CH2 CH2), 2.28­
2.42 (3H, m, C0 2CH(CH3)2), 2.68-2.84 (4H, m, CH2 NCH2), 3.67 (3H, s, CO2 CH3 ), 3.9­
3.93 (1H, d, 5-H, J = 10.0 Hz), 4.28-4.31 (1H, d, 1-H, J = 9.3 Hz), 5.03-5.14 (2H, 2 x t, 
2-H, J = 9.4 Hz, 4-H, J = 9.8 Hz), 5.2-5.26 (1H, t, 3-H, J = 9.5 Hz)
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13C NMR 6 C CDCI3: 17.7, 17.8, 17.9, 23.5, 32.8, 32.9, 32.9, 45.7, 51.5, 67.9, 68.7, 
71.7, 72.9, 89.1,174.3,174.5,174.9,181.5. m/z (ES +ve ion mode) 472 [M+H]+100 
%.
-Synthesis oftrifluoromethane sulfonate activated electrophiles
(3-Phenoxypropyl) trifluoromethane sulfonate (4.140)
To a solution of 3-phenoxypropan-l-ol (1 ml, 7 mmol) in DCM (3 ml) at 0°C under N2 
was added 2,3,6-collidine (1 ml, 7.7 mmol) followed by triflic anhydride (1.29 ml, 7.7 
mmol). The reaction was left at 0°C for 2 hrs and then the solvent removed in 
vacuo. The residue was dissolved with diethylether (50 ml) and water (30 ml) and 
the organic layer separated. The organic layer was then successively washed with 
1M HCI (2 X 20 ml), sat. NaHCC>3 (20 ml), water (30 ml) and then dried over MgS04. 
This material was used without further purification.
Yield: 30%
*H NMR 6 h CDCI3 250 MHz: 2.22-2.40 (2H, q, CH2CH^CH2), 4.0-4.18 (2H, t, CH2CH2- 
OAr), 4.68-4.90 (2H, t, TfOCH2), 6.82-7.10 (3H, m, ArH), 7.26-7.41 (2H, m, ArH).
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- Quaternisation of the pyrrolidine sugar with 3-phenoxypropyl trifluoromethane 
sulfonate, followed by deprotection
fi-D-glucopyranuronate-N-1 -(3-phenoxypropyl)pyrrolidinium-l -yl (4.141)
To a solution of (4.139) (740 mg, 1.57 mmol) in dry DCE (15 ml) under nitrogen was 
added (4.140) (488 mg, 1.72 mmol) in DCE (5 ml). The reaction was heated to 50°C 
for 24 hrs. The DCE was then removed in vacuo and the residue triturated with 
diethyl ether. Some of the residue (100 mg, 0.13 mmol) was then dissolved in 
methanol ( 8  ml) and cooled to -10°C. To the stirring solution was added 10 % aq. 
Na2 CC>3 (0.56 ml, 0.52 mmol). After addition the reaction was left stirring at -10°C 
for 2 hrs. Amberlite IR-120 H+ ion exchange resin was then added to the stirring 
solution until pH 6-7 was achieved. The methanol was then removed in vacuo and 
the residue partitioned between water (50 ml) and DCM (50 ml). The aqueous 
phase was then extracted with DCM (3 X 50 ml) and the aqueous phase was then 
evaporated to dryness to give an amphorous solid. NMR showed that this material 
was 4:1 product/eliminated by-product 
Yield: 61 % product.
HPLC was used to purify the material further; yield after HPLC 11 %
[a] 2 9 3  = -11.47 (0.8 gm l1 in MeOH). Found: [M]+ m/z 382.1871; Ci 9 H2807N requires 
m/z 382.1866
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*H NMR ôH MeOD 600MHz: 2.08-2.27 (4H, m, CH2 CH2 CH2 CH2 ), 2.28-2.46 (2H, m, 
NCH2CH2 CH2 O), 3.46-3.53 (2H, m, 3-H, 4-H), 3.61-3.69 (1H, m, CH2 NCH2), 3.71-3.79 
(4H, m, CH2 NCH2 , NCH2 CH2 CH2 0 , 5-H), 3.79-3.83 (1H, t, 2-H, J = 8.9 Hz), 3.92-4.11 
(4H, m, NCH2CH2CH2 0 , CHzNCH^), 4.67-4.71 (1H, d, 1-H, J = 8.9 Hz), 6.89-6.93 (3H, 
m, ArH), 7.22-7.28 (2H, m, ArH).
13C NMR 6 C MeOD: 23.5, 24.8, 25.6, 59.3, 62.4, 64.6, 66.2, 72.2, 73.2, 79.1, 79.8, 
96.3,115.9,122.6,130.9,160.4,175.4. m/z (ES +ve ion mode) 382 [M]+ 100 %.
-Formation ofa pyrrolidine ring by intramolecular quaternisation
-The condensation reaction
iPrCO.O
iPrCO.O
iPrCO.O
To a solution of hemiacetal (4.129) (2 g, 5 mmol) in toluene (15 ml) was added the 
amine (5 mmol) at 50°C. The reaction was left heating for 17 hrs and then allowed 
to cool and the solvent removed in vacuo.
Methyl ((2,3,4-tri-0-isobutyryl)-$-D-l-N-benzylamino)-glucopyranuronate (4.144)
C0 2Me h
iPrCO.O
i PrCO. O— N  
iPrCO.O Ph
Yield: ~95 % (taken from NMR integration), used without any further purification 
Found [M+H]+ m/z 508.252; C26Hb8N09 requires m/z 508.254.
XH NMR 6 h CDCI3: 0.99-1.12 (18H, m, (CHshCH), 2.32-2.49 (3H, m, (CH3 )2 CH), 3.68 
(3H, s, CO2 CH3 ), 3.78-3.82 (1H, d, CF^Ar), 3.89-3.92 (1H, d, 5-H, J = 10.0 Hz), 3.97-4.0
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(1H, d, CH2Ar), 4.05-4.07 (1H, d, 1-H, J = 9.12 Hz), 4.88-4.91 (1H, t, 2-H, J = 9.2 Hz),
5.06-5.11 (1H, t, 4-H, J = 9.8 Hz), 5.21-5.26 (1H, t, 3-H, J = 9.6 Hz), 7.15-7.22 (5H, m, 
ArH).
Methyl(2,3,4-tri-0-isobutyryl)-l-N-ethylphenylammo -$-D-glucopyranuronate 
(4.147)
iPrCO.O
iPrCO.O
iPrCO.O
Ph
5:2 product/hemiacetal sugar (taken from NMR integration). Used without further 
purification.
Found: [M+Na]+ m/z 544.254, C2 7 H3 9 0 9 NNa requires m/z 544.254 
*H NMR 6 h CDC!3: 0.99-1.18 (18H, m, (CHghCH), 2.32-2.50 (3H, m, (CH3 )2 CH), 2.61­
3.0 (3H, m, CH2 CH2Ar), 3.08-3.17 (1H, dt, NCH2 CH2, J = 11.9, 7.0 Hz), 3.64 (3H, s, C02- 
CH3), 3.89-3.92 (1H, d, 5-H, J = 9.9 Hz), 4.06-4.09 (1H, d, 1-H, J = 9.1 Hz), 4.78-4.82 
(1H, t, 2-H, J = 9.3 Hz), 5.04-5.09 (1H, t, 4-H, J = 9.9 Hz), 5.24-5.29 (1H, t, 3-H, J = 9.7 
Hz), 7.03-7.23 (5H, m, ArH).
13C NMR 6 C CDCI3: 17.6, 17.7, 17.9, 32.8 (x 2), 32.9, 35.9, 45.9, 51.7, 6 8 .8 , 69.2, 70.9, 
72.6, 8 8 .8 , 127.2, 127.3, 127.7, 128.0, 174.4, 174.9, 175.0, 181.1.
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Forming the alkylating agent
Butane-1,4-diyl bis(trifluoromethanesulfonate) (4.145)22.
OTf
TfO
To a solution of trifluoromethanesulfonic anhydride (4.95 g, 0.015 mmol) in DCM 
(50 ml) was added dropwise THF (1.08 g, 0.015 mmol) in DCM (50 ml) at -78°C. On 
complete addition the reaction was allowed to warm to room temperature (~lhr). 
The reaction mixture was then washed with water (100 ml) and dried over Na2 S04. 
A re-crystallisation was achieved using diethyl ether
Yield: 71 %
*H NMR 6 |h CDCI3: 2.01 (4H, m, CH2 CH2), 4.60 (4H, m, CH2 0 S0 2 CF3)
13C NMR 6 C CDCI3: 25.72, 76.30, 114.21, 117.39, 120.58,123.75.
-Alkylation, then intramolecular quaternisation
Methyl((2,3,4-tri-0-isobutyryl)-$-D-glucopyranuronate)-N-pyrrolldinium-l-benzyl 
trifluoromethane sulfonate (4.146)
To a solution of (4.144) (379 mg, 0.75 mmol) and 2,6-lutidine (0.095 ml, 0.83 mmol) 
in DCE (4 ml) at 50°C was added (4.145) (291mg, 0.83 mmol) in a solution of DCE (4 
ml) dropwise. The reaction was left heating at 50°C for 24 hrs, and the DCE 
removed in vacuo. The residue was filtered through a pad of silica (7 cm depth, 5cm 
diameter) with EtOAc, then 10 % EtOH/DCM. The solvent was removed in vacuo.
-OTf
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NMR showed some remaining impurities. Further purification on silica gel lead to 
hydrolysis.
Yield: 27%, p u rity -80%
*H NMR 6 h CD3 CN: 1.03-1.12 (18H, m, 3 x C0 2 CH(CH3)2), 1.65-1.88 (2H, m, CH2 CH2), 
1.94-2.11 (2H, m, CH2CH2), 2.41-2.52 (2H, sept, 2 x C0 2 CH{CH3)2), 2.57-2.68 (1H, 
sept, C0 2 CH{CH3)2), 3.37-3.42 (1H, m, CH2 NCH2), 3.51-3.58 (1H, m, CH2 NCH2), 3.71 
(3H, s, C0 2 CH3), 3.72-3.80 (2H, m, CH2 NCH2), 4.49-4.53 (2H, 2 x d, 5-H, J = 9.7 Hz, CH. 
2Ar, J = 13.2 Hz), 4.62-4.65 (1H, d, CH^Ar, J = 13.2 Hz), 5.12-5.15 (1H, d, 1-H J = 8.96 
Hz), 5.28 (1H, t, 3-H, J = 9.3 Hz), 5.52 (1H, t, 4-H, J = 9.3 Hz), 5.71 (1H, t, 2-H, J = 8 . 8  
Hz), 7.52-7.68 (5H, m, ArH).
-Alkylation, then intramolecular quaternisation and deprotection 
(i-D-glucopyranuronate-N-l-(2-phenylethyl)pyrrolidinium-l-yl (4.150)
To a solution of (4.147) (1.37 g, 2.72 mmol) in DCE ( 8  ml) was added 2,6-lutidine 
(0.63 ml, 5.44 mmol). The solution was evacuated with N2 and heated to 50°C. The 
bistriflate, (4.145) (1.45 g, 4.08 mmol) was then added in DCE ( 8  ml) to the stirring 
reaction. The reaction was left at 50°C for 18 hrs. The solvent was then removed in 
vacuo and the residue filtered through a pad of silica, using 100 % EtOAc, then 10 % 
IPA/DCM with the product eluting in the latter. The solvent was removed in vacuo 
and the residue triturated with diethyl ether. The residue (313 mg, 0.44 mmol) was 
then dissolved in MeOH ( 6  ml) and cooled to -10°C. A solution of 10 % Na2 C0 3 (aq) 
(1.87 ml, 1.76 mmol) was added drop wise. The reaction was then left at -10°C for 
2hrs and RT for lh. The reaction was quenched with the addition of Amberlite IR-
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120 H+ ion exchange resin until pH 6-7 was reached. The solvent was then removed 
in vacuo and the residue partitioned between DCM (20 ml) and water (30 ml). The 
water layer was extracted with DCM (3 x 10 ml) and then the water removed in 
vacuo to yield a yellow viscous oil. The residue was then purified by reverse phase 
preparative TLC using 20 % Me0H/H2 0. The reverse phase silica gel was washed 
with MeOH to liberate the product.
Yield: 10 %, purity ~ 60 %, the NMR spectrum suggests some hydrolysis of the 
aglycone.
Found: [M+H]+ m/z 352.176. Ci 8 H2 606N requires m/z 352.176 
*H NMR 6 h de-acetone: 2.11-2.15 (4H, m, CH2 CH2), 3.14-3.25 (2H, m, CH2 Ph), 3.61­
3.78 (2H, 2 x t 3-H J = 8 . 6  Hz, 4-H, J = 9.2 Hz), 3.79-3.89 (1H, m, NCH2 CH2 Ph), 3.90­
4.13 (2H, t and d, 2-H J = 8 . 6  Hz, 5-H, J = 9.3 Hz), 4.05-4.22 (1H, m, NCH2 CH2 Ph), 
4.68-4.79 (4H, m, CH2 NCH2), 5.0-5.03 (1H, d, 1-H, J = 9 Hz), 7.21-7.5 (5H, m, ArH).
13C NMR 6 C de-acetone: 23.8, 24.2, 49.9, 53.5, 61.9, 64.69, 71.8, 72.4, 78.1, 79.0, 
94.8,129.5, 130.1,130.5, 145.9, 156.9.
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6.1 Appendix
6.1.1 LCMS data of Amitriptyline /V*-Glucuronide (4.133)
Amitrlp. N-flluc [L19-6-3] acn[20-46%, 20m in]FA 
17:34:31
Amitrlp. N-flluc [LI9-5-3] acn[20^45%, 20min]FA
UB
6178 03-Jul-2008
17:34:31
Scan ES+
03^Jul-2008
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6.1.2 Crystallographic data for 2,3,4,6-Tetra-O-acetyI-6-D- 
glucopyranosyl(trimethylammonium) iodide (4.96)
0(8)
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Table 1. Crystal data and structure refinement for (4.96)
Identification code LI733
Empirical formula C17 H28 1 N 09
Formula weight 517.30
Temperature 173(2) K
Wavelength 0.71073 A
Crystal system Orthorhombic
Space group P212121
Unit cell dimensions a = 8.616(2) A a= 90°. 
b = 11.244(2) A 3=90°. 
C = 24.390(5) A y = 90°.
Volume 2362.9(8) A3
Z 4
Density (calculated) 1.454 Mg/m3
Absorption coefficient 1.397 mm' 1
F(0 0 0 ) 1048
Crystal size 0.44 x 0.42 x 0.29 mm3
Theta range for data collection 1.99 to 24.18°.
Index ranges -9<=h<=9, -12<=k<=12, -27<=l<=27
Reflections collected 18276
Independent reflections 3557 [R(int) = 0.0456]
Completeness to theta = 24.18° 94.2 %
Absorption correction Numerical
Max. and min. transmission 0.6874 and 0.5784
Refinement method Full-matrix least-squares on F^
Data / restraints / parameters 3557/0/260
Goodness-of-fit on F^ 0.854
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Final R indices [l>2sigma(l)] Rl = 0.0274, wR2 = 0.0519
R indices (all data) Rl = 0.0392, wR2 = 0.0544
Absolute structure parameter -0.030(17)
Largest diff. peak and hole 0.465 and -0.397 e.A'3
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Table 2. Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (A^x 
103)
for (4.96). U(eq) is defined as one third of the trace of the orthogonalized U'J tensor.
X y z U(eq)
1(1 ) 2070(1) 7812(1) 2283(1) 6 8 (1 )
0 (6 ) 2226(4) 6046(2) 4243(1) 51(1)
0(4) 5395(3) 5436(2) 4105(1) 48(1)
C(5) 2747(5) 8064(3) 3950(2) 46(1)
N(l) 5975(5) 9405(3) 3216(1) 51(1)
0 (1 ) 4026(3) 8834(2) 3813(1) 47(1)
0 (2 ) 6989(4) 6775(2) 3338(1) 55(1)
C(l) 5024(5) 8349(3) 3417(2) 43(1)
0(9) 2706(5) 11022(3) 4448(1) 71(1)
0(5) 4068(5) 4124(3) 3577(2) 75(1)
0 (8 ) 1083(4) 9761(3) 4041(1) 67(1)
0 (2 ) 5878(4) 7340(3) 3693(1) 42(1)
0(4) 3408(4) 6931(3) 4205(2) 40(1)
0(3) 4643(5) 6412(3) 3834(2) 40(1)
0(7) 1713(6) 8757(4) 4327(2) 56(1)
0(17) 7006(7) 9894(4) 3654(2) 71(1)
0 (1 0 ) 8419(6) 6544(4) 3560(3) 6 8 (2 )
0 (8 ) 1746(6) 10834(4) 4124(2) 65(1)
0(16) 4857(6) 10363(4) 3030(2) 79(2)
0(3) 8786(5) 6904(4) 3997(2) 118(2)
0(18) 6916(7) 9063(4) 2729(2) 83(1)
0 (1 2 ) 4981(6) 4305(4) 3935(2) 54(1)
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C(13) 5882(8) 3388(4) 4246(2) 81(2)
0(7) 1890(9) 6345(5) 5118(2) 176(3)
C(14) 1677(9) 5741(5) 4726(2) 103(2)
c ( i i ) 9405(7) 5861(5) 3173(3) 99(2)
C( 15) 582(8) 4724(5) 4705(3) 108(2)
C(9) 1035(8) 11759(5) 3760(3) 108(2)
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Table 3. Bond lengths [A] and angles [°] for (4.96).
0(6)-C(14) 1.313(6)
0(6)-C(4) 1.427(4)
0(4)-C(12) 1.384(5)
0(4)-C(3) 1.435(5)
C(5)-0(l) 1.440(5)
C(5)-C(7) 1.499(6)
C(5)-C(4) 1.529(5)
N(l)-C(18) 1.489(6)
N(l)-C(17) 1.495(5)
N(l)-C(16) 1.514(6)
N(l)-C(l) 1.523(5)
0(1)-C(1) 1.403(5)
O(2)-C(10) 1.371(6)
0(2)-C(2) 1.439(5)
C(l)-C(2) 1.511(5)
0(9)-C(8) 1.165(5)
0(5)-C(12) 1.192(5)
0(8)-C(8) 1.350(6)
0(8)-C(7) 1.435(5)
C(2)-C(3) 1.530(5)
C(4)-C(3) 1.513(5)
C(10)-0(3) 1.183(6)
C(10)-C(ll) 1.485(7)
C(8)-C(9) 1.498(7)
C(12)-C(13) 1.497(7)
0(7)-C(14) 1.187(6)
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C(14)-C(15) 1.483(8)
C(14)-0(6)-C(4) 119.8(4)
C(12)-0(4)-C(3) 116.7(3)
0(1)-C(5)-C(7) 106.5(3)
0(1)-C(5)-C(4) 108.1(3)
C(7)-C(5)-C(4) 113.8(3)
C(18)-N(l)-C(17) 110.0(4)
C(18)-N(l)-C(16) 106.9(4)
C(17)-N(l)-C(16) 109.3(4)
C(18)-N(l)-C(l) 110.4(3)
C(17)-N(l)-C(l) 112.1(3)
C(16)-N(l)-C(l) 107.9(4)
C(l)-0(1)-C(5) 113.2(3)
C(10)-O(2)-C(2) 116.4(3)
0(1)-C(1)-C(2) 106.5(3)
0(1)-C(1)-N(1) 104.4(3)
C(2)-C(l)-N(l) 117.8(4)
C(8)-0(8)-C(7) 118.0(4)
0(2)-C(2)-C(l) 112.9(3)
0(2)-C(2)-C(3) 107.3(3)
C(l)-C(2)-C(3) 105.9(3)
0(6)-C(4)-C(3) 105.8(3)
0(6)-C(4)-C(5) 110.0(3)
C(3)-C(4)-C(5) 109.9(3)
0(4)-C(3)-C(4) 109.7(3)
0(4)-C(3)-C(2) 108.1(3)
C(4)-C(3)-C(2) 111.1(3)
0(8)-C(7)-C(5) 109.5(3)
240
Appendix
O(3)-C(10)-O(2) 122.1(5)
O(3)-C(10)-C(ll) 126.7(6)
0(2)-C(10)-C(11) 111.1(5)
0(9)-C(8)-0(8) 124.4(4)
0(9)-C(8)-C(9) 124.5(5)
0(8)-C(8)-C(9) 111.0(5)
0(5)-C(12)-0(4) 123.1(4)
0(5)-C(12)-C(13) 126.5(4)
0(4)-C(12)-C(13) 110.4(4)
0(7)-C(14)-0(6) 121.1(5)
0(7)-C(14)-C(15) 124.5(5)
0(6)-C(14)-C(15) 113.5(5)
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Symmetry transformations used to generate equivalent atoms:
Table 4. Anisotropic displacement parameters (A2x 10^)for N733. The anisotropic 
displacement factor exponent takes the form: -2n2[ h2 a*2 U1 1  + ... + 2 h k a* b* U1 2  ]
u i i U2 2 1)33 U23 Ul3 U l2
1(1 ) 73(1) 58(1) 72(1) -16(1) -26(1) 9(1)
0 (6 ) 44(2) 54(2) 55(2) 2 (1 ) 1 1 (1 ) -1 0 (2 )
0(4) 50(2) 44(2) 48(2) 3(1) -3(1) -7(1)
C(5) 38(3) 50(2) 51(2) 2 (2 ) -4(2) -1 0 (2 )
N(l) 54(3) 55(2) 44(2) 15(2) -7(2) -23(2)
0 (1 ) 45(2) 44(2) 52(2) 4(1) -4(1) -1 0 (1 )
0 (2 ) 50(2) 57(2) 57(2) -7(1) 14(2) -17(2)
C(l) 41(3) 49(2) 39(2) 1 (2 ) -9(2) -17(2)
0(9) 71(3) 63(2) 79(2) -5(2) -29(2) -1 (2 )
0(5) 90(3) 60(2) 75(2) -9(2) -2 2 (2 ) -2 0 (2 )
0 (8 ) 55(2) 55(2) 92(2) 0 (2 ) -2 2 (2 ) 0 (2 )
C(2) 38(3) 47(2) 41(2) 1 (2 ) 1 (2 ) -14(2)
C(4) 38(3) 39(2) 44(2) 2 (2 ) 3(2) -1 0 (2 )
C(3) 38(3) 40(2) 42(2) 2 (2 ) -2 (2 ) -6 (2 )
C(7) 46(4) 54(3) 67(3) -1 (2 ) -6 (2 ) 0 (2 )
C(17) 76(4) 73(3) 65(3) 2 0 (2 ) -23(3) -41(3)
C(10) 27(4) 67(3) 110(4) -21(3) 7(3) -13(2)
C(8 ) 59(4) 58(3) 79(3) -3(2) -18(3) 6(3)
C(16) 81(4) 59(3) 97(4) 32(3) -29(3) -15(3)
0(3) 60(3) 130(4) 163(4) -77(3) -46(3) 27(2)
0(18) 101(4) 83(3) 65(3) 17(3) 20(4) -23(3)
C(12) 64(4) 46(3) 52(3) -1 (2 ) 8 (2 ) -6 (2 )
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C(13) 114(5) 48(3) 81(4) 6(3) -3(3) 4(3)
0(7) 283(8) 177(5) 68(3) -12(3) 54(4) -121(5)
C(14) 158(7) 93(4) 57(3) -13(3) 43(4) -50(4)
C(U) 49(4) 105(4) 142(6) -38(4) 27(3) -10(3)
0(15) 115(6) 88(4) 120(5) 3(4) 59(4) -46(4)
0(9) 104(5) 68(4) 153(6) 14(4) -73(4) 8(3)
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Table 5. Hydrogen coordinates ( x 104) and isotropic displacement parameters (A2x 103) 
for (4.96).
X y z U(eq)
H(5) 2162 7857 3608 56
H(l) 4394 8027 3106 52
H(2) 6399 7629 4034 51
H(4) 3850 7104 4576 48
H (3) 4147 6121 3489 48
H(7A) 859 8242 4460 67
H(7B) 2314 9032 4649 67
H(17A) 7817 9313 3741 107
H(17B) 6390 10057 3984 107
H(17C) 7486 10633 3525 107
H(16A) 4327 10700 3350 119
H(16B) 4089 10017 2780 119
H(16C) 5432 10992 2840 119
H(18A) 7451 9766 2585 124
H(18B) 6232 8735 2445 124
H(18C) 7683 8462 2835 124
H(13A) 5206 2712 4331 1 2 1
H(13B) 6273 3736 4587 1 2 1
H(13C) 6758 3116 4022 1 2 1
H(11A) 10359 5610 3359 148
H(11B) 9670 6363 2858 148
H(11C) 8838 5158 3045 148
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H(15A) 1160 3989 4636 162
H(15B) -170 4852 4409 162
H(15C) 33 4661 5055 162
H(9A) 49 12026 3919 162
H(9B) 847 11420 3396 162
H(9C) 1743 12438 3728 162
245
Appendix
Table 6 . Torsion angles [°] for (4.96)
C(5)-0(1)-C(l)-N(l) 164.2(3)
C(5)-0(1)-C(l)-C(2) -70.5(4)
C(l)-0(1)-C(5)-C(4) 63.2(4)
C(l)-0(1)-C(5)-C(7) -174.2(3)
C(10)-O(2)-C(2)-C(l) 135.0(3)
C(10)-O(2)-C(2)-C(3) -108.7(4)
C(2)-O(2)-C(10)-O(3) -8.2(7)
C(2)-O(2)-C(10)-C(ll) 174.6(4)
C(12)-0(4)-C(3)-C(2) -134.8(3)
C(12)-0(4)-C(3)-C(4) 103.8(4)
C(3)-0(4)-C(12)-0(5) 1 .2 (6 )
C(3)-0(4)-C(12)-C(13) 178.9(4)
C(14)-0(6)-C(4)-C(3) 131.4(4)
C(14)-0(6)-C(4)-C(5) -110.0(5)
C(4)-0(6)-C(14)-0(7) 16.1(9)
C(4)-0(6)-C(14)-C(15) -173.8(4)
C(8)-0(8)-C(7)-C(5) -100.3(5)
C(7)-0(8)-C(8)-0(9) -7.0(7)
C(7)-0(8)-C(8)-C(9) 175.3(4)
C(16)-N(l)-C(l)-0(1) -54.4(4)
C(17)-N(l)-C(l)-0(1) 66.1(4)
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C(18)-N{ 1)-C( l)-O(l) -170.9(3)
C(16)-N(l)-C(l)-C(2) -172.2(3)
C(17)-N(l)-C(l)-C(2) -51.8(5)
C(18)-N(l)-C(l)-C(2) 71.3(4)
0(l)-C(l)-C(2)-0(2) -178.2(3)
0(1)-C(1)-C(2)-C(3) 64.7(3)
N(l)-C(l)-C(2)-0(2) -61.6(4)
N(l)-C(l)-C(2)-C(3) -178.7(3)
0(2)-C(2)-C(3)-0(4) 59.9(3)
0(2)-C(2)-C(3)-C(4) -179.5(3)
C(l)-C(2)-C(3)-0(4) -179.3(3)
C(l)-C(2)-C(3)-C(4) -58.8(4)
0(4)-C(3)-C(4)-0(6) -68.4(4)
0(4)-C(3)-C(4)-C(5) 172.9(3)
C(2)-C(3)-C(4)-0(6) 172.0(3)
C(2)-C(3)-C(4)-C(5) 53.3(4)
0(6)-C(4)-C(5)-0(l) -168.1(3)
0(6)-C(4)-C(5)-C(7) 73.8(4)
C(3)-C(4)-C(5)-0(l) -52.0(4)
C(3)-C(4)-C(5)-C(7) -170.1(3)
0(l)-C(5)-C(7)-0(8) 64.3(4)
C(4)-C(5)-C(7)-0(8) -176.7(3)
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Table 7. Hydrogen bonds for (4.96) [A and °].
D-H...A d(D-H) d(H...A) d(D...A) <(DHA)
C(l)-H(l)...l(l) 1 . 0 0 0 0 2.8500 3.806(4) 161.00
C(2)-H(2)...0(3) 1 . 0 0 0 0 2 . 2 1 0 0 2.659(6) 105.00
C(2)-H(2)...0(7)#l 1 . 0 0 0 0 2.4100 3.371(6) 162.00
C(3)-H(3)...0(5) 1 . 0 0 0 0 2.2600 2.694(5) 105.00
C(4)-H(4)...0(7) 1 . 0 0 0 0 2.3100 2.665(6) 1 0 0 . 0 0
C(7)-H(7A)...0(3)#2 0.9900 2.5900 3.369(7) 135.00
C(7)-H(7B)...0(9) 0.9900 2.3200 2.703(6) 1 0 2 . 0 0
C(11)-H(11B)...I(1)#3 0.9800 2.9800 3.846(6) 148.00
C(11)-H(11C)...I(1)#4 0.9800 2.8700 3.822(6) 165.00
C(15)-H(15C)...0(9)#5 0.9800 2.4700 3.333(8) 148.00
C(16)-H(16C)...I(1)#6 0.9800 2.9800 3.896(5) 155.00
C(17)-H(17B)...0(1) 0.9800 2.4900 2.857(6) 1 0 2 . 0 0
C(18)-H(18B)...0(5)#6 0.9800 2.5400 3.298(6) 133.00
C(18)-H(18C)...0(2) 0.9800 2.3400 2.971(5) 1 2 2 . 0 0
Symmetry transformations used to generate equivalent atoms: 
#12 #2+0 #3+2 #4 l/2-x+l,-y-l,l/2+z #5+1 
# 6  l/ 2 -x+l,-y,l/2 +z
249
Appendix
6.1.3 Crystallographic data for $-D-Glucopyranosyl(trimethylammonium) iodide 
(4.99)
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Table 1. Crystal data and structure refinement for (4.99).
Identification code 
Empirical formula 
Formula weight 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions
Volume
Z
Density (calculated)
Absorption coefficient 
F(000)
Crystal size
Theta range for data collection
Index ranges
Reflections collected
Independent reflections
Completeness to theta = 27.51°
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [l>2sigma(l)]
R indices (all data)
Absolute structure parameter 
Largest diff. peak and hole
ck348m
C9 H20 1 N 05
349.16
100(2) K
0.71073 Â
Orthorhombic
P212121
a = 9.3032(19) Â Q ll CD O Û
b = 9.985(2) Â (3 = 90°
c= 14.663(3) Â y = 90°.
1362.0(5) Â3
4
1.703 Mg/m3  
2.358 mm' 1  
696
0.32 x 0.19 x 0.15 mm3  
2.47 to 27.51°.
-12<=h<=ll, -12<=k<=10, -14<=l<=18 
8145
3038 [R(int) = 0.0177]
99.0 %
Semi-empirical from equivalents 
0.7187 and 0.5192 
Full-matrix least-squares on F2  
3038/8/189 
1.026
Rl = 0.0182, wR2 = 0.0477 
R1 = 0.0184, wR2 = 0.0478 
0.02( 2)
0.738 and -0.347 e.A' 3
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Table 2. Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (A^x 
1 (P) for (4.99). U(eq) is defined as one third of the trace of the orthogonalized U'J tensor.
X Y z U(eq)
0 (1 ) 5656(2) 5478(2) 5276(1) 16(1)
0 (2 ) 4010(2) 2150(2) 5293(1) 18(1)
0(3) 5633(2) 2244(2) 6957(1) 16(1)
0(4) 5858(2) 4878(2) 7727(1) 17(1)
0(5) 5874(3) 8243(2) 6184(1) 2 0 (1 )
N(l) 4745(2) 4484(2) 3966(2) 14(1)
C(l) 4667(3) 4486(3) 5003(2) 13(1)
C(2) 5053(3) 3155(3) 5463(2) 13(1)
C(3) 5071(3) 3385(3) 6499(2) 14(1)
C(4) 5996(3) 4570(3) 6779(2) 14(1)
C(5) 5549(3) 5796(3) 6232(2) 13(1)
C(6 ) 6534(3) 6982(3) 6389(2) 17(1)
C(7) 6109(3) 3901(4) 3610(2) 28(1)
C(8 ) 4619(4) 5903(3) 3638(2) 31(1)
C(9) 3485(4) 3747(4) 3591(2) 36(1)
1(1 ) 5693(1) 9695(1) 4032(1) 18(1)
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Table 3. Selected bond lengths [A] and angles [°] for (4.99)
0(1)-C(1)
0(1)-C(5)
0(2)-C(2)
0(3)-C(3)
0(4)-C(4)
0(5)-C(6)
N(l)-C(l)
N(l)-C(7)
N(l)-C(8 )
N(l)-C(9)
1.410(3)
1.440(3)
1.418(3)
1.422(3)
1.429(3)
1.432(4)
1.522(4)
1.491(4)
1.501(4)
1.489(4)
C(l)-0(1)-C(5)
C(7)-N(l)-C(9)
C(8)-N(l)-C(9)
C(l)-N(l)-C(9)
C(l)-N(l)-C(7)
C(l)-N(l)-C(8 )
C(7)-N(l)-C(8)
0(1)-C(1)-N(1)
0(1)-C(1)-C(2)
N(l)-C(l)-C(2)
0(2)-C(2)-C(l)
0(2)-C(2)-C(3)
0(3)-C(3)-C(4)
0(3)-C(3)-C(2)
0(4)-C(4)-C(3)
0(4)-C(4)-C(5)
0(1)-C(5)-C(6)
0(1)-C(5)-C(4)
0(5)-C(6)-C(5)
112.7(2)
110.3(2)
106.6(2)
109.4(2)
113.0(2)
108.4(2)
108.8(2)
104.7(2)
109.3(2)
115.3(2)
1 1 2 .1 (2 )
106.7(2)
106.7(2)
1 1 0 .6 (2 )
112.3(2)
108.4(2)
106.2(2)
108.5(2)
113.3(2)
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Table 4. Bond lengths [A] and angles [°] for (4.99).
0(1)-C(1)
0(1)-C(5)
0(2)-C(2)
0(3)-C(3)
0(4)-C(4)
0(5)-C(6)
0(2)-H(20)
0(3)-H(30)
0(4)-H(40)
0(5)-H(50)
N(l)-C(l)
N(l)-C(7)
N(l)-C(8 )
N(l)-C(9)
C(l)-C(2)
C(2)-C(3)
C(3)-C(4)
C(4)-C(5)
C(5)-C(6)
C(l)-H(l)
C(2)-H(2)
C(3)-H(6)
C(4)-H(4)
C(5)-H(5)
C(6 )-H(6 A)
C(6 )-H(6 B)
C(7)-H(7A)
C(7)-H(7B)
C(7)-H(7C)
C(8 )-H(8 A)
C(8 )-H(8 B)
C(8 )-H(8 C)
C(9)-H(9A)
C(9)-H(9B)
1.410(3)
1.440(3)
1.418(3)
1.422(3)
1.429(3)
1.432(4)
0.98(3)
0.8400
0.98(3)
0.984(16)
1.522(4)
1.491(4)
1.501(4)
1.489(4)
1.533(4)
1.535(4)
1.520(4)
1.522(4)
1.515(4)
1.02(4)
0.94(4)
1.07(4)
0.99(3)
1.06(4)
0.97(2)
0.97(2)
0.9800
0.9800
0.9800
0.9800
0.9800
0.9800
0.9800
0.9800
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C(9)-H(9C)
C(l)-0(1)-C(5)
C(2)-0(2)-H(20)
C(3)-0(3)-H(30)
C(4)-0(4)-H(40)
C(6)-0(5)-H(50)
C(7)-N(l)-C(9)
C(8)-N(l)-C(9)
C(l)-N(l)-C(9)
C(l)-N(l)-C(7)
C(l)-N(l)-C(8 )
C(7)-N(l)-C(8)
0(1)-C(1)-N(1)
0(1)-C(1)-C(2)
N(l)-C(l)-C(2)
C(l)-C(2)-C(3)
0(2)-C(2)-C(l)
0(2)-C(2)-C(3)
0(3)-C(3)-C(4)
C(2)-C(3)-C(4)
0(3)-C(3)-C(2)
0(4)-C(4)-C(3)
0(4)-C(4)-C(5)
C(3)-C(4)-C(5)
0(1)-C(5)-C(6)
C(4)-C(5)-C(6)
0(1)-C(5)-C(4)
0(5)-C(6)-C(5)
0(1)-C(1)-H(1)
N(l)-C(l)-H(l)
C(2)-C(l)-H(l)
0(2)-C(2)-H(2)
C(l)-C(2)-H(2)
C(3)-C(2)-H(2)
0(3)-C(3)-H(6)
C(2)-C(3)-H(6)
0.9800
112.7(2)
108(2)
109.00
112.3(17)
117.6(19)
110.3(2)
106.6(2)
109.4(2)
113.0(2)
108.4(2)
108.8(2)
104.7(2)
109.3(2)
115.3(2)
108.0(2)
1 1 2 .1 (2 )
106.7(2)
106.7(2)
113.0(2)
1 1 0 .6 (2 )
112.3(2)
108.4(2)
109.2(2)
106.2(2)
112.5(2)
108.5(2)
113.3(2)
109(2)
106.6(17)
1 1 2 (2 )
106.3(19)
113.5(19)
110.2(19)
112.2(19)
106.1(16)
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C(4)-C(3)-H(6)
0(4)-C(4)-H(4)
C(3)-C(4)-H(4)
C(5)-C(4)-H(4)
0(1)-C(5)-H(5)
C(4)-C(5)-H(5)
C(6)-C(5)-H(5)
0(5)-C(6)-H(6A)
0(5)-C(6)-H(6B)
C(5)-C(6)-H(6A)
C(5)-C(6)-H(6B)
H(6 A)-C(6 )-H(6 B)
108(2)
108.6(16)
108.9(17)
109.3(17)
105.5(16)
112.5(19)
1 1 1 (2 )
103.6(18)
109.5(17)
109.5(17)
108.6(17)
1 1 2 (2 )
N(1)-C(7)-H(7A) 1 1 0 . 0 0
N(1)-C(7)-H(7B) 109.00
N(1)-C(7)-H(7C) 1 1 0 . 0 0
H(7A)-C(7)-H(7B) 109.00
H(7A)-C(7)-H(7C) 109.00
H(7B)-C(7)-H(7C) 109.00
N(1)-C(8)-H(8A) 109.00
N(1)-C(8)-H(8B) 109.00
N(1)-C(8)-H(8C) 1 1 0 . 0 0
H(8 A)-C(8 )-H(8 B) 109.00
H(8 A)-C(8 )-H(8 C) 109.00
H(8 B)-C(8 )-H(8 C) 109.00
N(1)-C(9)-H(9A) 1 1 0 . 0 0
N(1)-C(9)-H(9B) 109.00
N(1)-C(9)-H(9C) 109.00
H(9A)-C(9)-H(9B) 109.00
H(9A)-C(9)-H(9C) 109.00
H(9B)-C(9)-H(9C) 109.00
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Table 5. Anisotropic displacement parameters (A^x liP )  for (4.99) The anisotropic 
displacement factor exponent takes the form: -2 n2 [ h^a*^U^^ + ... + 2  h k a* b* 1 ) 1 2  ]
UH U 2 2 U33 1)23 Ul3 U 1 2
1(1) 23(1) 15(1) 15(1) - 1 ( 1 ) - 2 ( 1 ) 0 ( 1 )
0 ( 1 ) 2 1 ( 1 ) 13(1) 1 2 ( 1 ) 0 ( 1 ) 1 ( 1 ) -5(1)
0(4) 26(1) 15(1) 1 1 ( 1 ) - 2 ( 1 ) 1 ( 1 ) -4(1)
N(l) 16(1) 13(1) 14(1) 2 ( 1 ) 0 ( 1 ) 0 ( 1 )
0(5) 35(1) 1 0 ( 1 ) 16(1) 1 ( 1 ) 1 ( 1 ) - 1 ( 1 )
0(3) 2 1 ( 1 ) 1 2 ( 1 ) 16(1) 3(1) 1 ( 1 ) - 1 ( 1 )
C(4) 16(1) 14(1) 14(1) - 2 ( 1 ) K D 1 ( 1 )
0(3) 16(1) 1 1 ( 1 ) 14(1) 0 ( 1 ) 2 ( 1 ) 0 ( 1 )
C(5) 16(1) 1 1 ( 1 ) 13(1) -3(1) - 1 ( 1 ) - 2 ( 1 )
0 ( 2 ) 2 1 ( 1 ) 13(1) 2 1 ( 1 ) -3(1) 1 ( 1 ) -5(1)
C(6 ) 2 2 ( 1 ) 1 1 ( 1 ) 18(1) - 1 ( 1 ) 1 ( 1 ) -3(1)
C(l) 15(1) 14(1) 1 1 ( 1 ) -3(1) 2 ( 1 ) -3(1)
C(2 ) 1 2 ( 1 ) 1 2 ( 1 ) 16(1) - 2 ( 1 ) 0 ( 1 ) - 1 ( 1 )
C(7) 25(2) 44(2) 16(1) 2 ( 1 ) 7(1) 15(2)
0 (8 ) 59(2) 16(2) 18(1) 4(1) -3(1) 9(2)
0(9) 38(2) 48(2) 2 2 ( 2 ) 2 ( 2 ) - 1 0 ( 2 ) -26(2)
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Table 6 . Hydrogen coordinates ( x 1 0 )^ and isotropic displacement parameters (A^x 10 )^ 
for (4.99).
X y z U(eq)
H(l) 3660(40) 4790(40) 5170(20) 17(8)
H(2) 5940(40) 2800(30) 5270(20) 1 1 (8 )
H(20) 4470(40) 1430(30) 4950(20) 17(10)
H(30) 5023 1625 6948 19
H(4) 7010(30) 4360(30) 6650(18) 13(7)
H(40) 5500(40) 4120(30) 8080(20) 17(11)
H (5) 4460(40) 6060(40) 6340(20) 18(9)
H (50) 5750(50) 8480(30) 5538(9) 25(13)
H(6 ) 3980(40) 3590(40) 6690(20) 20(9)
H(6 A) 6760(30) 7050(30) 7034(14) 25(7)
H(6 B) 7390(20) 6870(30) 6015(18) 18(7)
H(7A) 6129 2937 3735 42
H(7B) 6929 4333 3910 42
H(7C) 6168 4051 2950 42
H(8 A) 4489 5908 2974 46
H(8 B) 5496 6396 3795 46
H(8 C) 3790 6332 3929 46
H(9A) 3441 3876 2929 54
H(9B) 2601 4090 3870 54
H(9C) 3583 2790 3727 54
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Table 7. Torsion angles [°] for (4.99).
C(5)-0(1)-C(l)-N(l) 169.6(2)
C(5)-0(1)-C(l)-C(2) -66.4(3)
C(l)-0(1)-C(5)-C(4) 65.8(3)
C(l)-0(1)-C(5)-C(6) -173.1(2)
C(7)-N (1)-C(1)-0(1) 71.6(3)
C(7)-N(l)-C(l)-C(2) -48.6(3)
C(8)-N(l)-C(l)-0(1) -49.1(3)
C(8)-N(l)-C(l)-C(2) -169.3(2)
C(9)-N(l)-C(l)-0(1) -165.0(2)
C(9)-N(l)-C(l)-C(2) 74.8(3)
0(l)-C(l)-C(2)-0(2) 173.8(2)
0(1)-C(1)-C(2)-C(3) 56.5(3)
N(l)-C(l)-C(2)-0(2) -68.7(3)
N(l)-C(l)-C(2)-C(3) 174.1(2)
0(2)-C(2)-C(3)-0(3) 68.2(3)
0(2)-C(2)-C(3)-C(4) -172.3(2)
C(l)-C(2)-C(3)-0(3) -171.2(2)
C(l)-C(2)-C(3)-C(4) -51.7(3)
0(3)-C(3)-C(4)-0(4) -65.8(3)
0(3)-C(3)-C(4)-C(5) 173.9(2)
C(2)-C(3)-C(4)-0(4) 172.5(2)
C(2)-C(3)-C(4)-C(5) 52.2(3)
0(4)-C(4)-C(5)-0(l) -178.7(2)
0(4)-C(4)-C(5)-C(6) 64.1(3)
C(3)-C(4)-C(5)-0(l) -56.1(3)
C(3)-C(4)-C(5)-C(6) -173.2(2)
0(l)-C(5)-C(6)-0(5) 84.1(3)
C(4)-C(5)-C(6)-0(5) -157.4(2)
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